



US 20250263455A1

(19) United States

(12) Patent Application Publication

Wathier et al.

(10) Pub. No.: US 2025/0263455 A1

(43) Pub. Date: Aug. 21, 2025

(54) **METHODS OF TREATING NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY**

(71) Applicant: **Life Biosciences, Inc.**, Boston, MA (US)

(72) Inventors: **Michel Wathier**, Boston, MA (US); **Jennifer Cermak**, Boston, MA (US); **Joan Mannick**, Boston, MA (US)

(21) Appl. No.: 19/046,313

(22) Filed: Feb. 5, 2025

Related U.S. Application Data

(63) Continuation of application No. 18/312,538, filed on May 4, 2023, now Pat. No. 12,252,518.

(60) Provisional application No. 63/499,864, filed on May 3, 2023, provisional application No. 63/478,843, filed on Jan. 6, 2023.

Publication Classification

(51) Int. Cl.

C07K 14/47 (2006.01)

A61K 31/65 (2006.01)

A61K 48/00 (2006.01)

A61P 25/02 (2006.01)

C07H 21/04 (2006.01)

C12N 15/86 (2006.01)



(52) U.S. Cl.

CPC C07K 14/4702 (2013.01); A61K 31/65 (2013.01); A61P 25/02 (2018.01); C12N 15/86 (2013.01); A61K 48/005 (2013.01); A61K 48/0058 (2013.01); C07H 21/04 (2013.01)

ABSTRACT

Disclosed herein are methods for preventing or treating non-arteritic anterior ischemic optic neuropathy in a subject by administering to the subject a nucleic acid molecule comprising a nucleic acid sequence encoding OCT4, a nucleic acid sequence encoding SOX2, and a nucleic acid sequence encoding KLF4.

Specification includes a Sequence Listing.






FIG. 1A





FIG. 1B






FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7





FIG. 8






FIG. 9

METHODS OF TREATING NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the right of priority to U.S. Provisional Patent Application No. 63/478,843, filed Jan. 6, 2023, and to U.S. Provisional Patent Application No. 63/499,864, filed May 3, 2023, the contents of each of which are hereby expressly incorporated by reference in their entirety.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted via EFS-Web. The content of the file named "061189-501001US_SequenceListing_ST26.xml", which was created on May 3, 2023 and is 86,016 bytes in size, is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

[0003] The present patent application relates to methods of treating non-arteritic anterior ischemic optic neuropathy in a subject in need thereof using gene therapy.

BACKGROUND

[0004] Ischemic optic neuropathy is the most common acute optic nerve disorder in patients over age 50 years. Ischemic optic neuropathy is generally categorized as anterior (affecting the optic disc) versus posterior (retrobulbar), and as arteritic versus nonarteritic. Anterior involvement is usual with both arteritic and nonarteritic ischemic optic neuropathy.

[0005] Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common form of ischemic optic neuropathy. It is an idiopathic, ischemic insult of the optic nerve head characterized by acute, monocular, painless visual loss with optic disc swelling. According to the American Academy of Ophthalmology, NAION affects between 2.3 and 10.3 people per 100,000 individuals per year making it the most common cause of acute optic neuropathy in patients over the age of 50. There are approximately 6000 new cases per year. Men and women are nearly equally affected. [www_eyewiki_aao_org/Non-Arteritic_Anterior_Ischemic_Optic_Neuropathy_(NAION)].

[0006] There are no known treatments for NAION that are proven to be effective. There have been many clinical trials studying over a dozen different therapies, but none have convincingly improved the visual outcome in patients with NAION. The present disclosure addresses the need for such a treatment.

SUMMARY

[0007] The present disclosure is directed to methods for preventing or treating non-arteritic anterior ischemic optic neuropathy in a subject by administering to the subject a nucleic acid molecule comprising a nucleic acid sequence encoding OCT4, a nucleic acid molecule comprising a nucleic acid sequence encoding SOX2, and a nucleic acid molecule comprising a nucleic acid sequence encoding KLF4. In some embodiments, the nucleic acid sequences

encoding OCT4, SOX2, and KLF4 are on a single nucleic acid molecule. In certain aspects, an adeno-associated viral (AAV) vector comprises the nucleic acid molecule encoding OCT4, SOX2, and KLF4. In some embodiments, the nucleic acid molecule does not encode c-Myc and/or another transcription factors, such as Nanog.

[0008] In some embodiments, the methods further comprise administering to the subject a nucleic acid molecule comprising a nucleic acid sequence encoding a reverse tetracycline-controlled transactivator (rtTA). According to some embodiments of the methods, an AAV vector comprises the nucleic acid molecule encoding reverse tetracycline-controlled transactivator (rtTA). In some embodiments, the rtTA is rtTA3 or rtTA4. The AAV vector comprising the nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding reverse tetracycline-controlled transactivator (rtTA) may be present in a single AAV composition or as separate AAV compositions.

[0009] In some embodiments of the disclosed methods, the nucleic acid molecule comprising a nucleic acid sequence encoding OCT4, a nucleic acid sequence encoding SOX2, and a nucleic acid sequence encoding KLF4 is operably linked to an inducible promoter. In some embodiments, the inducible promoter comprises a tetracycline class antibiotic response element (TRE). In some embodiments, the tetracycline class antibiotic is doxycycline. In some embodiments, the inducible promoter is a TRE2 promoter.

[0010] In some embodiments of the disclosed methods, the nucleic acid molecule comprising a nucleic acid sequence encoding a rtTA is operably linked to a CMV promoter.

[0011] In some embodiments, the nucleic acid molecule comprising a nucleic acid sequence encoding OCT4, a nucleic acid sequence encoding SOX2, and a nucleic acid sequence encoding KLF4 is an adeno-associated viral (AAV) vector. In some embodiments, the AAV vector is serotype-2 (AAV2).

[0012] In some embodiments of the disclosed methods, the nucleic acid molecule comprising a nucleic acid sequence encoding OCT4, a nucleic acid sequence encoding SOX2, and a nucleic acid sequence encoding KLF4 does not comprise a nucleic acid sequence encoding c-Myc.

[0013] In some embodiments of the disclosed methods, the nucleic acid molecule comprising a nucleic acid sequence encoding OCT4, a nucleic acid sequence encoding SOX2, and a nucleic acid sequence encoding KLF4 comprises a nucleic acid sequence encoding self-cleaving peptide. In some embodiments, the self-cleaving peptide is a 2A peptide.

[0014] In some embodiments of the disclosed methods, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 is flanked by inverted terminal repeats (ITRs), and wherein the distance between the ITRs is 4.7 kb or less.

[0015] In some embodiments, the methods further comprise administering to the subject an inducing agent.

[0016] In some embodiments of the disclosed methods, the nucleic acid molecule encoding reverse tetracycline-controlled transactivator (rtTA) is an AAV vector that does not comprise the nucleic acid molecule encoding OCT4, SOX2, and KLF4. The nucleic acid molecule encoding reverse tetracycline-controlled transactivator (rtTA) may be an AAV vector comprising SEQ ID NO: 36 or SEQ ID NO: 37.

[0017] In some embodiments of the disclosed methods, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises nucleic acid elements in the following order: a) a first inverted terminal repeat sequence (ITR) sequence; b) a TRE promoter sequence; c) a nucleic acid sequence encoding OCT4; d) a nucleic acid sequence encoding P2A; e) a nucleic acid sequence encoding SOX2; f) a nucleic acid sequence encoding T2A; g) a nucleic acid sequence encoding KLF4; h) an SV-40-derived terminator sequence; and i) a second inverted terminal repeat (ITR) sequence.

[0018] In some embodiments of the disclosed methods, the nucleic acid sequence encoding OCT4 comprises SEQ ID NO: 1. In some embodiments, the nucleic acid sequence encoding SOX2 comprises SEQ ID NO: 3. In some embodiments, the KLF4 is human KLF4 protein. In some embodiments, the nucleic acid sequence encoding KLF4 comprises SEQ ID NO: 5. In some embodiments, the nucleic acid sequence encoding P2A comprises SEQ ID NO: 8. In some embodiments, the P2A comprises the amino acid sequence of SEQ ID NO: 9. In some embodiments, the T2A comprises the amino acid sequence of SEQ ID NO: 11.

[0019] In some embodiments, the nucleic acid sequence encoding T2A is GAGGGCAGGGGAAGTCTTCTAA-CATGCGGGGACGTGGAGGAAAATCCGGGCCA (SEQ ID NO: 10).

[0020] In some embodiments, the TRE promoter sequence is SEQ ID NO: 7.

[0021] In some embodiments, the SV-40-derived terminator sequence is SEQ ID NO: 12.

[0022] In some embodiments, the first ITR sequence is SEQ ID NO: 16.

[0023] In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises SEQ ID NO: 13.

[0024] In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises SEQ ID NO: 14.

[0025] In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the nucleic acid molecule encoding rtTA are administered sequentially or simultaneously.

[0026] In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 is administered intravitreally.

[0027] In some embodiments, the nucleic acid molecule encoding the rtTA is administered intravitreally.

[0028] In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the nucleic acid molecule encoding rtTA are administered at a ratio of about 1:1.

[0029] In some embodiments, the AAV vector comprising the nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising the nucleic acid molecule encoding rtTA are administered at a ratio of about 1:1 (vg:vg).

[0030] In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 is AAV2-TRE-OSK vector and the nucleic acid molecule encoding rtTA is AAV2-CMV-rtTA3 or AAV2-CMV-rtTA4.

[0031] In some embodiments, the effective amount of the AAV2-TRE-OSK vector is in the range of from about 1×10^9 vg/eye to about 1×10^{14} vg/eye.

[0032] In some embodiments, the effective amount of the AAV2-CMV-rtTA3 vector is in the range of from about 1×10^9 vg/eye to about 1×10^{14} vg/eye.

[0033] In some embodiments, the effective amount of the AAV2-CMV-rtTA4 vector is in the range of from about 1×10^9 vg/eye to about 1×10^{14} vg/eye.

[0034] In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 is administered to the subject by oculus sinister (OS) injection, by oculus dexter (OS) injection, or by oculus uterque (OU) injection.

[0035] In some embodiments, the nucleic acid molecule encoding rtTA is administered to the subject by oculus sinister (OS) injection, by oculus dexter (OS) injection, or by oculus uterque (OU) injection.

[0036] In some embodiments, the methods further comprise administering to the subject an effective amount of an antibiotic. In some embodiments, the antibiotic is administered at least one day prior to administering the nucleic acid molecule encoding rtTA. In some embodiments, the antibiotic is administered when the nucleic acid molecule encoding rtTA is administered. In some embodiments, the antibiotic is administered at least one day following administration of the nucleic acid molecule encoding rtTA.

[0037] In certain aspects, provided herein are methods for recombinant preparation of an AAV, the method comprising introducing a vector into a cell under conditions whereby the AAV is produced, wherein the vector comprises one or more nucleic acid sequences encoding a) OCT4, SOX2, and KLF4. In some embodiments, the cell comprises a population of HEK293T cells.

[0038] Further provided herein are methods of generating an AAV comprising modifying a cell to express one or more plasmids comprising: one or more AAV2 Rep-Cap plasmids, one or more helper plasmids, and one or more transfer plasmids, wherein the one or more transfer plasmids comprise one or more nucleic acids encoding OCT4, SOX2, and KLF4. In some embodiments, the cell comprises a population of HEK293T cells.

[0039] In certain aspects, provided herein are methods for preventing or treating non-arteritic anterior ischemic optic neuropathy (NAION) in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of a composition comprising an expression vector comprising a polynucleotide encoding OCT4, SOX2, and KLF4, but not c-Myc. In some embodiments, the polynucleotide further does not encode one or more transcription factors, such as Nanog.

[0040] In certain aspects, provided herein are methods for preventing or treating non-arteritic anterior ischemic optic neuropathy (NAION) in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of a composition comprising an expression vector encoding three transcription factors, wherein the transcription factors consist of OCT4, SOX2, and KLF4.

[0041] In certain aspects, provided herein are methods for preventing or treating non-arteritic anterior ischemic optic neuropathy (NAION) in a subject in need thereof, the method comprising administering to the subject a composition comprising an expression vector comprising a polynucleotide encoding four or more transcription factors, wherein the transcription factors comprise OCT4, SOX2, and KLF4, but not c-Myc. In some embodiments, the

polynucleotide further does not encode one or more transcription factors, such as Nanog.

[0042] In some embodiments, the composition does not reprogram the cell, tissue, or organ to a pluripotent state in the subject. In some embodiments, the composition rejuvenates at least one cell, tissue, or organ in the subject. In some embodiments, the composition does not induce c-Myc expression in the subject. In some embodiments, the composition does not induce expression of one or more transcription factors (e.g., Nanog) in the subject. In some embodiments, the composition does not induce expression of at least one stem cell marker in the subject. Such at least one stem cell marker may comprise Esrrb, Nanog, Lin28, TRA-1-60/TRA-1-81/TRA-2-54, SSEA1, SSEA4, or any combination thereof. In some embodiments, the composition induces expression of RBPMS, Bm3a, or a combination thereof in the subject. In some embodiments, rejuvenating at least one cell, tissue, or organ comprises increasing repair and/or regeneration in the cell, tissue, or organ. In some embodiments, rejuvenating at least one cell, tissue, or organ comprises restoring epigenetic information in the subject. In some embodiments, rejuvenating at least one cell, tissue, or organ comprises restoring epigenetic information lost due to aging, injury, disease, or any combination thereof in the cell, tissue, or organ. In some embodiments, rejuvenating at least one cell, tissue, or organ comprises reestablishing the epigenetic status of the cell, tissue, or organ to an epigenetic status closer to fertilization or final differentiation. In some embodiments, rejuvenating at least one cell, tissue, or organ comprises increasing the number of healthy axons in the subject. In some embodiments, rejuvenating at least one cell, tissue, or organ comprises preventing damages to healthy axons in the subject.

[0043] In some embodiments, the polynucleotide comprises DNA, RNA, or a combination thereof. In some embodiments, the DNA comprises a plasmid DNA. In some embodiments, the RNA comprises an mRNA. In some embodiments, the polynucleotide comprises an inducible promoter, such as a TRE3G promoter, a TRE2 promoter, a P tight promoter, and a tetracycline response element (TRE).

[0044] In some embodiments, the methods described herein further comprises administering to the subject an inducing agent to induce expression of OCT4, SOX2, and KLF4 in the subject. In some embodiments, the inducing agent comprises a tetracycline class antibiotic, such as doxycycline. In some embodiments, the inducing agent comprises a reverse tetracycline-controlled transactivator (rtTA) or a polynucleotide encoding the rtTA. In some embodiments, the polynucleotide encoding the rtTA is in an expression vector.

[0045] In some embodiments, the composition and the inducing agent is administered sequentially or simultaneously. In some embodiments, the composition is administered prior to administering the inducing agent. In some embodiments, the composition is administered after administering the inducing agent. In some embodiments, the composition is administered simultaneously with the inducing agent.

[0046] In some embodiments, the composition and the inducing agent is administered at a ratio of about 100:1, 50:1, 40:1, 30:1, 25:1, 20:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:20, 1:25, 1:30, 1:40, 1:50 or 1:100. In some embodiments, the composition and the inducing agent is administered at a ratio

of more than about 100:1. In some embodiments, the composition and the inducing agent is administered at a ratio of less about 1:100. In some embodiments, the composition and the inducing agent is administered at a ratio of about 1:1.

[0047] In some embodiments, the polynucleotide comprises a self-cleaving peptide, such as a 2A peptide.

[0048] In some embodiments, the polynucleotide comprises inverted terminal repeats (ITRs).

[0049] In some embodiments, the expression vector is a viral expression vector selected from a lentivirus, a retrovirus, an adenovirus, alphavirus, vaccinia virus, and an adeno-associated virus (AAV) vector. In some embodiments, the AAV vector is serotype-2 (AAV2).

[0050] In some embodiments, the polynucleotide comprises nucleic acid elements in the following order:

[0051] a. a first inverted terminal repeat sequence (ITR) sequence;

[0052] b. a TRE3G promoter sequence;

[0053] c. an OCT4 sequence;

[0054] d. a P2A cleavage sequence;

[0055] e. a SOX2 sequence;

[0056] f. a T2A cleavage sequence;

[0057] g. a KLF4 sequence;

[0058] h. an SV-40-derived terminator sequence; and

[0059] i. a second inverted terminal repeat (ITR) sequence.

[0060] In some embodiments,

[0061] i) OCT4 comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, identity to SEQ ID NO: 2;

[0062] ii) SOX2 comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, identity to SEQ ID NO: 4; and/or

[0063] iii) KLF4 comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, identity to SEQ ID NO: 6.

[0064] In some embodiments,

[0065] i) OCT4 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 2;

[0066] ii) SOX2 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 4; and/or

[0067] iii) KLF4 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 6.

[0068] In some embodiments,

[0069] i) OCT4 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 2;

[0070] ii) SOX2 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 4; and/or

[0071] iii) KLF4 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 6.

[0072] In some embodiments,

[0073] i) OCT4 comprises the amino acid sequence of SEQ ID NO: 2;

[0074] ii) SOX2 comprises the amino acid sequence of SEQ ID NO: 4; and/or

[0075] iii) KLF4 comprises the amino acid sequence of SEQ ID NO: 6.

[0076] In some embodiments,

[0077] i) the polynucleotide comprises a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%,

- 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, identity to SEQ ID NO: 1;
- [0078] ii) the polynucleotide comprises a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, identity to SEQ ID NO: 3; and/or
- [0079] iii) the polynucleotide comprises a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, identity to SEQ ID NO: 5.
- [0080] In some embodiments,
- [0081] i) the polynucleotide comprises a nucleic acid sequence having at least 75% identity to SEQ ID NO: 1;
- [0082] ii) the polynucleotide comprises a nucleic acid sequence having at least 75% identity to SEQ ID NO: 3; and/or
- [0083] iii) the polynucleotide comprises a nucleic acid sequence having at least 75% identity to SEQ ID NO: 5.
- [0084] In some embodiments,
- [0085] i) the polynucleotide comprises a nucleic acid sequence having at least 90% identity to SEQ ID NO: 1;
- [0086] ii) the polynucleotide comprises a nucleic acid sequence having at least 90% identity to SEQ ID NO: 3; and/or
- [0087] iii) the polynucleotide comprises a nucleic acid sequence having at least 90% identity to SEQ ID NO: 5.
- [0088] In some embodiments,
- [0089] i) the polynucleotide comprises a nucleic acid sequence of SEQ ID NO: 1;
- [0090] ii) the polynucleotide comprises a nucleic acid sequence of SEQ ID NO: 3; and/or
- [0091] iii) the polynucleotide comprises a nucleic acid sequence of SEQ ID NO: 5.
- [0092] In some embodiments, the composition is administered systematically. In some embodiments, the composition is administered locally to a tissue or organ. In some embodiments, the composition is administered intravitreally. In some embodiments, the composition is administered to the subject by oculus sinister (OS) injection, by oculus dexter (OD) injection, or by oculus uterque (OU) injection.
- [0093] In some embodiments, administering the composition improves retinal ganglion cell (RGC) function and/or restores visual function in the subject.
- [0094] In some embodiments, the preventing or treating NAION is measurable by electroretinogram (pERG). In some embodiments, the preventing or treating NAION is measured by electroretinogram (pERG).

BRIEF DESCRIPTION OF THE DRAWINGS

- [0095] The summary, as well as the following detailed description, is further understood when read in conjunction with the appended drawings. For the purpose of illustrating the disclosed methods, there are shown in the drawings exemplary embodiments thereof; however, the methods are not limited to the specific embodiments disclosed. In the drawings:
- [0096] FIGS. 1A and 1B depict results from pattern electroretinogram (pERG) measurements showing induction of nonarteritic anterior ischemic optic neuropathy (NAION) results in decreased pERG signal. The pERG uses contrast

reversing pattern stimuli (checkerboards) to assess macular retinal ganglion cell (RGC) activity. Changes in the pERG waveform are indicative of RGCs dysfunctions. FIG. 1A shows pERG data from both left (OS) and right (OD) eyes from experiments where the right eye received no treatment and the left eye was treated with vehicle (phosphate-buffered saline (PBS)) and subjected to induction of the NAION injury. Results show laser-induced decrease in peak amplitude (the left panel) and the absolute amplitude (the right panel) that is similar to that seen in NAION and is indicative of retinal ganglion cell (RGC) dysfunction. FIG. 1B shows pERG data from both left (OS) and right (OD) eyes from experiments where the right eye received no treatment (contralateral eye) and the left eye was injured with laser and administered the vehicle 1 day post-injury. Results show significant decreases in p50 amplitude (the left panel) and absolute amplitude from p50 to n95 (the right panel) indicating impairment of retinal ganglion cell (RGC) function.

[0097] FIG. 2 is an illustrative vector map of TRE3G-OSK-SV40pA, an AAV2 vector encoding OSK (SEQ ID NO: 15).

[0098] FIG. 3 depicts an illustrative vector map of pAAV2-CMV-rtTA3(VP16) (SEQ ID NO: 21). This vector is a non-limiting example of a vector encoding rtTA.

[0099] FIG. 4 depicts an illustrative vector map of pAAV2-CMV-rtTA4 (SEQ ID NO: 28). This vector is a non-limiting example of a vector encoding rtTA.

[0100] FIG. 5 depicts a schematic showing a non-limiting example of a Tet-ON system to express OCT4, SOX2, and KLF4 (OSK) in the presence of a tetracycline.

[0101] FIG. 6 depicts a schematic comparing the p50 peak amplitude (the left panel) or the absolute amplitude from p50 to n95 (the right panel) when treated with vehicle (the left bar at each time point) or OSK (controlled by Dox; as Tet-on system; the right bar at each time point) before laser treatment (i.e., prevention study). pERG signals were measured at different days and compared under different treatment.

[0102] FIG. 7 depicts a schematic comparing the p50 peak amplitude (the left panel) or the absolute amplitude from p50 to n95 (the right panel) when treated with vehicle (the left bar at each time point) or OSK (controlled by Dox; as Tet-on system; the right bar at each time point) after laser treatment (i.e., rescue study). pERG signals were measured at different days and compared under different treatment.

[0103] FIG. 8 depicts optic nerve myelin-specific axon stain microscopy results, which are used for axon counting by using AxonNet, for control (“no injury”; no laser treatment), or laser treatment followed by vehicle or OSK treatment.

[0104] FIG. 9 depicts illustrative axon-counting results, from experiments as described in FIG. 8. Median values (middle bars) and interquartile ranges (top and bottom bars) are shown for each treatment/control.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

- [0105] The disclosed methods may be understood more readily by reference to the following detailed description taken in connection with the accompanying figures, which form a part of this disclosure. It is to be understood that the disclosed methods are not limited to the specific methods described and/or shown herein, and that the terminology used herein is for the purpose of describing particular

embodiments by way of example only and is not intended to be limiting of the claimed methods.

[0106] Unless specifically stated otherwise, any description as to a possible mechanism or mode of action or reason for improvement is meant to be illustrative only, and the disclosed methods are not to be constrained by the correctness or incorrectness of any such suggested mechanism or mode of action or reason for improvement.

[0107] Throughout this text, the description refers to compositions and methods of using the compositions. Where the disclosure describes or claims a feature or embodiment associated with a composition, such a feature or embodiment is equally applicable to the methods of using the composition. Likewise, where the disclosure describes or claims a feature or embodiment associated with a method of using a composition, such a feature or embodiment is equally applicable to the composition.

[0108] It is to be appreciated that certain features of the disclosed methods which are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosed methods that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination.

[0109] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the disclosed methods. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0110] The terms "comprise(s)," "include(s)," "having," "has," "can," "contain(s)," and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The term "comprising" is

intended to include examples encompassed by the terms “consisting essentially of” and “consisting of”; similarly, the term “consisting essentially of” is intended to include examples encompassed by the term “consisting of.” The present disclosure also contemplates other embodiments “comprising,” “consisting of,” and “consisting essentially of” the embodiments or elements presented herein, whether explicitly set forth or not.

[0111] The singular forms “a,” “and” and “the” include plural references unless the context clearly dictates otherwise.

[0112] For recitation of numeric ranges herein, each intervening number therebetween with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.

[0113] Some of the quantitative expressions given herein are not qualified with the term "about." It is understood that, whether the term "about" is used explicitly or not, every quantity given is intended to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such value.

[0114] “AAV” or “adeno-associated virus” is a nonenveloped virus that is capable of carrying and delivering nucleic acids (e.g., engineered nucleic acids encoding OCT4; KLF4; SOX2; or any combination thereof) and belongs to the genus Dependoparvovirus. In some instances, an AAV is capable of delivering a nucleic acid encoding an inducing agent. In general, AAV does not integrate into the genome. The tissue-specific targeting capabilities of AAV is often determined by the AAV capsid serotype (see, e.g., Table 1 below for examples of AAV serotypes and their utility in tissue-specific delivery). Non-limiting serotypes of AAV include AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10, AAV11, and variants thereof. In certain embodiments, the AAV serotype is a variant of AAV9 (e.g., AAV PHP.b).

TABLE 1

TABLE 1-continued

Non-limiting Examples of AAV Serotypes and their Use in Specific Tissues									
AAV Serotype	Relevant Tissue								
	Muscle (e.g., Skeletal Muscle)			Central Nervous System (CNS)		Central Nervous System (Blood-brain barrier)		Immune System (T-cells, B-cells and Dendritic Cells)	
	Liver	Heart	Muscle	Eye		Pancreas	Lung		
AAV10 (e.g., AAVrh10)	X	X	X	X	X	X	X	X	
AAVDJ	X		X		X				
AAVPHP.B					X	X			

[0115] A “recombinant virus” is a virus (e.g., lentivirus, adenovirus, retrovirus, herpes virus, alphavirus, vaccinia virus or adeno-associated virus (AAV)) that has been isolated from its natural environment (e.g., from a host cell, tissue, or a subject) or is artificially produced.

[0116] The term “AAV vector” as used herein is a nucleic acid that comprises AAV inverted terminal repeats (ITRs) flanking an expression cassette (e.g., an expression cassette comprising a nucleic acid encoding OCT4, KLF4, and SOX2, each alone or in combination, or an expression cassette encoding rtTA or tTA). An AAV vector may further comprise a promoter sequence.

[0117] The terms “administer,” “administering,” or “administration,” as used herein refers to introduction of any of the compositions described herein; any of the nucleic acids capable of inducing OCT4, KLF4, and/or SOX2 expression; any of the nucleic acids capable of inducing expression of one or more transcription factors selected from the group consisting of OCT4, KLF4, SOX2, and any combinations thereof; any of the engineered proteins described herein; any of the chemical agents activating (e.g., inducing expression of) OCT4, KLF4, and/or SOX2; any of the chemical agents activating (e.g., inducing expression of) one or more transcription factors selected from OCT4, KLF4, SOX2, and any combinations thereof; any of the antibodies activating (e.g., inducing expression of) OCT4, KLF4, and/or SOX2, and any combinations thereof; and/or any of the recombinant viruses (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV) described herein, alone, or in combination to any cell, tissue, organ, and/or subject. In some embodiments, a nucleic acid encoding an inducing agent, an engineered protein encoding an inducing agent, a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of an inducing agent, and/or a recombinant virus encoding an inducing agent is also administered to the cell, tissue, organ and/or subject. Any of the compositions described herein, comprising any of the nucleic acids capable of inducing expression of one or more transcription factors selected from OCT4, KLF4, SOX2, and any combinations thereof; any of the chemical agents activating (e.g., inducing expression of, e.g., tetracycline) OCT4, KLF4, and/or SOX2; any of the engineered proteins encoding OCT4, SOX2, KLF4, or any combinations thereof; any of the chemical agents activating (e.g., inducing expression of, e.g., tetracycline) OCT4, KLF4, SOX2, or any combination thereof; any of the antibodies activating (e.g., inducing expression of) OCT4, KLF4, and/

or SOX2; and/or any of the recombinant viruses (e.g., lentivirus, adenovirus, alphavirus, vaccinia virus, retrovirus, herpes virus, or AAV) described herein, alone, or in combination may be administered intravitreally, intraocularly, subconjunctivally, or subretinally. In other aspects, administration can be intravenously, intradermally, intraarterially, intralesionally, intratumorally, intracranially, intraarticularly, intraprostaticaly, intrapleurally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctival, intravesicularily, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, systemically, injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, in creams, in lipid compositions (e.g., liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences (1990), incorporated herein by reference). In some embodiments, a composition comprising a nucleic acid encoding an inducing agent, an engineered protein encoding an inducing agent, a chemical agent capable of modulating (e.g., activating or inhibiting) the activity of an inducing agent, and/or a recombinant virus encoding an inducing agent is also administered to the cell, tissue, organ and/or subject using any suitable method such as intravitreally, intraocularly, subconjunctivally, or subretinally.

[0118] As used herein, the term “cell” is meant not only to include an individual cell but refers also to the particular tissue or organ from which it originates.

[0119] The term “gene expression” refers to the degree to which certain genes or all genes in a cell or tissue are transcribed into RNA. In some instances, the RNA is translated by the cell into a protein. The epigenome dictates gene expression patterns.

[0120] The terms “condition,” “disease,” and “disorder” are used interchangeably. As used herein, an “ocular disease” or “eye disease” is a disease or condition of the eye. An example of an ocular disease is Non-arteritic anterior ischemic optic neuropathy.

[0121] Any suitable method may be used to measure ocular function. Non-limiting examples include visual acuity tests, pattern electroretinograms (pERGs), and pathology.

[0122] “Cellular causes of aging” as used herein include loss or modification of epigenetic information.

[0123] The terms “c-Myc” or “Myc” refer to a nuclear phosphoprotein that has been implicated in cell cycle pro-

gression. c-Myc is capable of forming a heterodimer with the transcription factor MAX and the heterodimer is capable of binding to an E box consequence sequence on nucleic acids (e.g., engineered nucleic acids) to regulate transcription of target genes. In certain embodiments, a nucleotide sequence encoding c-Myc comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a sequence as described in the NCBI RefSeq database under accession number NM_001354870.1 or NM_002467.5. In certain embodiments, an amino acid sequence encoding c-Myc comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NP_002458.2 or NP_001341799.1. In certain embodiments, the methods comprise inducing expression of OCT4; KLF4; SOX2; or any combination thereof in the absence of inducing c-Myc expression or in the absence of activating c-Myc. Absence of inducing c-Myc expression may refer to absence of substantial induction of c-Myc expression over endogenous levels of c-Myc expression in a cell, tissue, subject, or any combination thereof. Absence of substantial induction of c-Myc expression as compared to endogenous levels of c-Myc expression in a cell, tissue, subject, or any combination thereof, may refer to increasing c-Myc expression by less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or any values in between as compared to endogenous levels of c-Myc expression in the cell, tissue, subject, or any combination thereof. Absence of activating c-Myc expression may refer to absence of substantial activation of c-Myc (e.g., activity) over endogenous c-Myc activity in a cell, tissue, subject, or any combination thereof. Absence of substantial induction of c-Myc activity as compared to endogenous c-Myc activity in a cell, tissue, subject, or any combination thereof, may refer to increasing c-Myc activity by less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or any values in between as compared to endogenous c-Myc activity in the cell, tissue, subject, or any combination thereof.

[0124] The terms “effective amount” and “therapeutically effective amount,” as used herein, refer to the amount of a compound or composition, that, when administered to a subject, is effective to at least partially treat a condition from which the subject is suffering.

[0125] As used herein, a protein that is “functional” or “active” is one that retains its biological activity (e.g., capable of acting as a transcription factor or as an inducing agent). Conversely, a protein that is not functional or is inactive is one that is not capable of performing one or more of its wild-type functions.

[0126] The term “gene” refers to a nucleic acid fragment that expresses a protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” or “chimeric construct” refers to any gene or a construct, not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene or chimeric construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene

in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but which is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

[0127] “Homolog” or “homologous” refers to sequences (e.g., nucleic acid or amino acid sequences) that share a certain percent identity (e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% percent identity). Homologous sequences include but are not limited to paralogous or orthologous sequences. Paralogous sequences arise from duplication of a gene within a genome of a species, while orthologous sequences diverge after a speciation event. A functional homolog retains one or more biological activities of a wild-type protein. In certain embodiments, a functional homolog of OCT4, KLF4, or SOX2 retains at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% of the biological activity (e.g., transcription factor activity) of a wild-type counterpart.

[0128] “KLF4” may also be referred to as Kruppel-like factor 4, EZF, or GKLF and is a zinc-finger transcription factor. KLF4 has been implicated in regulation of differentiation and proliferation and is capable of interacting with co-activators, including members of the p300-CBP co-activator family. A KLF4 transcription factor, homolog (e.g., functional homolog), or variant thereof, as used herein, may be derived from any species, including humans. In certain embodiments, the nucleic acid encoding human KLF4 comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid described in the NCBI RefSeq database under accession number NM_004235.5 or NM_001314052.1. Non-limiting examples of KLF4 variants include Kruppel-like factor 4 transcript variant 1 and Kruppel-like factor 4 transcript variant 2. In certain embodiments, KLF4 is encoded by a nucleic acid molecule comprising a nucleic acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 5. SEQ ID NO: 5 is a non-limiting example of a nucleotide sequence encoding human KLF4. In certain embodiments, KLF4 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to NP_001300981.1 or NP_004226.3. In certain embodiments, KLF4 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 6. SEQ ID NO: 6 is a non-limiting example of an amino acid sequence of human KLF4.

[0129] “Inverted terminal repeats” or “ITRs” are nucleic acid sequences that are reverse complements of one another. In general, in an AAV vector, ITRs are found on either side of a cassette (e.g., an expression cassette comprising a

nucleic acid encoding OCT4; KLF4; SOX2; or any combination thereof). For example, the ITRs flanking the OSK cassette may comprise SEQ ID NOs: 16 and 32. Similarly, in some instances, the AAV2-CMV-rtTA3 vector disclosed herein can include ITRs comprising SEQ ID NOs: 22 and 33, and the AAV2-CMV-rtTA4 vector disclosed herein can include ITRs comprising SEQ ID NOs: 29 and 34. In some instances, the cassette encodes an inducing agent. AAV ITRs include ITRs from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10, AAV11, and AAV variants thereof.

[0130] The terms "nucleic acid," "polynucleotide", "nucleotide sequence", "nucleic acid molecule", "nucleic acid sequence", and "oligonucleotide" refer to a series of nucleotide bases (also called "nucleotides") in DNA and RNA, and mean any chain of two or more nucleotides. These terms include double- or single-stranded genomic and cDNA, RNA, any synthetic and genetically manipulated polynucleotide, and both sense and antisense polynucleotides. This includes single- and double-stranded molecules, i.e., DNA-DNA, DNA-RNA and RNA-RNA hybrids.

[0131] The nucleic acids described herein may be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as those that are commercially available from Biosearch, Applied Biosystems, etc.). Such DNA sequences may be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. A vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of the nucleic acid molecule. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence can be by any promoter known in the art to act in mammalian, preferably human, cells. Such promoters can be inducible or constitutive. Any type of plasmid, cosmid, yeast artificial chromosome, or viral vector can be used to prepare the recombinant DNA construct that can be administered to the subject.

[0132] The nucleic acid molecules may include natural regulatory (expression control) sequences or may be associated with heterologous sequences, including promoters, internal ribosome entry sites (IRES) and other ribosome binding site sequences, enhancers, response elements, suppressors, signal sequences, polyadenylation sequences, introns, 5'- and 3"-non-coding regions, and the like. A "recombinant nucleic acid molecule" or "engineered nucleic acid molecule" is a nucleic acid molecule that has undergone a molecular biological manipulation, i.e., non-naturally occurring nucleic acid molecule or genetically engineered nucleic acid molecule. Furthermore, the terms "recombinant DNA molecule" or "engineered nucleic acid" refer to a nucleic acid sequence which is not naturally occurring, or can be made by the artificial combination of two otherwise separated segments of nucleic acid sequence, i.e., by ligating together pieces of DNA that are not normally contiguous. By "recombinantly produced" is meant artificial combination often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques using restriction enzymes, ligases, and similar recombinant techniques as

described by, for example, Sambrook et al, Molecular Cloning, second edition, Cold Spring Harbor Laboratory, Plainview, N.Y.; (1989), or Ausubel et al, Current Protocols in Molecular Biology, Current Protocols (1989), and DNA Cloning: A Practical Approach, Volumes I and II (ed. D. N. Glover) IREL Press, Oxford, (1985); each of which is incorporated herein by reference.

[0133] Such manipulation may be done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it may be performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in nature. Restriction enzyme recognition sites are often the target of such artificial manipulations, but other site-specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, open reading frames, or other useful features may be incorporated by design.

[0134] "OCT4" may also be referred to as Octamer-binding transcription factor 4, OCT3, OCT3/4, POU5F1, or POU class 5 homeobox 1 and is a transcription factor that has been implicated in embryonic development and determination of cell fate. Similar to other OCT transcription factors, OCT4 is characterized by a bipartite DNA binding domain called a POU domain. An OCT4 transcription factor, homolog, or variant thereof, as used herein, may be derived from any species, including humans. In certain embodiments, the nucleic acid encoding human OCT4 is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid described in the NCBI RefSeq under accession number NM_002701, NM_203289, NM_001 173531, NM_001285986, or NM_001285987. In certain embodiments, the nucleic acid molecule encoding a human OCT4 comprises a nucleic acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid sequence provided as SEQ ID NO: 1. SEQ ID NO: 1 is a non-limiting example of a nucleotide sequence encoding human OCT4. Non-limiting examples of OCT4 variants encompassed herein include POU5F1, transcript variant 1, POU5F1, transcript variant 2, POU5F1, transcript variant 3, POU5F1, transcript variant 4, and POU5F1 transcript variant 5. In certain embodiments, the nucleic acid molecule encodes an OCT4 comprising an amino acid sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to an amino acid sequence described in the NCBI RefSeq under accession number NP_001167002.1, NP_001272915.1, NP_001272916.1, NPJ302692.2, or NP_976034.4. In certain embodiments, the nucleic acid molecule encodes an OCT4 comprising an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 2. SEQ ID NO: 2 is a non-limiting example of an amino acid sequence of human OCT4. Other OCT4 transcription factors (e.g., from other species) are known and nucleic acids encoding OCT4 transcription factors can be found in publicly available databases, including GenBank.

[0135] The term "promoter" refers to a control region of a nucleic acid sequence at which initiation and rate of transcription of the remainder of a nucleic acid sequence are controlled. A promoter may also contain sub-regions at which regulatory proteins and molecules may bind, such as RNA polymerase and other transcription factors. Promoters

may be constitutive, inducible, activatable, repressible, tissue-specific, or any combination thereof. A promoter drives expression or drives transcription of the nucleic acid sequence that it regulates. Herein, a promoter is considered to be “operably linked” when it is in a correct functional location and orientation in relation to a nucleic acid sequence it regulates to control (“drive”) transcriptional initiation of that sequence, expression of that sequence, or a combination thereof.

[0136] A promoter may promote ubiquitous expression or tissue-specific expression of an operably linked nucleic acid sequence from any species, including humans. In some embodiments, the promoter is a eukaryotic promoter. Non limiting examples of eukaryotic promoters include TDH3, PGK1, PKC1, TDH2, PYK1, TPI1, AT1, CMV, EF1 alpha, SV40, PGK1 (human or mouse), Ube, human beta actin, CAG, TRE, UAS, Ac5, Polyhedrin, CaMKIIa, GAL1, GAL10, TEF1, GDS, ADH1, CaMV35S, Ubi, H1, and U6, as would be known to one of ordinary skill in the art (see, e.g., Addgene website: blog.addgene.org/plasmids-101-the-promoter-region).

[0137] Non-limiting examples of ubiquitous promoters include tetracycline-responsive promoters (under the relevant conditions), CMV (e.g., SEQ ID NO: 17), EF1 alpha, a SV40 promoter, PGK1, Ube, CAG, human beta actin gene promoter, a RSV promoter, an EFS promoter, and a promoter comprising an upstream activating sequence (UAS). In certain embodiments, the promoter is a mammalian promoter.

[0138] Non-limiting examples of tissue-specific promoters include eye-specific promoters. Non-limiting examples of eye-specific promoters include human GRK1 (rhodopsin kinase) promoter, human CRX (cone rod homeobox transcription factor) promoter, and human NRL promoter (neural retina leucine zipper transcription factor enhancer upstream of the human TK terminal promoter).

[0139] In some embodiments, a promoter of the present disclosure is suitable for use in AAV vectors. See, e.g., U.S. Patent Application Publication No. 2018/0155789, which is hereby incorporated by reference in its entirety for this purpose.

[0140] Non-limiting examples of constitutive promoters include CP1, CMV, EF1 alpha, SV40, PGK1, Ube, human beta actin, beta tubulin, CAG, Ac5, Rosa26 promoter, COL1A1 promoter, polyhedrin, TEF1, GDS, CaM3 5S, Ubi, H1, U6, red opsin promoter (red promoter), rhodopsin promoter (rho promoter), cone arrestin promoter (car promoter), rhodopsin kinase promoter (rk promoter). In some instances, the constitutive promoter is a Rosa26 promoter. In some instances, the constitutive promoter is a COL1A1 promoter. A tissue-specific promoter may be used to drive expression of an engineered nucleic acid, including e.g., a nucleic acid encoding a rtTA, tTA, OCT4, KLF4, SOX2, or any combination thereof. In some embodiments, a tissue-specific promoter is used to drive expression of a rtTA or a tTA. In some embodiments, a tissue-specific promoter is used to drive expression of OCT4, KLF4, and SOX2. In some embodiments, the SV40 promoter is used to drive expression of OCT4, KLF4, and SOX2.

[0141] “Tetracycline” refers to the tetracycline class of antibiotic compounds that includes, but is not limited to, tetracycline, chlortetracycline, oxytetracycline, demeclocycline, lymecycline, mecloxycline, methacycline, minocycline, rolitetracycline, doxycycline, tigecycline, eravacycline, sarecycline, and omadacycline.

[0142] An “inducible promoter” is one that is characterized by initiating or enhancing transcriptional activity when in the presence of, influenced by, or contacted by an inducing agent. An inducing agent may be endogenous or a normally exogenous condition, compound, agent, or protein that contacts an engineered nucleic acid in such a way as to be active in inducing transcriptional activity from the inducible promoter. In certain embodiments, an inducing agent is a tetracycline-sensitive protein (e.g., tTA or rtTA, TetR family regulators).

[0143] Inducible promoters for use in accordance with the present disclosure include any inducible promoter described herein or known to one of ordinary skill in the art. Examples of inducible promoters include, without limitation, chemically/biochemically-regulated and physically-regulated promoters such as alcohol-regulated promoters, tetracycline-regulated promoters (e.g., anhydrotetracycline (aTc)-responsive promoters and other tetracycline responsive promoter systems, which include a tetracycline repressor protein (TetR, or TetRKRB), a tetracycline operator sequence (tetO) and a tetracycline transactivator fusion protein (tTA), and a tetracycline operator sequence (tetO) and a reverse tetracycline transactivator fusion protein (rtTA)), steroid-regulated promoters (e.g., promoters based on the rat glucocorticoid receptor, human estrogen receptor, moth ecdisone receptors, and promoters from the steroid/retinoid/thyroid 25 receptor superfamily), metal-regulated promoters (e.g., promoters derived from metallothionein (proteins that bind and sequester metal ions) genes from yeast, mouse and human), pathogenesis-regulated promoters (e.g., induced by salicylic acid, ethylene or benzothiadiazole (BTH)), temperature/heat-inducible promoters (e.g., heat shock promoters), pH-regulated promoters, and light-regulated promoters. A non-limiting example of an inducible system that uses a light-regulated promoter is provided in Wang et al, Nat. Methods. 2012 Feb. 12; 9(3):266-9.

[0144] In certain embodiments, an inducible promoter comprises a tetracycline (Tet)-responsive element. For example, an inducible promoter may be a TRE3G promoter (e.g., a TRE3G promoter that comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 7). As an example, a TRE (e.g., TRE2) promoter may comprise a nucleic acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 7.

[0145] Additional non-limiting examples of inducible promoters include mifepristone-responsive promoters (e.g., GAL4-Elb promoter) and coumermycin-responsive promoters. See, e.g., Zhao et al., Hum Gene Ther. 2003 Nov. 20; 14(17):1619-29.

[0146] A “reverse tetracycline transactivator” (“rtTA”), as used herein, is an inducing agent that binds to a TRE promoter (e.g., a TRE3G, a TRE2 promoter, or a P tight promoter) in the presence of a tetracycline (e.g., doxycycline) and is capable of driving expression of a transgene that is operably linked to the TRE promoter. rtTAs generally comprise a mutant tetracycline repressor DNA binding protein (TetR) and a transactivation domain (see, e.g., Gossen et al, Science. 1995 Jun. 23; 268(5218): 1766-9 and any of the transactivation domains listed herein). The mutant TetR domain is capable of binding to a TRE promoter when

bound to tetracycline. See, e.g., US Publ. Appl. No. 2021-0403923 A, and the International Publ. No. WO2020/069339, entitled MUTANT REVERSE TETRACYCLINE TRANSACTIVATORS FOR EXPRESSION OF GENES, each of which is herein incorporated by reference in its entirety.

[0147] “SRY-box 2” or “SOX2” is a member of the SRY-related HMG-box (SOX) family of transcription factors. SOX2 has been implicated in promoting embryonic development. Members of the SOX (SRY-related HMG-box) family of transcription factors are characterized by a high mobility group 5 (HMG)-box DNA sequence. This HMG box is a DNA binding domain that is highly conserved throughout eukaryotic species. A SOX2 transcription factor, homolog or variant thereof, as used herein, may be derived from any species, including humans. In certain embodiments, the nucleic acid molecule encoding SOX2 comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid described in the NCBI RefSeq under accession number NM_01 1443.4. In certain embodiments, the nucleic acid molecule encoding a human SOX2 comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to a nucleic acid molecule described in the NCBI RefSeq under accession number NM_003106.4. SEQ ID NO: 3 is a non-limiting example of a nucleotide sequence encoding human SOX2. In certain embodiments, the nucleic acid molecule encoding human SOX2 comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 3. According to some embodiments, the nucleic acid molecule encodes a SOX2 comprising an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to the amino acid sequence described in the NCBI RefSeq under accession number NP_003097.1. According to some embodiments, the nucleic acid molecule encodes a SOX2 comprising the amino acid sequence described in the NCBI RefSeq under accession number NP_003097.1. In some instances, the nucleic acid molecule encodes a SOX2 comprising an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 4. SEQ ID NO: 4 is a non-limiting example of an amino acid sequence of human SOX2.

[0148] A “multicistronic vector” is a vector that encodes more than one amino acid sequence (e.g., a vector encoding OCT4 and KLF4, OCT4 and SOX2, KLF4 and SOX2, or OCT4, SOX2, and KL4 (OSK)). A multicistronic vector allows for expression of multiple amino acid sequences from a nucleic acid sequence. Nucleic acid sequences encoding each transcription factor (e.g., OCT4, KLF4, or SOX2) may be connected or separated such that they produce unconnected proteins. For example, internal ribosome entry sites (IRES) or polypeptide cleavage signals may be placed between nucleic acid sequences encoding each transcription factor in a vector. Exemplary polypeptide cleavage signals include 2A peptides (e.g., T2A, P2A, E2A, and F2A). A T2A peptide may comprise a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 10. A P2A peptide may comprise a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 8.

[0149] In some embodiments, an expression vector of the present disclosure is a multicistronic expression vector.

[0150] A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) and/or other non-human animals, for example, mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals, such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds (e.g., commercially relevant birds, such as chickens, ducks, geese, and/or turkeys). In certain embodiments, the animal is a mammal. The animal may be a male or female and at any stage of development. A non-human animal may be a transgenic animal.

[0151] A “terminator” or “terminator sequence,” as used herein, is a nucleic acid (s, engineered nucleic acid) sequence that causes transcription to stop. A terminator may be unidirectional or bidirectional. It is comprised of a DNA sequence involved in specific termination of an RNA transcript by an RNA polymerase. A terminator sequence prevents transcriptional activation of downstream nucleic acid sequences by upstream promoters. Thus, in certain embodiments, a terminator that ends the production of an RNA transcript is contemplated.

[0152] The most commonly used type of terminator is a forward terminator. When placed downstream of a nucleic acid sequence that is usually transcribed, a forward transcriptional terminator will cause transcription to abort. In some embodiments, bidirectional transcriptional terminators may be used, which usually cause transcription to terminate on both the forward and reverse strand. In some embodiments, reverse transcriptional terminators may be used, which usually terminate transcription on the reverse strand only.

[0153] Non-limiting examples of mammalian terminator sequences include bovine growth hormone terminator, and viral termination sequences such as, for example, the SV40 terminator, spy, yejM, secG-leuU, thrLABC, rrnB T1, his-LGDCHAF1, metZWV, rrnC, xapR, aspA, and arcA terminator. In certain embodiments, the terminator sequence is SV40 and comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 12.

[0154] A “Tet-Off” system, as used herein, is a type of inducible system that is capable of repressing expression of a particular transgene in the presence of a tetracycline (e.g., doxycycline (DOX)). Conversely, a Tet-Off system is capable of inducing expression of a particular transgene in the absence of a tetracycline (e.g., doxycycline, DOX). In certain embodiments, a Tet-Off system comprises a tetracycline-responsive promoter operably linked to a transgene (e.g., encoding OCT4; KLF4; SOX2; or any combination thereof) and a tetracycline-controlled transactivator (tTA). The transgene with the tetracycline-responsive promoter (e.g., TRE3G, P tight, or TRE2) and the tetracycline-controlled transactivator may be encoded on the same vector or be encoded on separate vectors. See, e.g., US Publ. Appl. No. 2021-0403923 A, and the International Publ. No. WO2020/069339, entitled MUTANT REVERSE TETRACYCLINE TRANSACTIVATORS FOR EXPRESSION OF GENES, each of which is herein incorporated by reference in its entirety.

[0155] A “Tet-On” system, as used herein, is a type of inducible system that is capable of inducing expression of a particular transgene in the presence of a tetracycline (e.g., doxycycline (DOX)). In certain embodiments, a Tet-On system comprises a tetracycline-responsive promoter operably linked to a transgene (e.g., encoding OCT4; KLF4; SOX2; or any combination thereof) and a reverse tetracycline-controlled transactivator (rtTA). For example, the rtTA may be rtTA3, rtTA4, or variants thereof. In certain embodiments, a nucleic acid encoding rtTA3 comprises a sequence that is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%) identical to SEQ ID NO: 19. In certain embodiments, rtTA3 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%) identical to SEQ ID NO: 20. In certain embodiments, a nucleic acid encoding rtTA4 comprises a sequence that is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%) identical to SEQ ID NO: 26. In certain embodiments, rtTA4 comprises an amino acid sequence that is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%) identical to SEQ ID NO: 27. The expression cassette encoding a tetracycline-responsive promoter (e.g., a promoter comprising a TRE, including TRE3G, P tight, and TRE2) and a reverse tetracycline-controlled transactivator may be encoded on the same vector or be encoded on separate vectors. See, e.g., US Publ. Appl. No. 2021-0403923 A, and the International Publ. No. WO2020/069339.

[0156] The term “tissue” refers to any biological tissue of a subject (including a group of cells, a body part, or an organ) or a part thereof, including blood and/or lymph vessels, which is the object to which a compound, particle, and/or composition as disclosed herein is delivered. A tissue may be an abnormal, damaged, or unhealthy tissue, which may need to be treated. A tissue may also be a normal or healthy tissue that is under a higher than normal risk of becoming abnormal or unhealthy, which may need to be prevented. In certain embodiments, the tissue is considered healthy but suboptimal for performance or survival in current or future conditions. In certain embodiments, the tissue is the central nervous system. In certain embodiments, the cell or tissue is from eye. In certain embodiments, the tissue is damaged (e.g., due to a congenital defect, an injury, an accident, or an iatrogenic injury), diseased, and/or aged. In certain embodiments, the tissue is a deep tissue that is reachable with a fiber optic probe.

[0157] As used herein, a “TRE promoter” is a promoter comprising a tetracycline-responsive element (TRE). As used herein, a TRE comprises at least one (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) Tet-O sequences. In some embodiments, a TRE promoter further comprises a minimal promoter located downstream of a tet-O sequence. A minimal promoter is a promoter that comprises the minimal elements of a promoter (e.g., TATA box and transcription initiation site), but is inactive in the absence of an upstream enhancer (e.g., sequences comprising Tet-O). As an example, a minimal promoter may be a minimal CMV promoter that comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 17 or 24. For example, a TRE promoter may be a TRE3G promoter (e.g.,

a TRE3G promoter that comprises a sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 7).

[0158] The term “tissue repair” in the context of damaged tissue refers to restoration of tissue architecture, function following tissue damage, or a combination thereof. Tissue repair includes tissue regeneration, cell growth, tissue replacement, and/or rewiring of existing tissue (reprogramming).

[0159] The term “tissue regeneration” refers to production of new tissue or cells within a tissue that are the same type as the tissue of interest (e.g., same type as the damaged tissue or cell). In some embodiments, the methods provided herein promote organ regeneration.

[0160] The term “tissue replacement” refers to production of a different type of tissue compared to the tissue of interest (e.g., connective tissue to replace damaged tissue).

[0161] As used herein, the terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In certain embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. In other embodiments, treatment may be administered to improve one or more of retinal perfusion, ocular pressure, thickness of retinal layers, survival of RGCs, retinal electrical response, macular nerve electrical response, optic nerve activity, retinal nerve light response, thickness of retinal layer (OCT), survival of retinal RGC cells, visual acuity, and the like. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms. Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.

[0162] The term “variant” refers to a sequence that comprises a modification relative to a wild-type sequence. Non-limiting modifications in an amino acid sequence include insertions, deletions, and point mutations. Non-limiting modifications to nucleic acid sequences include frameshift mutations, nucleotide insertions, and nucleotide deletions.

[0163] The term “WPRE” refers to a Woodchuck Hepatitis Virus (WHV) Posttranscriptional Regulatory Element (WPRE). WPREs create tertiary structures in nucleic acids (e.g., expression vectors) and are capable of enhancing transgene expression (e.g., from a viral vector). In certain embodiments, a WPRE sequence is at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%) identical to SEQ ID NO: 23 or 31.

Nucleic Acid Molecules

[0164] The present disclosure provides nucleic acid molecules that include a nucleic acid sequence encoding OCT4, a nucleic acid sequence encoding SOX2, a nucleic acid sequence encoding KLF4, or any combination thereof, and in the absence of an exogenous nucleic acid sequence encoding c-Myc. The nucleic acid molecule may be a vector, including for example an expression vector. In certain embodiments, the nucleic acid molecule includes a nucleic acid sequence encoding OCT4. In certain embodiments, the nucleic acid molecule includes a nucleic acid sequence encoding SOX2. In certain embodiments, the nucleic acid molecule includes a nucleic acid sequence encoding KLF4.

In certain embodiments, the nucleic acid molecule includes any two of a nucleic acid sequence encoding OCT4, a nucleic acid sequence encoding SOX2, and a nucleic acid sequence encoding KLF4. In certain embodiments, the nucleic acid molecule includes a first nucleic acid sequence encoding OCT4, a second nucleic acid sequence encoding SOX2, and a third nucleic acid sequence encoding KLF4. In certain embodiments, OCT4 comprises an amino acid sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 2. In certain embodiments, the nucleic acid sequence encoding OCT4 is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 1. In certain embodiments, SOX2 comprises an amino acid sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 4. In certain embodiments, the nucleic acid sequence encoding SOX2 is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 3. In certain embodiments, KLF4 comprises an amino acid sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 6. In certain embodiments, the nucleic acid sequence encoding KLF4 is at least 70% identical (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) to SEQ ID NO: 5. In certain embodiments, OCT4, SOX2, KLF4, or any combination thereof is a human protein. In certain embodiments, OCT4, SOX2, KLF4, or any combination thereof is a non-human protein, for example, a protein from one or more mammals including from one or more primates (e.g., cynomolgus monkeys, rhesus monkeys). If two or more of OCT4, SOX2, and KLF4 are on one nucleic acid molecule, they may be in any order. The words "first," "second," and "third" do not necessarily imply an order of the genes on the nucleic acid molecule.

[0165] In some embodiments, the nucleic acid molecule of the present disclosure includes an inducible promoter. In some embodiments, the nucleic acid molecule has one inducible promoter. In such instances, the expression of OCT4, SOX2, and KLF4 are under the control of the same inducible promoter. In some embodiments, the nucleic acid molecule has more than one inducible promoter. The inducible promoter may include a tetracycline-responsive element (TRE) (e.g., a TRE3G promoter, a TRE2 promoter, or a P tight promoter), mifepristone-responsive promoters (e.g., GAL4-Elb promoter), or a coumermycin-responsive. As an example, a TRE (e.g., TRE3G) promoter may comprise a nucleic acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 7. See, e.g., US Publ. Appl. No. 2021-0403923 A, and the International Publ. No. WO2020/069339.

[0166] In certain embodiments, the inducing agent is capable of inducing expression of the first (e.g., OCT4), second (e.g., SOX2), third (e.g., KLF4) nucleic acids, or any combination thereof from the inducible promoter in the presence of a tetracycline (e.g., doxycycline). In certain embodiments, the inducing agent is reverse tetracycline-controlled transactivator (rtTA) (e.g., M2-rtTA, rtTA3 or rtTA4). In certain embodiments, the rtTA is rtTA3 comprising an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 20. In certain embodiments, rtTA3 is encoded by a nucleic acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%)

identical to SEQ ID NO: 19. In certain embodiments, the rtTA is rtTA4 and comprises an amino acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 27. In certain embodiments, rtTA4 is encoded by a nucleic acid sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 26.

[0167] In certain embodiments, the inducing agent is capable of inducing expression of expression of the first nucleic acid (e.g., OCT4), second nucleic acid (e.g., SOX2), third nucleic (e.g., KLF4), or any combination thereof from the inducible promoter in the absence of a tetracycline (e.g., doxycycline).

[0168] In certain embodiments, the inducing agent is tetracycline-controlled transactivator (tTA).

[0169] In certain embodiments, the nucleic acid molecule of the present disclosure comprises a constitutive promoter, for example, one or more of CP1, CMV, EF1 alpha, SV40, PGK1, Ube, human beta actin, CAG, Ac5, polyhedrin, TEF1, GDS, CaM3 5S, Ubi, H1, and/or U6 promoter. The constitutive promoter may be operably linked to nucleic acid sequences encoding OCT4, KLF4, SOX2, an inducing agent, or a combination thereof. In some embodiments, the nucleic acid molecule comprises one constitutive promoter. In some embodiments, the nucleic acid molecule comprises more than one constitutive promoter.

[0170] In certain embodiments, the nucleic acid molecule of the present disclosure comprises an SV40-derived terminator sequence. In certain embodiments, the SV40-derived sequence is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 12 or 30.

[0171] In certain embodiments, the nucleic acid molecule of the present disclosure comprises a separator sequence, which may be useful in producing two separate amino acid sequences from one transcript. The separator sequence may encode a self-cleaving peptide (e.g., 2A peptide, including a 2A peptide sequence that is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 8 or 10). In certain embodiments, the separator sequence is an Internal Ribosome Entry Site (IRES).

[0172] In certain embodiments, the nucleic acid molecule is a viral vector (e.g., a lentiviral, a retroviral, or an adeno-associated virus (AAV) vector). An AAV vector of the present disclosure generally comprises inverted terminal repeats (ITRs) flanking a transgene of interest (e.g., a nucleic acid sequence encoding OCT4, SOX2, KLF4, an inducing agent, or a combination thereof). In some embodiments, the distance between two inverted terminal repeats is less than 5.0 kilobases (kb) (e.g., less than 4.9 kb, less than 4.8 kb, less than 4.7 kb, less than 4.6 kb, less than 4.5 kb, less than 4.4 kb, less than 4.3 kb, less than 4.2 kb, less than 4.1 kb, less than 4 kb, less than 3.5 kb, less than 3 kb, less than 2.5 kb, less than 2 kb, less than 1.5 kb, less than 1 kb, or less than 0.5 kb).

[0173] In certain embodiments, the nucleic acid molecule (e.g., an expression vector encoding OCT4, KLF4, SOX2, an inducing agent, or a combination thereof) of the present disclosure may further comprise a nucleic acid sequence encoding a selection agent (e.g., an antibiotic, including blasticidin, geneticin, hygromycin B, mycophenolic acid, puromycin, zeocin, actinomycin D, ampicillin, carbenicillin, kanamycin, and neomycin) and/or detectable marker (e.g.,

GFP, RFP, luciferase, CFP, mCherry, DsRed2FP, mKate, biotin, FLAG-tag, HA-tag, His-tag, Myc-tag, V5-tag, etc.).

[0174] In some embodiments, the expression vector encoding OCT4, KLF4, and SOX2 comprises the sequence provided in SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. In some embodiments, the expression vector encoding OCT4, KLF4, and SOX2 comprises the elements depicted in FIG. 2, or a combination thereof. The expression vector may be a viral vector. The viral vector may be an adeno-associated virus (AAV) vector, retroviral vector, lentiviral vector, herpes viral vector, and the like.

[0175] In another aspect, the present disclosure provides recombinant viruses. The recombinant viruses can include one or more lentivirus, adenovirus, retrovirus, herpes virus, alphavirus, vaccinia virus or adeno-associated virus (AAV) comprising any of the expression vectors described herein. In certain embodiments, the recombinant virus encodes a transcription factor selected from OCT4; KLF4; SOX2; and any combination thereof. In certain embodiments, the recombinant virus encodes two or more transcription factors selected from the group consisting of OCT4, KLF4, and SOX2. In certain embodiments, the recombinant virus encodes OCT4 and SOX2, OCT4 and KLF4, or SOX2 and KLF4. In certain embodiments, the recombinant virus encodes OCT4, KLF4, and SOX2. In certain embodiments, the recombinant virus encodes four or more transcription factors, for example OCT4, SOX2, KLF4, and another transcription factor.

Methods of Treatment of NAION

[0176] Further provided herein are methods for treating non-arteritic anterior ischemic optic neuropathy (NAION) in a subject in need thereof wherein the method includes administering to the subject one or more agents for upregulating OCT4, SOX2, KLF4, and/or one or more combinations thereof to the subject. The one or more agents do not upregulate c-Myc. The one or more agents for upregulating OCT4, SOX2, KLF4 (OSK) may include one or more means for inducing expression of OSK, including DNA, RNA, small molecules, and the like. In some embodiments, the methods include administering to the subject one or more nucleic acid molecules as contemplated herein. In some embodiments the one or more nucleic acid molecules include a nucleic acid molecule system having at least two nucleic acid molecules.

[0177] In some embodiments of the methods for treating NAION in a subject, the agent for upregulating OSK expression includes at least one nucleic acid molecule encoding OSK as described herein above. The nucleic acid molecule encoding OSK does not comprise a nucleic acid sequence encoding c-myc. The nucleic acid molecule encoding OSK may be an adeno-associated viral (AAV) vector. According to some embodiments, the methods further comprise administering to the subject a nucleic acid molecule encoding a reverse tetracycline-controlled transactivator (rtTA). The nucleic acid molecule encoding a reverse tetracycline-controlled transactivator (rtTA) may be an AAV vector. In some embodiments, the AAV vector comprising a nucleic acid molecule encoding reverse tetracycline-controlled transactivator (rtTA) is not the same AAV vector as the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4.

[0178] The nucleic acid molecule encoding OCT4, SOX2, and KLF4 is operably linked to an inducible promoter. In

some embodiments, the inducible promoter is induced by a tetracycline class antibiotic. Tetracycline class antibiotics are known in the art and include, for example, tetracycline, chlortetracycline, oxytetracycline, demeclocycline, lymecycline, mecloxycline, methacycline, minocycline, rolitetracycline, doxycycline, tigecycline, eravacycline, sarecycline, and omadacycline. Doxycycline is an exemplary tetracycline class antibiotic. In some embodiments, the inducible promoter is a tetracycline class antibiotic response element (TRE) including for example a TRE2 promoter.

[0179] The reverse tetracycline-controlled transactivator (rtTA) may be rtTA3, rtTA4, or combinations thereof.

[0180] In some embodiments, the nucleic acid molecule encoding rtTA is operably linked to a constitutive promoter including one or more of CP1, CMV, EF1 alpha, SV40, PGK1, Ubc, human beta actin, CAG, Ac5, polyhedrin, TEF1, GDS, CaM3 5S, Ubi, H1, and/or U6 promoter. In some embodiments, the nucleic acid molecule encoding rtTA is operably linked a CMV promoter.

[0181] In some embodiments, the AAV vector is serotype-2 (AAV2). In some embodiments, the AAV vector is a hybrid vector comprising capsid proteins from one or more serotypes including AAV1, AAV2, AAV5, AAV6, AAV7, AAV8 and AAV9 (e.g., AAV2/2, AAV2/6, AAV2/1, AAV2/5, AAV2/7, AAV2/8 and AAV2/9).

[0182] In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises a self-cleaving peptide, for example a 2A peptide.

[0183] In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises inverted terminal repeats (ITRs) flanking the first nucleic acid. In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises inverted terminal repeats (ITRs) flanking the second nucleic acid. In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises inverted terminal repeats (ITRs) flanking the third nucleic acid. In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises inverted terminal repeats (ITRs) flanking one or more combinations of the first nucleic acid, the second nucleic acid, and/or the third nucleic acid. In some embodiments, the distance between two inverted terminal repeats (ITRs) is less than 5.0 kilobases (kb) (e.g., less than 4.9 kb, less than 4.8 kb, less than 4.7 kb, less than 4.6 kb, less than 4.5 kb, less than 4.4 kb, less than 4.3 kb, less than 4.2 kb, less than 4.1 kb, less than 4 kb, less than 3.5 kb, less than 3 kb, less than 2.5 kb, less than 2 kb, less than 1.5 kb, less than 1 kb, or less than 0.5 kb). In some embodiments, the distance between two ITRs is 4.7 kb or less.

[0184] The method can further include administering an inducing agent to the subject. The inducing agent can include for example a tetracycline-controlled transactivator (tTA). In certain aspects, the inducing agent is capable of inducing expression of expression of the first nucleic acid (e.g., OCT4), the second nucleic acid (e.g., SOX2), the third nucleic (e.g., KLF4), or any combination thereof from the inducible promoter in the absence of a tetracycline (e.g., doxycycline).

[0185] In some embodiments, the AAV-OSK vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises nucleic acid elements in a specific order. For example, the AAV vector comprising a nucleic acid

molecule encoding OCT4, SOX2, and KLF4 can include elements in the following order: a) a first inverted terminal repeat sequence (ITR) sequence; b) a TRE2 promoter sequence; c) an OCT4 sequence; d) a P2A cleavage sequence; e) a SOX2 sequence; f) a T2A cleavage sequence; g) a KLF4 sequence; h) an SV-40-derived terminator sequence; and i) a second inverted terminal repeat (ITR) sequence, as described, for example in U.S. patent application Ser. No. 17/280,384, published as Int'l. Publ. No. WO2020/069373 titled CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION, incorporated by reference herein in its entirety.

[0186] In certain embodiments, the encoded OCT4 comprises an amino acid sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 2. In certain embodiments, the nucleic acid sequence encoding OCT4 is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 1. In certain embodiments, the encoded SOX2 comprises an amino acid sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 4. In certain embodiments, the nucleic acid sequence encoding SOX2 is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 3. In certain embodiments, the encoded KLF4 comprises an amino acid sequence at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) identical to SEQ ID NO: 6. In certain embodiments, the nucleic acid sequence encoding KLF4 is at least 70% identical (e.g., at least 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100%) to SEQ ID NO: 5. In some embodiments, the nucleic acid sequence encoding OCT4 is SEQ ID NO: 1, the nucleic acid sequence encoding SOX2 is SEQ ID NO: 3, and the nucleic acid sequence encoding KLF4 is SEQ ID NO: 5.

[0187] In some embodiments, the P2A sequence encodes for a polypeptide with the sequence ATNFSLLKQAGD-VEENPGP (SEQ ID NO: 9). In some embodiments, the P2A sequence is GCCACGAACCTCTCTCTGT-TAAAGCAAGCAGGAGATGTT-GAAGAAAACCCGGGCCT (SEQ ID NO: 8).

[0188] In some embodiments, the T2A sequence encodes a polypeptide of SEQ ID NO: 11. In some embodiments, the T2A sequence is GAGGGCAGGGGAAGTCTTCTAACATCGGGGACGTGGAGGAAATCCGGCCCA (SEQ ID NO: 10).

[0189] In some embodiments, the TRE2 promoter sequence is SEQ ID NO: 7. In some embodiments, the TRE2 promoter sequence comprises at least one minimal CMV promoter sequence. In some embodiments, the at least one minimal SV40 promoter sequence is SEQ ID NO: 12.

[0190] In some embodiments, the SV-40-derived terminator sequence is SEQ ID NO: 12.

[0191] In some embodiments, the ITR sequence is SEQ ID NO: 16.

[0192] In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises SEQ ID NO: 13 or 14. In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises SEQ ID NO: 15.

[0193] The AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA are administered sequentially or simultaneously.

[0194] The nucleic acid molecules disclosed herein can be administered to a subject by any appropriate route including, without limitation, intravenous, intraperitoneal, subcutaneous, intramuscular, intranasal, topical, or intradermal routes. In certain embodiments, the composition is formulated for administration via intravenous injection or subcutaneous injection. In some embodiments, the dual vector system including an AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and an AAV vector comprising a nucleic acid molecule encoding rtTA is administered intravirally.

[0195] In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the nucleic acid molecule encoding rtTA (e.g., rtTA3, rtTA4, etc.) are administered at a ratio (nucleic acid molecule:nucleic acid molecule) of about 1:20, 1:19, 1:18, 1:17, 1:16, 1:15, 1:14, 1:13, 1:12, 1:11, 1:10; 1:9; 1:8; 1:7; 1:6; 1:5; 1:4; 1:3; 1:2; 1:1; 1:0.5; 2:1; 3:1; 4:1; 5:1; 6:1; 7:1; 8:1; 9:1; 10:1; 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, or 20:1. In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the nucleic acid molecule encoding rtTA (e.g., rtTA3, rtTA4, etc.) are administered at a ratio of about 1:2; 1:1.9; 1:1.8; 1:1.7; 1:1.6; 1:1.5; 1:1.4; 1:1.3; 1:1.2; 1:1.1; 1:1; 1:0.9; 1:0.8; 1:0.7; 1:0.6; 1:0.5; 1:0.4; 1:0.3; 1:0.2; 1:0.1; 0:1:1; 0:2:1; 0:3:1; 0:4:1; 0:5:1; 0:6:1; 0:7:1; 0:8:1; 0:9:1; 1:1; 1:1.1; 1:2:1; 1:3:1; 1:4:1; 1:5:1; 1:6:1; 1:7:1; 1:8:1; 1:9:1 or 2:1. In some embodiments, the nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the nucleic acid molecule encoding rtTA are administered at an about 1:1 ratio.

[0196] In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA (e.g., rtTA3, rtTA4, etc.) are administered at a ratio (vector genome:vector genome (vg:vg)) of about 1:20, 1:19, 1:18, 1:17, 1:16, 1:15, 1:14, 1:13, 1:12, 1:11, 1:10; 1:9; 1:8; 1:7; 1:6; 1:5; 1:4; 1:3; 1:2; 1:1; 1:0.5; 2:1; 3:1; 4:1; 5:1; 6:1; 7:1; 8:1; 9:1; 10:1; 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, or 20:1. In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA are administered at an about 1:1 (vg:vg) ratio. In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA (e.g., rtTA3, rtTA4, etc.) are administered at a ratio (vg:vg) of about 1:10; 1:9; 1:8; 1:7; 1:6; 1:5; 1:4; 1:3; 1:2; 1:1; 1:0.5; 2:1; 3:1; 4:1; 5:1; 6:1; 7:1; 8:1; 9:1; or 10:1. In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA (e.g., rtTA3, rtTA4, etc.) are administered at a ratio (vg:vg) of about 1:2; 1:1.9; 1:1.8; 1:1.7; 1:1.6; 1:1.5; 1:1.4; 1:1.3; 1:1.2; 1:1.1; 1:1; 1:0.9; 1:0.8; 1:0.7; 1:0.6; 1:0.5; 1:0.4; 1:0.3; 1:0.2; 1:0.1; 0:1:1; 0:2:1; 0:3:1; 0:4:1; 0:5:1; 0:6:1; 0:7:1; 0:8:1; 0:9:1; 1:1; 1:1.1; 1:2:1; 1:3:1; 1:4:1; 1:5:1; 1:6:1; 1:7:1; 1:8:1; 1:9:1 or 2:1. In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA are administered at an about 1:1 (vg:vg) ratio. According to some embodiments of the disclosed methods, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises SEQ ID NO: 13, 14, or 35.

According to some embodiments, the AAV vector comprising a nucleic acid molecule encoding rtTA comprises SEQ ID NO: 19, 26, 36, or 37. According to some embodiments of the disclosed methods, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises SEQ ID NO: 13, 14, or 35 and the AAV vector comprising a nucleic acid molecule encoding rtTA comprises SEQ ID NO: 19, 26, 36, or 37. According to some embodiments of the disclosed methods, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 comprises SEQ ID NO: 35 and the AAV vector comprising a nucleic acid molecule encoding rtTA comprises SEQ ID NO: 36 or 37.

[0197] In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 is an AAV2-TRE-OSK vector and the AAV vector comprising a nucleic acid molecule encoding rtTA is an AAV2-CMV-rtTA3. The AAV composition may include an AAV2-TRE-OSK vector and an AAV2-CMV-rtTA3 vector. The methods may include the AAV2-TRE-OSK vector and the AAV2-CMV-rtTA3 vector in the same or in separate compositions.

[0198] In some embodiments, the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 is an AAV2-TRE-OSK vector and the AAV vector comprising a nucleic acid molecule encoding rtTA is an AAV2-CMV-rtTA4. The AAV composition may include an AAV2-TRE-OSK vector and an AAV2-CMV-rtTA4 vector. The methods may include the AAV2-TRE-OSK vector and the AAV2-CMV-rtTA4 vector in the same composition or in separate compositions.

[0199] The concentration of the AAV2-TRE-OSK vector to be administered in accordance with the disclosed methods includes an amount in the range of from about 1×10^{10} vg/mL to about 2×10^{13} vg/mL, for example, 1×10^{12} vg/mL to about 2×10^{12} vg/mL. For example, the effective amount of the AAV2-TRE-OSK vector can include from about 1.0×10^{12} vg/mL to about 1.1×10^{12} vg/mL, from about 1.1×10^{12} vg/mL to about 1.2×10^{12} vg/mL, from about 1.2×10^{12} vg/mL to about 1.3×10^{12} vg/mL, from about 1.3×10^{12} vg/mL to about 1.4×10^{12} vg/mL, from about 1.4×10^{12} vg/mL to about 1.5×10^{12} vg/mL, from about 1.5×10^{12} vg/mL to about 1.6×10^{12} vg/mL, from about 1.6×10^{12} vg/mL to about 1.7×10^{12} vg/mL, from about 1.7×10^{12} vg/mL to about 1.8×10^{12} vg/mL, from about 1.8×10^{12} vg/mL to about 1.9×10^{12} vg/mL, from about 1.9×10^{12} vg/mL to about 2.0×10^{12} vg/mL and any and all increments therebetween.

[0200] The concentration of the AAV2-CMV-rtTA3 vector administered in accordance with the disclosed methods includes an amount in the range of from about 1×10^{10} vg/mL to about 2×10^{13} vg/mL, for example, about 1×10^{13} vg/mL to about 2×10^{13} vg/mL. For example, the effective amount of the AAV2-CMV-rtTA3 vector can include from about 1.0×10^{13} vg/mL to about 1.1×10^{13} vg/mL, from about 1.1×10^{13} vg/mL to about 1.2×10^{13} vg/mL, from about 1.2×10^{13} vg/mL to about 1.3×10^{13} vg/mL, from about 1.3×10^{13} vg/mL to about 1.4×10^{13} vg/mL, from about 1.4×10^{13} vg/mL to about 1.5×10^{13} vg/mL, from about 1.5×10^{13} vg/mL to about 1.6×10^{13} vg/mL, from about 1.6×10^{13} vg/mL to about 1.7×10^{13} vg/mL, from about 1.7×10^{13} vg/mL to about 1.8×10^{13} vg/mL, from about 1.8×10^{13} vg/mL to about 1.9×10^{13} vg/mL, from about 1.9×10^{13} vg/mL to about 2.0×10^{13} vg/mL and any and all increments therebetween.

vg/mL to about 1.9×10^{13} vg/mL, from about 1.9×10^{13} vg/mL to about 2.0×10^{13} vg/mL and any and all increments therebetween.

[0201] The concentration of the AAV2-CMV-rtTA4 vector administered in accordance with the disclosed methods includes an amount in the range of from about 1×10^{10} vg/mL to about 2×10^{13} vg/mL, for example, about 1×10^{13} vg/mL to about 2×10^{13} vg/mL. For example, the effective amount of the AAV2-CMV-rtTA4 vector can include from about 1.0×10^{13} vg/mL to about 1.1×10^{13} vg/mL, from about 1.1×10^{13} vg/mL to about 1.2×10^{13} vg/mL, from about 1.2×10^{13} vg/mL to about 1.3×10^{13} vg/mL, from about 1.3×10^{13} vg/mL to about 1.4×10^{13} vg/mL, from about 1.4×10^{13} vg/mL to about 1.5×10^{13} vg/mL, from about 1.5×10^{13} vg/mL to about 1.6×10^{13} vg/mL, from about 1.6×10^{13} vg/mL to about 1.7×10^{13} vg/mL, from about 1.7×10^{13} vg/mL to about 1.8×10^{13} vg/mL, from about 1.8×10^{13} vg/mL to about 1.9×10^{13} vg/mL, from about 1.9×10^{13} vg/mL to about 2.0×10^{13} vg/mL and any and all increments therebetween.

[0202] According to some embodiments, the effective dose of the AAV2-TRE-OSK vector administered in accordance with the disclosed methods includes the amount of vector administered per eye. The effective dose can include an amount of vector in the range of from about 1×10^9 vg/eye to about 1×10^{14} vg/eye. In some embodiments, the effective dose of the AAV2-TRE-OSK vector can include an amount of vector in the range of from about 1×10^{11} vg/eye to about 10×10^{11} vg/eye. For example, the dose of the AAV2-TRE-OSK vector can include from about 1×10^{11} vg/eye to about 2×10^{11} vg/eye, from about 2×10^{11} vg/eye to about 3×10^{11} vg/eye, from about 3×10^{11} vg/eye to about 4×10^{11} vg/eye, from about 4×10^{11} vg/eye to about 5×10^{11} vg/eye, from about 5×10^{11} vg/eye to about 6×10^{11} vg/eye, from about 6×10^{11} vg/eye to about 7×10^{11} vg/eye, from about 7×10^{11} vg/eye to about 8×10^{11} vg/eye, from about 8×10^{11} vg/eye to about 9×10^{11} vg/eye, from about 9×10^{11} vg/eye to about 10×10^{11} vg/eye, including any and all increments therebetween. In some embodiments, the effective dose of the AAV2-TRE-OSK vector is about 3.06×10^{11} vg/eye.

[0203] The effective dose of the AAV2-CMV-rtTA3 vector administered in accordance with the disclosed methods includes the amount of vector administered per eye. The effective dose of the AAV2-CMV-rtTA3 vector can include an amount of vector in the range of from about 1×10^9 vg/eye to about 1×10^{14} vg/eye. In some embodiments, the effective dose of the AAV2-CMV-rtTA3 vector can include an amount of vector in the range of from about 1×10^{11} vg/eye to about 10×10^{11} vg/eye. For example, the dose of the AAV2-CMV-rtTA3 vector can include from about 1×10^{11} vg/eye to about 2×10^{11} vg/eye, from about 2×10^{11} vg/eye to about 3×10^{11} vg/eye, from about 3×10^{11} vg/eye to about 4×10^{11} vg/eye, from about 4×10^{11} vg/eye to about 5×10^{11} vg/eye, from about 5×10^{11} vg/eye to about 6×10^{11} vg/eye, from about 6×10^{11} vg/eye to about 7×10^{11} vg/eye, from about 7×10^{11} vg/eye to about 8×10^{11} vg/eye, from about 8×10^{11} vg/eye to about 9×10^{11} vg/eye, from about 9×10^{11} vg/eye to about 10×10^{11} vg/eye, including any and all increments therebetween. In some embodiments, the effective dose of the AAV2-CMV-rtTA3 vector is about 2.66×10^{11} vg/eye.

[0204] The effective dose of the AAV2-CMV-rtTA4 vector administered in accordance with the disclosed methods includes the amount of vector injected per eye. The effective dose can include an amount of vector in the range of from about 1×10^9 vg/eye to about 1×10^{14} vg/eye. In some

embodiments, the effective dose the AAV2-CMV-rtTA4 vector can include an amount of vector in the range of from about 1×10^{11} vg/eye to about 10×10^{11} vg/eye. For example, the dose the AAV2-CMV-rtTA4 vector can include from about 1×10^{11} vg/eye to about 2×10^{11} vg/eye, from about 2×10^{11} vg/eye to about 3×10^{11} vg/eye, from about 3×10^{11} vg/eye to about 4×10^{11} vg/eye, from about 4×10^{11} vg/eye to about 5×10^{11} vg/eye, from about 5×10^{11} vg/eye to about 6×10^{11} vg/eye, from about 6×10^{11} vg/eye to about 7×10^{11} vg/eye, from about 7×10^{11} vg/eye to about 8×10^{11} vg/eye, from about 8×10^{11} vg/eye to about 9×10^{11} vg/eye, from about 9×10^{11} vg/eye to about 10×10^{11} vg/eye, including any and all increments therebetween. In some embodiments, the effective dose of the AAV2-CMV-rtTA4 vector is about 2.66×10^{11} vg/eye.

[0205] Embodiments of the methods include administering the AAV composition comprising an AAV vector including a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and an AAV vector including a nucleic acid molecule encoding rtTA to the subject by one or more suitable routes including oculus sinister (OS) injection, oculus dexter (OD) injection, or oculus uterque (OU) injection. Administration may include one or more injections, for example, administration may include one injection comprising the AAV composition comprising an AAV vector including a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector including a nucleic acid molecule encoding rtTA. In other aspects, the administration may include two (or more) injections, for example, one injection comprising the AAV composition comprising an AAV vector including a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and one injection comprising the AAV vector including a nucleic acid molecule encoding rtTA. The injection comprising the AAV vector including a nucleic acid molecule encoding OCT4, SOX2, and KLF4 may be administered and the injection comprising the AAV vector including a nucleic acid molecule encoding rtTA may be administered simultaneously or sequentially. For example, the injection comprising the AAV composition comprising an AAV vector including a nucleic acid molecule encoding OCT4, SOX2, and KLF4 may be administered before, at the same time as, or after the injection comprising the AAV vector including a nucleic acid molecule encoding rtTA.

[0206] Embodiments of the methods further include administering to the subject an effective amount of an antibiotic. In some embodiments, the antibiotic includes tetracycline or doxycycline. In some embodiments, the antibiotic is administered at least one day prior to administering the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA.

[0207] The antibiotic may be administered when the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA are administered. The antibiotic may be administered at least one day following administration of the AAV composition comprising the AAV vector comprising a nucleic acid molecule encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA. The antibiotic may be administered 2 days, 3 days, 4 days, 5 days, or more than 5 days following administration of the AAV composition comprising the AAV vector comprising a nucleic acid molecule

encoding OCT4, SOX2, and KLF4 and the AAV vector comprising a nucleic acid molecule encoding rtTA.

[0208] The disclosed methods of treating NAION include methods of administering to a subject in need thereof an effective amount of an AAV genome including one or more polynucleotide sequences expressing OCT4, SOX2, and KLF4 and an AAV genome comprising a nucleic acid sequence encoding transactivator 3 or transactivator 4.

Methods of Preparing AAV-OSK Vectors

[0209] Provided herein are methods for recombinant preparation of an AAV. In some embodiments, the method comprises introducing one or more vectors as contemplated herein into a cell under conditions whereby the AAV is produced. The cell may include a population of cells. The population of cells may include any suitable cells as understood in the art, including for example HEK293 cells, HEK293T cells, COS cells, CHO cells, BHK cells, HeLa cells, and the like. The one or more vectors may be introduced into the cell using one or more suitable techniques including for example transfection, transduction, and/or infection. Exemplary methods for recombinant preparation of the AAV include transient transfection (e.g., with one or more transfer plasmids containing a first, and a second, and optionally a third vector as described herein), viral infection (e.g., with one or more recombinant helper viruses, such as a adenovirus, poxvirus (such as vaccinia virus), herpes virus (including HSV, cytomegalovirus, or baculovirus, containing a first, and a second, and optionally a third vector as described herein)), and stable producer cell line transfection or infection (e.g., with a stable producer cell, such as a mammalian or insect cell, containing a Rep nucleotide sequence encoding one or more AAV Rep proteins and/or a Cap nucleotide sequence encoding one or more AAV capsid proteins as described herein, and with an AAV genome as described herein being delivered in the form of a plasmid or a recombinant helper virus). The first vector may include one or more nucleic acid sequences expressing OCT4, SOX2, and/or KLF4 encoded by one or more of SEQ ID NOs: 13, 14, 15, and 35. The second vector may include one or more nucleic acid sequences expressing transactivator 3, for example SEQ ID NO: 21 or 36. Alternatively, the second vector may include one or more nucleic acid sequences expressing transactivator 4, for example SEQ ID NO: 28 or 37.

[0210] Further provided herein are methods for generating an AAV comprising modifying a cell to express one or more plasmids. The one or more plasmids may include one or more AAV2 Rep-Cap plasmids, one or more helper plasmids, and one or more transfer plasmids. The one or more transfer plasmids may include a first transfer plasmid including one or more nucleic acids encoding one or more of: OCT4, SOX2, and KLF4; a second transfer plasmid including one or more nucleic acids encoding transactivator 3; or a transfer plasmid including one or more nucleic acids encoding transactivator 3. The one or more transfer plasmids may also include a first transfer plasmid including one or more nucleic acids encoding one or more of: OCT4, SOX2, KLF4, and transactivator 3. The one or more transfer plasmids may also include a first transfer plasmid including one or more nucleic acids encoding one or more of: OCT4, SOX2, and KLF4; a second transfer plasmid including one or more nucleic acids encoding transactivator 4; or a transfer plasmid including one or more nucleic acids encoding one or more of: OCT4, SOX2, KLF4, and transactivator 4.

EXAMPLES

Example 1—Methods of Producing Vectors

[0211] The present study set out to develop a method for manufacturing batches of vectors and to assess the stability of the prepared batches.

AAV production protocol

Materials

Cells:

[0212] HEK293T cells were used to produce the vectors as described herein. The cells were grown in DMEM media (Invitrogen, cat. no. 11995073) containing 10% fetal bovine serum (FBS) (Invitrogen HI FBS, cat. no. 16140), penicillin/streptomycin (Invitrogen, cat. no. 15140-122), Glutamine (Invitrogen cat. no. 25030).

Plasmids

[0213] The recombinant AAV2-TRE-OSK plasmid (shown in FIG. 2) was prepared using the following components: (1) a nucleic acid sequence encoding an AAV2 capsid protein or a fragment thereof, (2) a nucleic encoding a functional rep gene, (3) a recombinant AAV transfer vector comprising AAV2 inverted terminal repeats (SEQ ID NO: 16, SEQ ID NO: 32) flanking a transgene encoding OCT4, KLF4, and SOX2 (SEQ ID NO: 13) operably linked to an inducible TRE promoter (TRE3G, SEQ ID NO: 7), and (4) a helper vector with rAAV2 Rep-Cap proteins. Plasmids were obtained from Stratagene/Agilent (Stratagene cat no: 240071). The AAV2 Rep-Cap plasmid included an pAAV-RC plasmid (Stratagene cat. no. 240071). In some cases, AAV2 hybrid vectors e.g., AAV2/1 AAV2/2, AAV2/5, AAV2/6, AAV2/7, AAV2/8 and AAV2/9 with capsid proteins from AAV1, 2, 3, 5, 6, 7, 8, and 9 serotypes. The helper plasmid included a pHelper plasmid (Stratagene, cat. no. 240071) and carried adenovirus-derived genes for introducing helper functions. As shown in FIG. 2 the entire AAV2-

promoter (SEQ ID NO: 17) operably linked to rtTA3 (SEQ ID NO 19) inducing agent having 3 vp16 domains at the 3' end. An alternative recombinant pAAV2-CMV-rtTA, pAAV2-CMV-rtTA3(V16) (shown in FIG. 4), may be prepared in the same way.

Polyethyleneimine (PEI) Solution

[0216] PEI solution (1 µg/µl, Polysciences, cat. no. 23966-2) was prepared by dissolving PEI powder in H₂O that was heated to 80° C., cooled to room temperature, neutralized to pH 7.0, filter sterilized, aliquoted and stored at -20° C. The transfection efficiency was tested when each new batch was prepared.

Methods

Vector Production

[0217] On day 1, HEK293T cells were plated on 10 15-cm dishes before transfecting for 24 hours. Cells were seeded with 25 mL medium per 15-cm culture dish. Cells were split to a density of 70-90% (standard transfection density) ten times on 15 cm plates in order to provide a yield of 5E12 viral genomes (vg). Media was changed with 5% FBS to slow growth and reduce purification time one plate at a time in order to prevent cells from dying.

[0218] On day 2, 1 hour before transfection, medium was changed to 20 mL of freshly warmed medium. A DNA solution was prepared in a 50 mL FALCON™ tube. The amounts of DNA and reagents per dish are shown in the Table 2 below. Based on the size of inverted terminal repeat (ITR) plasmid, the amount of DNA was calculated. A tube of master mixture was prepared for 5 15-cm dishes. As shown in Table 2 below, all plasmids were diluted to 1 µg/µl in sterile H₂O.

[0219] A 10-mL sample of DMEM (without phenol red, Invitrogen cat. no. 31053-036) was prepared. A 785 µl aliquot of PEI solution was added, and the media was mixed. It was then incubated at room temperature for 20-30 minutes.

TABLE 2

Plasmid	Amounts of Reagents per Plate				
	Plasmid size	Amount of Plasmid Per Plate	Amount of Plasmid Per 5 Plates	[plasmid] (µg/µl)	VOLUME
AAV2-RC	7.3 kb	15.2 µg	76 µg	1 µg/µl	76 µl
HELPER	11.6 kb	24 µg	120 µg	1 µg/µl	120 µl
ITR plasmid-Gene of Interest (e.g., OSK)	6.3 kb	13.117808 µg	65.58904 µg	1 µg/µl	65.5 µl

TRE3G-OSK-SV40pA vector is 7250 base pairs in length, and two inverted terminal repeats (ITRs) flank the OSK sequences.

[0214] The first expression vector encoding OCT4, SOX2, and KLF4 includes the nucleic acid sequence set forth in SEQ ID NO: 15. The recombinant AAV vector can include a nucleic acid encoding an inducing agent.

[0215] The recombinant pAAV2-CMV-rtTA, pAAV2-CMV-rtTA3(V16) (shown in FIG. 3), for the Tet-On plasmid was prepared using a similar approach to that described above but using a transfer plasmid with a CMV constitutive

[0220] Next, 2 mL of DNA-PEI mixture was added to each of 10 15-cm dishes. The transfected cells were then incubated.

[0221] On Day 3, the medium was removed, and 25 mL of freshly warmed medium was added. Serum-containing medium was added for AAV2/2, AAV2/6. Serum-free medium was used for AAV2/1, AAV2/5, AAV2/7, AAV2/8 and AAV2/9.

[0222] On Day 5, cells were scraped with a cell scraper in their current medium and transferred to a 50 mL tube. The

cell suspension was then spun at 1000 relative centrifugal force (rcf) for 5 minutes. The supernatant was then discarded.

Transfection Procedures

[0223] All cells were combined into 1 50-mL tube, washed with PBS, and spun at 1000 rpm for 5 minutes. The supernatant was then discarded.

[0224] The cell pellet was resuspended in a volume of hypotonic buffer five times the volume of the packed cell volume (approximately 25 mL). It was then incubated on ice for 10 minutes. A 0.11% by volume amount of 10× restore buffer was then added and mixed by pipetting (generally a volume of 3.3 mL).

[0225] The nuclei were then spun down at 2000 ref for 10 minutes, generating a nuclear pellet of about 1 mL per 10 15-cm dishes. The pellet was stored at -80° C. for further purification.

Preparation of Solutions

5 M NaCl Salt Solution

[0226] A mass of 292.2 g NaCl was added to 200 of deionized (DI) water in a 2 L bottle. The mixture was shaken to mix, and poured into a large, graduated cylinder. DI water was then added up to 1 L and poured back into the 2 L bottle. A stir bar was added, and the volume was heated and stirred until dissolved. Alternatively, the volume was autoclaved. The solution was then cooled and sterile filtered through 0.2 µm filter.

40% PEG-8000, 2.5M NaCl (5× Stock Solution).

[0227] In a 1 L graduated cylinder, 400 g PEG-8000 and 500 mL 5 M NaCl were mixed. DI water was added to 1 L. This generally required about 100 mL of water. The solution was transferred to a 2 L flask and shaken to mix. A large stir bar was added, and the solution was heated overnight in a water bath at 55° C. The next day, the solution was sterile filtered with a 0.2 m filter. This filtration step generally takes about 30 minutes.

Harvesting AAV from Media and Cells

[0228] The media and cells were harvested without use of trypsin. The media was collected with a pipetman and sterile filtered with a 0.2 µm filter. The cells were collected and spun down. Any remaining supernatant was added to the media sterile filtered with a 0.2 µm filter. The cells were harvested in one of several ways. Cells were collected with a cell scraper. Alternatively, cells were "blasted" with calcium- and magnesium-free PBS at a volume of 10 mL per 2 plates. A 40% solution of PEG 8000 adjusted to pH 7.4 was added to a final concentration of 12%. Approximately 25 mL per 100 mL of media/cells were used. The solution was stirred in a cold room for 1 hour and was either left to sit for 3 hours without spinning or was left overnight in cold room. The next day, the PEG mixture was spun at 3000×g for 20 minutes. The supernatant was discarded. The pellet was resuspended in less than about 7 mL of 1×PBS. The pellet was first suspended with about 5 mL and a volume of up to 2 mL was added once nearly suspended. A solution of benzonase at 1:10,000 was then added and the mixture was incubated for 45 minutes at 37° C. Optionally, the mixture was spun down at 2415×g for 10 minutes at 4° C. The supernatant was transferred to new tube.

Concentrating AAV with Ultracentrifugation

Preparation of Solutions

[0229] A 1 M MgCl₂ stock solution was prepared which was at 1000× and was used for making MK buffer. A 2.5 M stock solution of KCl was prepared which was a 1000× and was also used for preparing MK buffer.

[0230] A 1 M solution of NaCl/phosphate-buffered saline (PBS) MK buffer was prepared by dissolving 58.4 g of NaCl in 1 mL of 1 M MgCl₂ and 1 mL of 2.5 M KCl. Then, 1×PBS (Ca⁺ Mg⁺ Dulbecco's phosphate-buffered saline (DPBS), Gibco) was added to final volume of 1 L. The solution was sterilized by passing through a 0.22-µm filter and stored at 4° C. The solution was brought to final concentration of 1 M NaCl, 1 mM MgCl₂, and 2.5 mM KCl.

[0231] A 1×PBS-MK buffer was prepared by dissolving 1 mL of 1 M MgCl₂, and 1 mL 2.5 M KCl to 2×500 mL bottles of Ca- Mg- DPBS (Gibco). The solution was sterilized by passing through a 0.22-µm filter and stored at 4° C. The solution was brought to final concentrations of 1 mM MgCl₂ and 2.5 mM KCl.

[0232] A 0.001% Pluronic-F68 (formulation buffer) solution was prepared by adding 500 µL of sterile 1000× Pluronic F-68 (1% solution) to 500 mL of 1×DPBS (Gibco, TC stock). The solution was stored at 4° C. for up to one month, or aliquoted and stored at -80° C. for up to one year.

[0233] A 0.001% PLURONIC™-F68+5% sorbitol (freezing buffer) solution was prepared by adding 25 g of sorbitol to 500 µL of sterile 1000× PLURONIC™ F-68 (1% solution) to 500 mL of 1×DPBS (Gibco, TC stock). The solution was stored at 4° C. for up to one month, or aliquoted and stored at -80° C. for up to one year.

[0234] As shown in Table 3, 15% iodixanol solution was prepared by mixing 30 mL of 60% iodixanol and 90 mL of 1 M NaCl/PBS-MK buffer. A 25% iodixanol solution was prepared by mixing 112.5 mL of 60% iodixanol, 157.5 mL of 1×PBS-MK buffer, and 900 µL of phenol red. A 40% iodixanol solution was prepared by mixing 202.5 mL of 60% iodixanol and 67.5 mL of 1×PBS-MK buffer. A 60% iodixanol solution was prepared by mixing 150 mL of 60% iodixanol and 675 µL of phenol red.

TABLE 3

Iodixanol solutions				
% soln	mL 60% iodixanol	mL 1M NaCl PBS-MK	mL PBS-MK	µL phenol red
15	30	90	0	0
25	112.5	0	157.5	675
40	180	0	90	0
60	150	0	0	675

Note

all solutions were sterile-filtered with 0.2 um filters.

[0235] In order to create an ultra-gradient, the benzonased supernatants were added to Beckman optiseal tubes. If volumes were unequal, 1 M NaCl, PBS-MK mix was added to make them equal, to a final volume of approximately 7 mL.

[0236] The tubes were filled from the bottom using 10 mL syringes and long hypodermic needles. For each solution the same syringe was reused but the needles were changed after

every sample in order to prevent cross-contamination between AAV preparations. 5 mL was the minimum volume for any layer.

[0237] The tubes were balanced to 5-10 µg. The tubes were balanced in pairs. They were first sorted so that the most similar tubes were paired, and then PBS was added to the lighter tube in each pairing. PBS was added by touching the tip to the side of the tube to prevent droplets from disturbing the layers. Caps were added and tubes were loaded into the ultracentrifuge.

[0238] The tubes were then spun in an ultracentrifuge using a VTi50 rotor for 1 hour at max speed (50,000 rpm=242,000 \times g). The fractions were collected from the ultracentrifuged tubes by piercing the bottom with an 18-gauge needle. The black stopper was removed at the top before piercing with the needle, otherwise air bubbles were created that disturb the layers. The majority of the 60% fraction was removed. The remaining part of the 60% layer was then collected along with the 40% fraction in a 50 mL tube. Sample collection was complete when the color changed significantly, or the solution was cloudy

Separation of Fractions on a Protein Gel

[0239] Samples were denatured with 4xLDS with 2.5% β -mercaptoethanol at 70° C. for 10 minutes. In order to prepare 20 µL aliquots, 10 µL of sample was combined with 5 µL of H₂O, 5 µL of LDS with 2.5% β -mercaptoethanol. If necessary, extra running buffer (200 mL 10x Tris-Glycine SDS buffer, 1800 mL Millipure water) was prepared.

[0240] Samples were then loaded into a Tris Glycine gel. Either a 4-12% or 4-20% gradient gel was used. For AAV capsids, either is suitable.

[0241] The gel box was assembled, and the wells of the gel were loaded with 20 µL of sample per well. Gels were run at 225 V for 30-45 minutes, until the blue dye reached the bottom of the gel.

[0242] The gels were then stained with SYPRO™ red and imaged. First, a staining solution was prepared (7.5% acetic acid, SYPRO™ red is 5000 \times) by adding 10 µL of SYPRO™ red to 50 mL of stain solution. This was enough for 1 gel. Gels were stained for 1 hour while covered at room temperature on a slow rocker. The stain solution was then removed and acetic acid solution with no dye was added. The gels were incubated for 1 to 5 minutes in order to de-stain. The gels were images on a gel dock with EtBr settings (UV).

[0243] Good fractions were then combined and washed with 1xPBS with 0.001% F68. In some cases about 20 mL PBS+F68 was added to bring the final volume to just less than 30 mL in order to dilute the iodixanol which facilitates passing through the filter.

[0244] Samples were spun at 4700 g for 5 minutes. After everything flowed through, the samples were washed 3x more with 15 mL per wash in order to prepare a clear final solution. The samples were then aliquoted into labelled tubes (name of virus, payload, date) and stored at 4° C. for up to 1 week. For longer storage, the final elution was prepared with 1xPBS with 0.001% F68 and 5% sorbitol. Samples were frozen at -80° C.

Titering Virus with qPCR

[0245] Samples were prepared by aliquoting 12.5 µL Master Mix into tubes. Either fast advanced TAQMANTM Master Mix from ThermoFisher or IDT Primetime Master Mix was used. To each tube, 0.0625 µL of primer 1, 0.0625 µL of

primer 2, 0.125 µL of probe, 1 µL of virus, and 11.3 µL of H₂O was added for a total volume of 25 µL.

Example 2—Method of Treating NAION in Non-Human Primates

[0246] This study set out to determine whether epigenetic reprogramming improves RGC function and restores visual function (pERG) in a nonhuman primate (NHP) model of NAION (Non-arteritic Anterior Ischemic Optic Neuropathy). The efficacy of the neuroprotective effect of the doxycycline responsive dual vector system AAV2-TRE-OSK (SEQ ID NO: 35)/AAV2-CMV-rtTA3V16 (SEQ ID NO: 36), in a photothrombotic experimental model of non-arteritic anterior ischemic optic neuropathy (NAION) was evaluated. The vector system was administered intravitreally (IVT) in African green monkeys induced by laser excitation of a systemically administered fluorophore at the optic nerve head (ONH).

Methods

Subject Recruitment

[0247] Monkeys with normal slit lamp and fundus exams, color fundus photographs (CFP), optical coherence tomography (OCT), confocal scanning laser ophthalmoscopy (cSLO), pattern electroretinograms (pERG), and pattern visual evoked potentials (pVEP) were recruited to the study. For baseline screening and all subsequent procedures, anesthesia was achieved with intramuscular ketamine (8 mg/kg) and xylazine (1.6 mg/kg) to effect, and pupil dilation with topical 10% phenylephrine and/or 1% cyclopentolate.

Test Article

[0248] Subjects were administered a composition comprising a dual vector system including a AAV2-TRE-OSK vector and a AAV2-CMV-rtTA3V16 vector. The AAV2-TRE-OSK vector was prepared to a concentration of approximately 1.53 \times 10¹² vg/mL and administered at a dose of 200 µL per dose to the subject. The AAV2-CMV-rtTA3V16 vector was prepared to a concentration of approximately 1.33 \times 10¹³ vg/mL and administered at a dose of 20 µL per dose to the subject. Accordingly, the two vectors were administered in a ratio of 10:1 by volume (v/v) or a ratio of approximately 1:1 by viral genome ratio (vg/vg).

Intravitreal Dosing

[0249] Eyes received a single intravitreal (IVT) injection of test article or vehicle in accordance with the treatment assignment (Table 4). For IVT dosing a drop of proparacaine hydrochloride 0.5% was applied to the eye followed by a lid speculum and 5% Betadine solution, and a rinse with sterile 0.9% saline. Injections were administered to the central vitreous using a 31-gauge 0.375 inch needle inserted inferotemporally at the level of the ora serrata ~2.5 mm posterior to the limbus. Following injection, 1% topical atropine, a topical triple antibiotic neomycin, polymyxin, bacitracin ophthalmic ointment (or equivalent) was administered.

TABLE 4

Treatment Conditions									
Group	N	Eye	NAION Induction	Treatment	Route	Concentration (vg/mL)	Volume	Dose (vg/eye)	Test Article Required
1A	4	OD	No Laser	No treatment	—	—	—	—	—
		OS	Laser	Vehicle (PBS) 28 days pre- NAION induction	IVT	PBS	220	—	(220 µL + 66 µL overage) × 4 = 1144 µL
1B	4	OD	No Laser	No treatment	—	—	—	—	—
		OS	Laser	Vehicle 1 day post- NAION induction	IVT	PBS	220	—	(220 µL + 66 µL overage) × 4 = 1144 µL
2	6	OD	No Laser	No treatment	—	—	—	—	—
		OS	Laser	Candidate #1 28 days pre- NAION induction	IVT	OSK: 1.53×10^{12} rtTA3: 1.33×10^{13}	220	OSK: 3.06×10^{11} rtTA3: 2.66×10^{11}	(220 µL + 66 µL overage) × 6 = 1716 µL
3	6	OD	No Laser	No treatment	—	—	—	—	—
		OS	Laser	Candidate #1 1 day post- NAION induction	IVT	OSK: 1.53×10^{12} rtTA3: 1.33×10^{13}	220	OSK: 3.06×10^{11} rtTA3: 2.66×10^{11}	(220 µL + 66 µL overage) × 6 = 1716 µL

Doxycycline Dosing

[0250] Monkeys received oral doxycycline (5 mg/kg) in a food item (banana slice) starting one day prior to dosing and continuing through study terminus (Table 5).

TABLE 5

Dosing Schedule for Monkey Study											
Event	# Eyes	Base-line*	Study Day								
			-21	-19	-7	0	1	3	7	14	28
CBC EDTA blood	24	—	X	—	—	—	—	—	—	—	—
DNA Methylation blood	20	—	X	—	—	—	—	—	—	—	—
Serum	20	—	X	—	—	—	—	—	—	—	—
Photothrombosis	20	OS	—	—	—	X	—	—	X	—	—
IVT dosing Group 1A & 2	10	OS	—	Gp1A	—	—	—	—	—	—	—
IVT dosing Group 1B & 3	10	OS	—	—	—	—	Gp1B	—	—	—	—
Vitreous Tap	10	OS	—	X§	—	—	X§	—	—	—	—
Doxycycline**	20	—	X	X	X	X	X	X	X	X	X
Methylprednisolone	20	—	—	Gp1A	—	Gp1A	X	—	X	X	X
Body weights	20	—	X	X	—	X	X	—	X	X	X
Detailed clinical exams	20	—	X	—	—	—	—	—	—	—	—
Tonometry	20	OU	X	—	—	X	—	—	X	X	X
Slit lamp exams	20	OU	X	—	Gp1A	X	—	—	Gp1B	X	X
Fundus imaging	20	OU	X*	—	—	X	X	—	X	X	X
Spectralis cSLO	20	OU	X	—	—	X	X	—	X	X	X
Spectralis OCT	20	OU	X	—	—	X	X	—	X	X	X

TABLE 5-continued

Event	# Eyes	Base-line*	Study Day											
			-21	-19	-7	0	1	3	7	14	28	35	42	49
Pattern ERG***	20 OU	X	—	—	X	—	—	—	X	X	X	X	—	X
Pattern VEP***	20 OU	X	—	—	—	—	—	—	X	X	X	X	—	X
fERG***	20 OU	—	—	—	—	—	—	—	—	—	—	—	X	X
Enucleation	20 OU	—	—	—	—	—	—	—	—	—	—	—	—	X

X = event for all treatment groups; Gp1A = event for Group 1A; Gp1B = event for Group 1B; Gp2 = event for Group 2; Gp3 = event for Group 3.

*Baseline prescreen assessments will include evaluation of up to 24 monkeys to meet the targeted number of study recruits.

**Daily oral doxycycline dosing will begin at day -21 for all animals and continue until day 42.

***Exams will be completed within +4 days.

§Vitreous tap done immediately prior to dosing

Immunosuppression

[0251] Monkeys received methylprednisolone (40 mg IM) weekly starting on Day 0 (Table 5). If inflammation exceeding 2+ anterior and/or vitreous cell was observed on subsequent exam subconjunctival dexamethasone (100 mL of 40 mg/mL) was administered, with repeat dosing guided by clinical observations. If inflammation did not respond to dexamethasone, methylprednisolone was increased to 80 mg IM weekly. Administered steroids were applied consistently across all treatment animals.

NAION Induction

[0252] Monkeys were divided by exam and weight criteria into two cohorts. After achieving mydriasis and placement of a saphenous vein catheter, rose bengal (2.5 mg/kg; 0.1 mL/kg of 25 mg/ml) were administered intravenously (IV), followed 25 seconds later by initiation of laser spot application to the ONH. Laser spots were applied with an Iridex Oculight TX 532 nm laser using a 0.9x contact laser lens. Four spots were placed in the four quadrants of the ONH, each of pulse duration 6 seconds, spot size 500 µm, power 100 mW. The first spot was applied in the superotemporal aspect of the ONH, the second in the inferotemporal, the third in the inferonasal, and the fourth in the superonasal. Branched retinal veins and arteries were avoided in the placement of each spot. Post-laser CFP imaging was performed immediately to document response to laser photocoagulation procedure.

Tonometry

[0253] Intraocular pressure (IOP) was measured oculus uterque (OU) or in both eyes using a TonoVet tonometer set to the dog (d) calibration setting. Three measures were taken from each eye at each ophthalmic examination time point (Table 8) and the mean IOP was defined.

Vitreous Humor Collection

[0254] At designated time points (Table 5) vitreous humor (~170 µL) was collected OU with a 1.0 mL syringe with a 27-gauge needle introduced into the mid-vitreous by temporal scleral puncture at the level of the ora serrata. Vitreous humor aliquots were transferred to pre-labeled cryotubes, flash frozen, and stored and shipped for analysis.

Full Field Electroretinography (fERG)

[0255] At designated time points (Table 5), slit lamp biomicroscopy and retinoscopy were performed in both eyes (OU), employing an LKC UTAS full-field ERG apparatus and emWin software (Version 9.8.0). Immediately after sedation and topical instillation of 10% phenylephrine and 1% cyclopentolate, eyes were dark-adapted for 30 minutes. Additional mydriatic were administered prior to stimulus exposure. fERGs were performed OD then OS (or OS then OD in random order). After placement of a DTL electrode (or Burian-Allen contact lens electrode), a subdermal reference electrode at the ipsilateral lateral canthus, and ground electrode in the upper limb for unilateral sequential testing a scotopic rod-specific response was elicited by a dim white flash in a LED Ganzfeld stimulator bowl. Mixed rod and cone responses were obtained using standard bright white flashes under scotopic conditions. To evaluate the photopic function of cone photoreceptors, monkeys were light-adapted to ambient room light for 10 minutes, after which a strobe white-flash stimulus was presented to the dilated eye using maximum flash intensity. The following ISCEV stimulus standards for toxicology studies were applied:

[0256] Scotopic 0.158 cd·s m² (-12 dB) stimulus (rod-driven response of on bipolar cells measured, b-wave)

[0257] Scotopic 2.51 cd·s m² (0 dB) stimulus (rod and cone-driven response of both photoreceptors, a-wave, and on bipolar cells, b-wave)

[0258] Photopic 2.51 cd·s m² (0 dB) stimulus (cone driven response of both photoreceptors, a-wave, and on and off bipolar cells, b-wave)

[0259] Photopic 30 Hz flicker stimulus at 2.51 cd·s m² (0 dB) stimulus (cone driven response)

[0260] Stimulus induction was denoted by a marker. The time integrated luminance of the stimulus and the background was recorded in absolute values. Monkeys underwent scotopic exams before photopic exams and underwent stimulus exposure order of increasing stimulus strength for a given adaptation. Single stimulus exposures preceded flicker stimulus exposure to avoid bleaching and loss of adaptation. Waveforms were analyzed for a- and b-wave amplitudes and latency. The amplitude of the b-wave was measured from the a-wave trough to the peak of the b-wave or, if no a-wave was present, from the pre-stimulus baseline to the peak of the b-wave. The amplitude of the a-wave was measured from the pre-stimulus baseline to the peak of the a-wave. A nonhuman primate ophthalmic scoring system was employed to assess ocular pathology changes in

response to NAION induction and treatment intervention with a summary score derived from exam components. Incidence of papilledema and flame hemorrhage was also evaluated.

Imaging

[0261] Color anterior segment and fundus photography was performed using a Topcon TRC-50EX retinal camera with Canon 6D digital imaging hardware and New Vision Fundus Image Analysis System software.

Optical Coherence Tomography (OCT) and Confocal Scanning Laser Ophthalmoscopy (cSLO)

[0262] At designated time points (Table 5), cSLO and OCT were performed using a Heidelberg Spectralis HRA OCT with HEYEX image capture and analysis software. cSLO infrared (IR) and autofluorescence (AF) images were obtained at 300 field of view centered on the fovea and the follow-up imaging function referencing the baseline images. An overall OCT volume scan of the optic nerve and entire macula was performed by posterior pole. Images were qualitatively assessed with quantitative analysis of calculated retinal thickness. For the macula centered posterior pole scan, ganglion cell layer (GCL) and retinal nerve fiber layer (RNFL) thickness maps were generated, and the thickness data exported to an electronic spreadsheet. Peripapillary retinal nerve fiber layer thickness (pRNFL) thickness was determined in each quadrant (superior, inferior, temporal, nasal). HEYEX raw data files were generated for additional analyses.

Pattern ERG and VEP

[0263] At designated time points (Table 5), pattern ERGs (pERGs) and pattern VEP (pVEP) recordings were performed OU by positioning the monkeys with a DTL electrode and an additional active electrode placed in the inion in the midline at the posterior of the skull, with a ground electrode placed in the arm. A VERIS retinal projecting stimulator was used to project an alternating black and white checkerboard pattern at 2 Hz with a luminance of 100 cd/m² at a contrast of 80% over a field of 45% generated by a VERIS multifocal ERG instrument. Grid size was varied in logarithmic steps, recordings at each grid size repeated twice and latencies and amplitudes determined. pVEP amplitude and pERG N95 amplitude were determined.

Clinical Observations

[0264] General wellbeing was assessed twice daily by cage side observation beginning one week prior to dosing and extending to study terminus.

Detailed Clinical Examination

[0265] Detailed clinical observations and physical exams were performed at designated time points (Table 5). Respiratory rate, heart rate, blood pressure, auscultation and integrity of the integument were also assessed. Body temperature was determined using a digital rectal thermometer.

Body Weights

[0266] Body weights were collected at ophthalmic exam intervals (Table 5).

CBC with Differential

[0267] Blood (0.5 mL) was transferred directly to K₂EDTA lavender top vacutainer tubes (Greiner MiniCollect EDTA tubes REF #450475) and maintained on ice until CBC with differentials analysis on a Hemavet analyzer.

DNA Methylation Blood

[0268] Blood was transferred directly to K₂EDTA anticoagulated 0.5 mL microcentrifuge tube. Samples will then be lysed, and DNA isolated on QIAamp MiniElute columns per the manufacturer's instructions (Qiagen). DNA samples were analyzed for DNA methylation measures of biologic age.

Serum

[0269] At designated time points (Table 5), blood (3 ml) was transferred directly to serum separator tubes (red top) and allowed to sit at room temperature for 30 to 60 minutes prior to centrifugation at 3000 rpm for 10 minutes at 4° C. Two serum aliquots (~0.5 mL×2) as available were carefully transferred to labeled 1.8 mL cryotubes and stored and shipped below -70° C. to a designated lab for nAb analysis.

Enucleation and Eye Processing

[0270] At study terminus (Table 5), after confirmation of the quality of in-life imaging and electrophysiology, monkeys were sedated with intramuscular ketamine (8 mg/kg) and xylazine (1.6 mg/kg) to effect, animals were then euthanized with sodium pentobarbital (100 mg/kg IV) to effect. Globes (OU) were enucleated after placing a suture marker at the 12 o'clock position. Globes with attached optic nerve were trimmed of excess tissue and placed in Davidson's fixative at room temperature for 24 hours with injection of ~300 µl of Davidson's fixative into the globe. The globes were transferred to phosphate buffered saline (PBS) with 0.05% sodium azide and stored and shipped in a container maintained at 4° C. to the designated histology lab for histological and immunohistochemical processing and analysis by a board-certified veterinary pathologist. Additional quantitative scoring of histology was conducted, guided by qualitative findings.

pERG Results

[0271] A NAION-like injury was induced on Day 0 in all NHPs (African Green monkeys; N=20) by iv rose bengal followed by laser treatment of the OS eye ONH. Pre-treated NHPs (n=6) received on Day -28 an intravitreal (IVT) injection of OSK (doxycycline-inducible AAV2-OSK; 1:1 ratio of AAV2-TRE-OSK+AAV2-CMV-rtTA3), or vehicle (n=4) into the OS eye. Post-treatment NHPs received on Day +1 an IVT injection of OSK (n=6), or vehicle (n=4) into the OS eye. All NHPs received daily oral doxycycline throughout the experiment. Both eyes were examined at baseline then at weekly intervals until Day +35 post-laser treatment (corresponding to Day 42) for multiple imaging and functional measures of retinal ganglion cells (RGCs).

[0272] Consistent with NAION pERG deficits in humans, the laser induced a NAION-like injury in vehicle treated OS eyes with a significant loss in pERG amplitude relative to OD (untreated) eyes (FIGS. 1A and 1B). Pretreatment with OSK in OS eyes increased pERG amplitude and partially reversed the NAION-like pERG deficits compared with vehicle-treated control eyes at the endpoint (p50-n95 amplitude: 5.36±0.91 vs 3.95±1.01, n.s., 5 weeks post-laser treat-

ment; see FIG. 6). Post-treatment with OSK showed a significant recovery of pERG function by 5 weeks post-laser treatment (p50-n95 amplitude: 4.60±0.24 vs 2.89±0.79, P=0.039) (FIG. 7).

Results on Rescuing Axon Damage

[0273] Optic Nerve Myelin-Specific (PPD) Axon Stain was used to show the function of OSK expression to rescue axon damages subjected to induction of the NAION injury. As shown in FIG. 8, compared to vehicle treatment, post-expression of OSK rescued axon damages and increased axon numbers (counted with AxonNet; for a review of AxonNet, see Ehrlich and Rivera, AxonNet: A self-supervised Deep Neural Network for Intravoxel Structure Estimation from DW-MRI. ArXiv abs/2103.11006 (2021)). The enhancement of axon survival by OSK, compared to vehicle treatment, after laser-induced damage is further shown in FIG. 9.

[0274] As a summary for the NHP NAION study described herein, treatment with OSK improves RGC func-

tion, consistent with potential improvement in vision. In addition, treatment with OSK increases the number of healthy axons in the optic nerve, consistent with the potential for regeneration in the animals.

EQUIVALENTS AND INCORPORATION BY REFERENCE

[0275] All references, articles, publications, patents, patent publications, and patent applications cited herein are incorporated by reference in their entireties for all purposes. However, mention of any reference, article, publication, patent, patent publication, and patent application cited herein is not, and should not be taken as an acknowledgment or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.

[0276] While various specific embodiments have been illustrated and described, it will be appreciated that various changes can be made without departing from the spirit and scope of the disclosure.

TABLE 6

AAV2-TRE-OSK Vector Sequences			
	SEQ ID NO:	Component	Sequence
1	Human OCT4 nucleic acid sequence		ATGGCGGGACACCTGGCTTCGGATTTCGCCCTCTGCCCGCC CAGGTGGTGGAGGTGATGGGCAAGGGGGCCGGAGCGGGCTG GGTTGATCCTCGGACCTGGCTAAGCTTCCAAGGCCCTCTGG GGCCAGGAATCGGGCCGGGGTTGGCCAGGCTCTGAGGTGT GGGGGATCCCCCATGCCCGCCGTATGAGTTCTGTGGGG GATGGCGTACTGTGGGCCCAAGGTGGAGGTGGGCTAGTGCC CAAGGCGGCTGGAGAACCTCTCAGCCTGAGGGGAAGCAGGAG TCGGGGTGGAGAGCAACTCCGATGGGGCTCCCGGAGGCCCTG CACCGTCACCCCTGGTGGCGTGAAGCTGGAGAAGGAGAAGCTG GAGCAAAACCAGGAGGACTCCAGGACATCAAAGCTCTGCAGA AAGAACTCGAGCAATTGCAAGCTCTGAAGCAGAAGAGGAG CACCCCTGGGATAATACACAGGGCATGTGGGCTCACCTGGGG GTCTCTATTGGGAAGGTATTCAAGCCAAACGACCATCTGCCCT TTGAGGCTCTGAGCCTAGCTTAGCTCAAGAACATGTGTAAGCTG GCCCTTGCTGAGAAGTGGGGAGGAAGCTGACAACAATGAA AATCTCAGGAGATATGCAAAAGCAGAACCTCTGTGCAGGGCC GAAAGAGAAAGCGAACCAAGTATCGAGAACCGAGTGAGAGGCAA CCCTGGAGATTGTTCTCTGCACTGCCCCAACCCACACTGAG CAGATCAGCCACATCGCCCAAGCAGCTGGGCTCGAGAGGATG TGGTCAGTGTGGTTCTGTAACGGGCCAGAAGGGCAAGGG ATCAAGCAGCAGTATGCACAAACGAGAGGATTGGCTGCT GGGTCTCTTCTCAGGGGGACCAAGTGTCCCTTCCTCTGGGCC CAGGGCCCCATTGGTACCCCAAGGCTATGGAGGCCCTCACT CACTGCACTGTACTCCTGGCTTCCCTGAGGGGGAAAGCC TTTCCCCCTGTCCTGTCACCACACTGGCTCTCCCATGCATT CAAAC
2	Human OCT4 amino acid sequence		MAGHLASDFAFSPPPGGGGDPGPPPEPGWVDPRTWLSFQGPPG GPGIGPGVPGPSEWGIPCP CPPYEF CCGMAYCGPQVGVLVP QGGLETSQPEGEAVGVVESNSD GASPEPCTVTPGAVKLEKEKL EQNPEESQDI KALQKELEQFAKLLKQKRITLGYTQADVGTLTG VLF GK VFS QTTICR FEAL QSM FPK NMCK LRP LLQ KVWEADNN NLQEICKAETLVQARKRRTSIE NR VRGNL ENFL QCPKPTLQ QISHIAAQQLGEKDV RVWF CNR RQKG RSS SDY AQR ED FEEA GSPFSGGPVSPFLAPGPHFGPTG YGSPHFT ALYSS VP FPEG EA FPPV SVT TL GSP MHSN
3	Human SOX2 nucleic acid sequence		ATGTACAACATGATGGAGACGGAGCTGAAGCCGCCGGCC AGCAAAACTTCGGGGGGCGCCGGCGCAACTCCACCGCGGCC GGCCGGCGCAACCAAGAAAAACAGCCGGACCGCGTCAAGCGG CCC ATGAATGCCCTCATG GTGTG CCG CGGG CAG CGG CGCA AGATGGCCCAAGGAGAACCCCAAGATGCACA ACTCGGAGATCAG CAAGCGCTGGCGCCGAGTGGAAACTTTGTGGAGACGGAG AAGCGGCCGTATCGACGAGGCTAAGCGGCTGCGAGCGCTGC ACATGAAGGAGCACCCGGATATAAATACGGCCCCGGCGAA

TABLE 6-continued

AAV2-TRE-OSK Vector Sequences		
SEQ ID NO:	Component	Sequence
		AACCAAGACGCTCATGAAAGAAGGATAAGTACACGCTGCCCGC GGGCTGCTGGCCCCCGCGCGCAATAGCATGGCGAGCGGGGTG GGTGGGGCCCGGCCCTGGCGCGGGCGTGAACCAAGCGGCATG CAGTTACGCGCACATGAAACGGCTGGAGCAACGGCAGCTACAG ATGATGCAAGGACAGCTGGCTACCCGAGCACCCGGGCTCA ATGCGCACGGCGCAGCGCAGATGCAAGCCCAGCACCGCTACGA CGTGAGGCCCTCGAGTACAACCTCCATGACCAGCTCCAGAC TACATGAACGGCTCGCCACACTACAGCATGTCCTACTCGCAG AGGGCACCCCTGGCATGGCTTGGCTTACATGGTTGGTGTG CAAGTCGAGGCCAGCTCCAGGCCCTGTGGTTACCTTCTCC TCCCACTCCAGGGCGCCCTGCCAGGCCGGGACCTCCGGGACA TGATCAGCATGATCTCCCCGGCGCCGAGGTGCGGAAACCCG CGCCCCCAGCAGACTTACATGTCCAGCAGTACCCAGAGCGG CCGGTCCCCGGCACGGCATTACAGGCACACTGCCCTCTCAC ACATG
4	Human SOX2 amino acid sequence	MYNMMETELKPPGPQQTSGGGGGNSTAAAAGGNQKNSPDRVKR PMNAFMVWSRGQRKMAQENPKMHNSEISKRLGAEWKLLETE KRPFIIDEAKRLRALHMKHPDYKYPKPRKTKTLMKDKYTLPG GLLAPGGNSMASGVGVGAGLGAAGVQNRMDSYAHMNGWSNGSYS MMQDQLGYQPQHPLNNAHQAQMPHMRYDVSLQYNSMTSSQT YMGNSPTYSMSYSQQGTPGMALGSMGSVVKSSEASSPVPVITS SHSRAPCQAGDLRDMISMYLPGAEVPEPAAPSLRHMSQHYQSG PVPGTAINGTLPPLSHM
5	Human KLF4 nucleic acid sequence	ATGGCTGTCAAGCGACCGCCTGCTCCCATTTCTCCACGTTG CGTCTGGCCCGCGGGAAAGGGAGAACACTCGCTCAAGCAGG TGGCCCGAATAACCGCTGGCGGGAGGAGCTCTCCACATGAAG CGACTTCCCCCAGTGCTTCCCGCCCGCCCCCTATGACCTGGCGG CGGGACCGTGGCCACAGACCTGGAGAGCGGGAGCGGGTGC GGCTTGCGGGTAGCACCTGGCGCCCTACCTCGGAGAGAG ACCGAGGAGATCAACGATCTCTGGACCTGGACTTTATTCTCT CCAATTCGCTGACCCATCCTCCGGAGTCAGTGGCCGCCACCGT GTCTTCGTCAGCGTCAGCTCTCTCGTCGCTCGCCGTGAGC AGCGGCCCTGCCAGCGCGCCCTCACCTGCACTTCACCTATC CGATCCGGCCCGGAAACGACCCGGCGCTGGCCGCCGGCAC GGCCGGAGCCCTCTATGCCAGGGAGTCGGCTCCCCCTCCG ACGGCTCCCTCAACCTGGGGACATCAACGACGTGAGCCCT CGGGCGCTTCGTGGCGAGCTCTGGCCGAGAATTGGACCC GGTGTACATTCCGCCAGCAGCGCCAGCCGGAGGTGGCGGG CTGATGGCAAGTTCGTCGTAAGGGCGTCGCTGAGCGCCCTG GCAAGCAGTACGGCAGCCCGTCGTCAGCGTCAGCAAAGG CAGCCCTGACGGCAGGCCACCGGGTGGTGGCGCCCTAACAC GGCGGGCCGCCCGCAGCTGGCCCAAGATCAAGCAGGAGGGCG TCTCTTCGTCACCCACTTGGCGCTGAGGCCAGGCGCC TGGCCACCGCCGGCTGACAGACTTCCCTGGGGCGAG CTCCCCAGCAGGACTACCCGACCCCTGGGCTTGGAGAAGTGC TGAGCAGCAGGGACTGTCACCTGGCCCTGCGCTTCTCCCG CTTCCATCCCCACCCGGGGCCAATTACCCATCTTCCCTGCCC GATCAGATGCAAGCCGAAGTCCCGCCGCTCATTACCAAGAGC TCATGCCACCCGGTTCTGCAATGCCAGAGGAGCCCAAAGCCAA GAGGGGAAGACGATCGTGGCCCGGAAAAGGACGCCACCCAC ACTTGTGATTACCGGGCTCGCGCAAACACTACACAAAGAGTT CCCCATCTCAAGGCACACCTGGCAACCCACACAGGTGAGAAACC TTACCACTGTGACTGGGAGCGCTGTGGATGAAATTGCCCGC TCAGATGAACGTGACCAAGGCACTACCGTAAACACACGGGGCACC GGCGGTTCCAGTGGCCAAAATGCGACCGAGCATTTCAGGTC GGACCACTCGCTTACATGAAAGAGCATTTC
6	Human KLF4 amino acid sequence	MAVSDALLPSFSTFASGPAGREKTLRQAGAPNNRWREELSHMK RLPPVLPGRPYDLAAATVATDLESGGAGAACCGGSNLAPLPRRE TEEFNDLDDLFILSNSLTHPPESVAATVSSSASASSSSPSS SGPASAPSTCSPTYPIRAGNDPGVAPPGTGGLLYGRESAPP TAPFNLADINDVSPSGGFVAELLRPELDPVYIIPPQQPQPPGG LMGKFVULKASLSAPGSEYGSPSVISVSKGSPDGSHPVVVAPYN GGPPRTCPKIKQEAWSCTHILGAGPPLSNGHHRPAAHDFPLGRQ LPSRTTPTLGEEVLSRDCPHALPLPPGFPHPGPNYPSLPLP DQMQPQVPLHYQELMPPGSCMPEEPKPKRGRRSWRPKRTATH TCDYAGCGKTYTKS SHLKAHLRHTGEKPYHCDWDGCGWKFAR SDELTRHYRKHTGHRPFQCQKCDRAFSRSRSDHLALHMKRHF

TABLE 6-continued

AAV2-TRE-OSK Vector Sequences		
SEQ ID NO:	Component	Sequence
7	TRE3G (TRE promoter)	TTTACTCCCTATCAGTGATAGAGAACGTATGAAGAGTTACTC CCTATCAGTGATAGAGAACGTATGCAGACTTACTCCCTATCA GTGATAGAGAACGTATAAGGAGTTACTCCCTATCAGTGATAG AGAACGTATGACCAGTATTACTCCCTATCAGTGATAGAGAACGT ATCTACACTTTACTCCCTATCAGTGATAGAGAACGTATAATCCA GTTTACTCCCTATCAGTGATAGAGAACGTATAAGCTTAGCGC TGTCAGGGTGGGCCCTATAAAAGCAGAGCTCGTTAGTGAACC GTCAGATGCGCTGGAGCAATTCCACAAACACTTTGTCTTATAC CAACTTCCGTACCACTTCTACCCCTCGTAAA
8	P2A peptide from porcine teschovirus-1 polyprotein	GCCACGAACTTCTCTGTAAAGCAAGCAGGAGATGTTGAAG AAAACCCCAGGCT
9	P2A amino acid	ATNFSLLKQAGDVEENPGP
10	T2A peptide from Thosea asigna virus capsid protein	GAGGGCAGGGGAAGTCTTCTAACATGCGGGACGTGGAGGAAA ATCCCGGCCCA
11	T2A cleavage sequence amino acid	EGRGSLLTCGDVEENPGP
12	SV40	AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAGCAATA GCATCACAAATTTCACAAATAAGCATTTCCTACTGCATTC TAGTTGTGGTTGTCCAACACTCATCAATGTATCTTATCATGTC TGGATC
13	OCT4-2A- SOX2-2A- KLF4 (Whole insert sequence including Tet operators and SV40, minus ITRs)	CTATGCGGCATCAGAGCAGATTGACTGAGAGTGCACCATATG CGGTGTAAATACCGCACAGATCGTAAGGGAAAAATACCGCA TCAGGCCCATTCGCCATTCAAGCTGCCAACTGTTGGAAAG GCGATCGTGCAGGCGATTAAGTTGGTAACGCCAGGGT GGGGGATGTGCGCAAGCGATTAAGTTGGTAACGCCAGGGT TTTCCCACTCACGACGTTGAAACAGCACGGCAGTGAATTGAC GCGTATTGGGATCCATGATTACGCCAGATTAAATTAGGCCCT AATTAGGCTGGCGCTCGCTCGTCACTGAGGCCGGCG AAGCCCGGGCGTCGGCGACCTTGGTCGCCCGCCTCAGTGA GCGAGCGAGCGCCAGAGAGGGAGTGGCCAACCTCCATCAG GGGTTCTTGTAGTTAATGATTAACCCGCCATGCTACTTATCT ACGTAGCCATGCTCTAGGAAGATCGGAATTCTTACTCCCTAT CAGTGATAGAGAACGTATGAAGAGTTACTCCCTATCAGTGAT AGAGAACGTATGAGACTTACTCCCTATCAGTGATAGAGAAC GTATAAGGAGTTACTCCCTATCAGTGATAGAGAACGTATGAC CAGTTACTCCCTATCAGTGATAGAGAACGTATCTACAGTTTA CTCCCTATCAGTGATAGAGAACGTATATCCAGTTACTCCCTA TCAGTGATAGAGAACGTATAAGCTTAAAGCGTGTACCGTGGC GCCCTATAAAAGCAGAGCTGTTAGTGAACCGTCAGATGCC GGAGCAATTCCAACACTTTGTCTTATACCAACTTCCGTA CCACTTCCCTACCCCTCGTAAAGCGGCCGCCACATGGCGGA CACCTGGCTTCGGATTTCGCCTTCTGCCCGCTCCAGGTGGT GAGGTGATGGGCCAGGGGGGGGGAGCGGGCTGGTTGATCC TCGGACCTGGCTAAGCTTCAAGGCCCTCTGGAGGGCAGGA ATCGGGCGGGGGTTGGGCCAGGCTGTGAGGTGTGGGGGATTC CCCCATGCCCGCCGTAGTTCTGTGGGGGATGGCGTA CTGTGGGGCCCAAGGTTGGAGTGGGGCTAGTGCCTTCAAGGCC TTGGAGACCTCTCAGCTTGAGGGCGAAGCAGGAGTCGGGTG AGAGCAACTCCGATGGGCCCTCCCGGAGCCCTGCACCGTAC CCCTGGTGCCGTGAAGCTGGAGAAGGAGAACGTGGAGCAAAC CCGGAGGAGTCCCAAGGACATCAAAGCTCTGCAGAAAGAACCTG AGCAATTGCAAGCTCTGAGCAGAGAGGATCACCTGG ATATACACAGGCCATGTGGGCTCACCTGGGGTCTATT GGGAAGGTATTAGCCAAACGACCATCTGCCCTTGGGCT TGCAGCTTAGCTCAAGAACATGTGTAAGCTGCCCTTGT GCAGAAGTGGGGAGGAAGCTGACAACAAATGAAAATTCAG GAGATATGCCAAAGCAGAAACCCCTCGTGCAGGCCGAAAGAGA

TABLE 6-continued

AAV2-TRE-OSK Vector Sequences		
SEQ ID	NO: Component	Sequence
		AGCGAACCGAGTATCGAGAACCGAGTGAGAGGGCAACCTGGAGAA TTTGTTCCTGCAGTGCCCAGAACCCACACTGCGAGCAGATCAGC CACATCGCCAGCAGCTTGGGCTCGAGAAGGGATGTGGTCCGAG TGTGGTTCTGTAACCCGGCGCAGAAGGGCAAGCGATCAAGCAG CGACTATGCCAACGAGGGATTGAGGCTCTGGGTCTGGGTCTCTT TTCTCAGGGGACAGTGTCTTCCTCTGGCCCCAGGGCCCC ATTGGTACCCAGGCTATGGGAGCCCTCACTTCACTGCAC GTACTCTCGGTCCCTTCCCTGAGGGGGAAAGCCTTCCCCCT GTCTCTGTCACCACTCTGGGCTCTCCATGCAATTCAAACGCTA GCGGAGCGGGCGCACGAACCTCTCTGTAAAGCAAGCAGG AGATGTTGAAGAAAACCCCGGGCTGCATGATGTAACACATG ATGGAGACGGAGCTGAAGCCGGGGGGCGCAGCAAACCTTCGG GGGGCGCGCGCGCAACTCCACCGCGGGGGCGCGCGCAA CCAGAAAAACAGCCCGGACCAGCGCTCAAGCGGCCATGAATGCC TTCATGGTGTGGTCCCGGGGAGCGGCCAGAAGATGCCAGG AGAACCCCAAGATGCAAAACTCGGAGATCAGCAAGGGCTGGG CGCGAGTGGAAACTTTGTCGGAGACGGAGAAGCGGCCGTTTC ATCGACGAGGCTAACGGGCTGCGAGCGCTGCACATGAAGGAGC ACCGGATTATAATACGGGCCCCGGCGAAACCAAGACGCT CATGAAAGAAGGATAAGTACACGCTGCCCCGGGGCTGCTGGCC CCCCGGCCAATAGCATGGCAGCGGGTGGGGTGGCGCCCG GCCCTGGGCGGGCGTGAACACAGCGCATGGCAGTTACGCCA CATGAACCGCTGGAGCACGGCAGCTACAGCATGATGCAAGGAC CAGCTGGGCTAACCGCAGCACCCGGGCTCAATGCGCACGGG CAGCGCAGATGCAAGCCATGCAACGGCTACGACGTGAGGCC GCAGTACAACCTCATGACCAAGCTCGCAGACATGAACGCC TCGCCACCTACAGCATGTCCTACTCGCAGCAGGGCACCCCTG GCATGGCTCTGGCTCATGGGTTGGTCAAGTCCGAGGC CAGCTCCAGCCCCCTGTGGTTACCTCTCCACTCCAGG GCCCTGCGCAGGGCACCTCGGGACATGAGCATGAGTGT ATCTCCCCGGCGCGAGGTGGCGGAACCGCCGCCAGCAG ACTTCACATGTCCAGCACTACCCAGAGCGGGCCGGTCCCCCG ACGGCCATTAAACGGCACACTGCCCCCTCAACATGGCAGCG GCTCGGGAGGGCAGGGGAAGTCTTCAACATGCGGGAGCT GGAGGAAAATCCGGCCCCTCGAGATGGCTGAGCGACCG CTGCTCCCATCTTCTCACGTTGGCGCTTGCGGGGGAA GGAGAAGACACTCGCTAACCAAGGTCCCCAATAACCGCTG GCGGGAGGAGCTTCCACATGAAGGACTTCCCCAGTGT CCCGGCCGCCCCATGACCTGGCGGGCGACCGTGGCACAG ACCTGGAGAGCGGGCGAGCCGGTGGCGCTTGCGGGTAGCAA CCTGGCGCCCCCTACCTCGGAGAGAGACCGAGGGATTCAACGAT CTCTGGACCTGGACTTATCTCTCAATTGCTGACCCATC CTCCGGAGTCAGTGGCGCCACCGTGTCTCGTCAGCGTCAGC CTCTCTCGTCGCGCTCGAGCAGCGGGCTGCGAGCG CCCTCCACCTGCGCTTCACTATCCGATCGGGGCCGGAAACG ACCCGGGCTGGCGCCGGGGCACGGGGAGGGCTCTCTA TGGCAGGGAGTCGCTCCCCCTCCGACGGCTCCCTCAACCTG GCCGACATCAACGACGTGAGGCCCTCGGGCGCTTGTGGCG AGCTCTCGGCCAGAAATTGGACCCGGTGTACATTCCGCC GCAGCGCAGGCCAGGTGGCGGTGATGGGAAGTCCGAGCG CTGAAGGCTCGCTGAGCGCCCTGGCAGCAGTACGGCAGCC CGTGGTCACTCGCTCAGCAAAAGGAGCCCTGACGGCAGCCA CCGGTGGTGGTGGCGCCCTAACACGGGGGGGGGGGG TGGCCCAAGATCAAGCAGGGGGCTCTTGTGACCCACT TGGGGCTGGACCCCTCTCAGCAATGGCCACCGGGGCGCTGC ACACGACTTCCCTCTGGGGCCAGCTCCCAAGCAGGACTAAC CCGACCCCTGGGTCTTGAGGAAGTGTGAGCAGCAGGGACTGTC ACCCCTGCCCTGCCGCTTCTCCGGCTTCCATCCCCACCCGG GCCCAATTACCCATCTTCTGCCGATCAGATGCAGCGCAA GTCCCGCCGCTCCATTACCAAGAGCTCATGCCACCCGGTCT GCATGCCAGAGGGAGCCAAGGCAAAGGGGAAGACGATCGTG GCCCGGAAAGGACCGCACCCACACTTGTATTAGCGGG TGCGGCAAACCTACACAAAGAGTCCATCTCAAGGCACACC TGCGAACCCACACAGGTGAGAAACCTTACCACTGTACTGGG CGGCTGTGGATGGAATTGCCCGCTCAGATGAACCTGACCG CACTACCGTAAACACACGGGACCGGCCGTTCCAGTGC AATGCGACCGAGCATTTAAATGACTAGTGCAGCTTAA CATGAAGAGGCATTTAAATGACTAGTGCAGCTTAA CCATGGCCCAACTTGTGTTATGCAAGCTTAAATGGTTACA AAAGCAATAGCATCACAAATTTCACAAATAAGCATT ACTGCATTCTAGTTGTGGGTTGTCCAAACTCATCAATGTATCT

TABLE 6-continued

AAV2-TRE-OSK Vector Sequences		
SEQ	ID	NO: Component Sequence
		TATCATGTCTGGATCTCGGACCGGATCCAATTCCCGATAAG GATCTTCCTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGG TTAATCATTAACTACAAGGAACCCCTAGTGATGGAGTTGGCCA CTCCCTCTCGCGCGCTCGCTCACTGAGGCCGGCGACC AAAGGTGCCCGACGCCCGGGCTTGGCCGGCGCTCAGTG AGCGAGCGAGCGCGCAGCCTTAATTAACCTAATTCAATCCAAT GGCGCGCCGAGCTTGGCTCGAGCATGGTCAT
14	OCT4-2A- SOX2-2A- KLF4 (Whole insert sequence, does not include SV40 or Tet Operators)	ATGGCGGGACACCTGGCTTGGGATTTGCCCTTCGCCCCCTC CAGGTGGTGGAGGTGATGGGCAGGGGGCCGGAGCCGGCTG GGTGTGATCTCGGACCTGGCTAAGCTTCCAAGGCCCTCTGG GGGGCAGGAATCGGGCGGGGGTTGGGCCAGGGCTCTGAGGTGT GGGGGATTCCCCATGCCCGCCCGCTATGAGTTCTGTGGGG GATGGCGTACTGTGGGCCAGGTTGGAGTGGGGCTAGTGGCC CAAGGCCTGAGCTTGGAGACCTCTCAGCCTGAGGCCGAAGCAGGAG TCGGGTGGAGGAGCAACTCCGATGGGGCTCCCGGAGCCCTG CACCGTACCCCTGGCTGGTGAAGCTGGAGAGGAGAGCTG GAGCAAACCCGGAGGAGTCCAGGACATCAAAGCTCTGCAGA AAGAACCTGAGCAATTGCCAAGCTCTGAAGCAGAAGAGGAT CACCCCTGGGATATAACAGGCCATGTGGGCTCACCTGGGG GTTCTATTGGGAAGGTATTCAAGCCAAACGACCATCTGCCGT TTGAGGCTCTGAGCTTAGCTTCAGAACATGTGAAGCTGG GCCCTTGCTGAGAAGTGGGTGGAGGAAGCTGACAACAATGAA AATTTCAAGGAGATATGCAACAGCAGAAACCTCTGTGAGGGCC GAAAGAGAAAGCGAACCAAGTATCAGAGAACCGAGTGAAGGGCAA CCTGGAGAATTGTTCTGAGTGGCCGAAACCCACACTGCAG CAGATCAGCACATGCCAGCAGCTGGGCTGAGAACAGGATG TGGTCCAGAGTGTGGCTCTGTAACCGGCCAGAACAGGCAAGG ATCAAGCAGCAGTATGCAACAGAGGATTTGAGGCTGCT GGGTCTCTTCTCAGGGGACCAAGTGTCTTCTCTGGCC CAGGGCCCATTTGGTACCCAGGCTATGGAGGCCCTCACTT CACTGCACTGACTCTCGGCTTCCCCTGAGGGGAAGCC TTTCCCCCTGTCTCTGTCACACTCTGGCTCTCCCATGATT CAAACGCTAGCGCAGCGCGCCACGAACTCTCTGTAA GCAAGCAGGAGATGTTGAAGAAAACCCGGCCTGAGTCAG TACAACATGATGGAGACGGAGCTGAAGCCGGGGCCGAGC AAACTTCCGGGGCGCCGGCGCAACTCCACCCGGGGCCG CGGGCGAACAGAAAACAGCCGGACCGCGTCAAGCGGGCC ATGAATGCTTATGGTGTGGTCCCAGGGCAGCGCGCAAGA TGGCCAGGAGAACCCCAAGATGCAAAACTCGGAGATCAGCAA GCGCTGGCGCCGAGTGGAAACTTTGTGGAGACGGAGAAG CGGGCGTTATCGACGAGGCTAAGCGCTGGAGCGCTGCACA TGAAGGAGCACCGGATTATAAAACCGCCCGGGAAAAC CAAGACGCTCATGAAGAAGGATAAGTACACGCTGCCCCGGG CTGCTGGGCCCCGGCGCAATAGCATGGGAGCGGGGCTGGGG TGGCGCCGGCTGGCGGGGTGAACCAAGGCAATGGACAG TTACGCGCACATGAACGGCTGGAGCAACGGCAGCTACAGCATG ATGCGAGGACAGCTGGCTACCGCAGCACCGGGCTCAATG CGCACGGCGAGCGCAGATGAGCCCATGACCGCTACGACGT GAGCGCCCTGCACTAACCTCATGACCGCTGCAGACCTAC ATGAACCGCTGCCACCTACAGCATGTCCTACTCGCAGCAGG GCAACCCCTGGCATGGCTTGGCTTACCTCTTCC GTCCGAGGCCAGCTCCAGCCCCCTGTGGTTACCTCTTCC CACTCCAGGGCGCCCTGCAAGGGGGGACCTCGGGACATGA TCAGCATGTATCTCCCGCGCCAGGTGCGGAAACCGCCGC CCCCAGCAGACTTCACATGTCCTCCAGCACTACAGAGGGCCG GTGGCATGGCTCGGGAGGGAGCTCTCCACATGAGCAGCT TGGGGAGGAAATCCGGCCACTCGAGATGGCTGTC AGCGACGCGCTGCTCCCATCTTCCACGTTGCGCTGCGC CGGGCGGAAGGGAGAACACTGCGTCAAGCAGGTGCCCCG TAACCGCTGGCGGGAGGGAGCTCTCCACATGAGCAGCT CCAGTGTCTCCGGCCGCCCCATGACCTGGCGCGGACCG TGGGCACAGACCTGGAGAGCGGGAGCCGGTGCAGGCTTGG CGGTAGCAACCTGGCGCCCTACCTCGGAGAGAGACCGAGGAG TTCAACGATCTCTGGACCTGGACTTTATTCTCTCCAATTGG TGACCCATCTCCGGAGTCAGTGCCTGCACCGTGTCTCGTC AGCGTCAGCCTCTCTGCTCGTGCCTCGAGCAGGGCCCT GCCAGCGCCCTCCACCTGCAGCTCACCTATCCGATCCGG CGGGGAACGACCCGGCGTGGCGCCGGCGACGGCGGAGG CTCCTCTATGGCAGGGAGTCCGCTCCCCCTCGACGGCTCCC

TABLE 6-continued

AAV2-TRE-OSK Vector Sequences		
SEQ ID NO:	Component	Sequence
		TTCAACCTGGCGGACATCAACGACGTGAGCCCTCGGGCGCT TCGTGGCCGAGCTCTGC GGCGAAGATTGGACCCGGTGTACAT TCGGCCGAGCAGCCGAGCCGGCAGGTGGCGGGCTGATGGC AAGTCGTCTGAAGGGCTGCTGAGGCCCTGGCAGCGAGT ACGGCAGCCCGTGGTCACTCAGGGTCAAGCAAAGGCAAGCC CGGCAGCCACCCGGTGGTGGCGCTACAACGGCGGGCG CCGGCAGCCGGCCAAAGATCAAGCAGGAGGCGGTCTTCTG GCAAGGACTTGGGCGCTGGACCCCTCTCAGCAATGGCCACCG GCCGGCTGCACACGACTTCCCCCTGGGGCGAGCTCCCCAGC AGGACTACCCGACCCCTGGGTTTGAGGAAGTGCTGAGCAGCA GGGAAGTGTACCCCTGCCCTGCCGCTTCTCCGGCTTCCATCC CCACCCGGGGGGCCAAATTACCATCCTTCTGCCCAGATCAGATG CAGCCGAAGTCCCCTGGCCATTACCAAGAGCTCATGCCAC CCGGTCTCTGCATGCCAGAGGAGGCCAAAGCCAAGAGGGGAAAG ACGATCGTGGCCCCGGAAAAGGACCGCCACCCACATTGTGAT TACCGGGCTGGGCAAACACTACACAAAGAGTTCCCATCTCA AGGCACACCTTGCAGACCCACAGGTGAGAAACCTTACCACTG TGACTGGGACGGCTGTGGATGGAATTGCGCCGCTCAGATGAA CTGACCAGGCACCTACCGTAACACACGGGGCACCGCCGTTCC AGTGCACAAAGATGCGACCGAGCATTTCAGGTCGGACCACT CGCCTTACACATGAAGAGGCATTTC
15	pAAV2- TRE3G- OSK-SV40 (full plasmid sequence, including selection cassettes)	TGCGCGCTTCGGTGTGACGGTGAACACCTCTGACACATGCA GCTCCCGGAGACTGTACAGCTTGTCTGTAAGCGGATGCCGG AGCAGACAAAGCCGTCAAGGCCGGTCAAGCGGTGTTGGCGGG GTCGGGGCTGGCTTAACTATGCGGCATCAGACAGATTGTACT GAGAGTCACCATATGCGGTGTGAAATACCGCACAGATGCGTA AGGAGAAAATACCGCATCAGGCCCATTCGCCATTCAAGGCTG GCAACTGTGGGAAGGGCATGGTGCGGGCTTTCGCTATT ACGCCAGCTGGCAAAGGGGATGTGCTGCAAGCGATTAAAGT TGGGTAACGCCAGGGTTTCCAGTCAGCACGTTGTAAAACGA CGGCCAGTGAATTGACCGGTATTGGGATCCATGATTACGCCAG ATTAAATTAAAGGCCCTAAATTAGGCTGCGCCTCGCTCGCTCAC TGAGGCCGCCGGCAAAAGCCCGGGCTGGCGACCTTGGT CGCCCGGCTCAGTGAGCAGCGAGCGCAGAGAGGGAGTGG CCAACCTCCATCACTAGGGGTCTTTGAGTTAATGATTAACCC GCCATGCTACTTATCTACGTACCCATGCTCTAGGAAGATCGGA ATTCTTACTCCCTATCAGTGTAGAGAACGTATGAGAAGAGTTT ACTCCATCAGTGTAGAGAACGTATAAGGAGTTACTCCCTATCAGTG ATAGAGAACGTTATGACCGATTTACTCCCTATCAGTGTAGAGA ACGTATCTACAGTTACTCCCTATCAGTGTAGAGAACGTATA TCCAGTTACTCCCTATCAGTGTAGAGAACGTATAAGCTTA GGCGTGTACGGTGGCGCTATAAAAGCAGACGCTCGTTAGTG AACCGTCAGATCGCCTGGAGAACATTCCACACACTTTGTCTT ATACCAACTTCCGTACCACTTCTACCCCTGTAAGCGGGCG CGCACCATGGCGGACACCTGGCTTGGGTTCGCCTCTCG CCCCCTCCAGGTGGTGGAGGTGATGGCCAGGGGGCGGAGC CGGGCTGGGTGATCCTGGAGCTGGCTAAAGCTTCAAGGGCC TCTGGAGGGCAGGAATCGGGGGGGTTGGCCAGGCTCT GAGGTGTGGGGATTCCCCATGGCCCCGGTATGAGTTCT GTGGGGGGATGGCTACTGTGGGCCAGGTGGAGTGGGGT AGTGCACCAAGGGCGTTGGAGACCTCTCAGCTGAGGGCGA GCAGGAGTCGGGTGGAGAGCACTCGATGGGCCCTCCCG AGCCCTGCACCGTACCCCTGGTGCCTGAAGCTGGAGAAGGA GAAGCTGGAGCAAAACCCGGAGGAGTCCAGGACATCAAAGT CTGCAGAAAGAACCTCGAGCAATTGCAAGCTCTGAAAGCAGA AGAGGATCACCTGGGATATAACAGGCCGATGTGGGCTCAC CCTGGGGTTCTATTGGGAAGGTATTCAAGCAAACGACCATC TGCCTGTTGAGGCTCTGCAGCTTAGCTCAAGAACATGTGTA AGCTGCGGCCCTTGCTGAGAAGTGGTGGAGGAAGCTGACAA CAATGAAATCTCAGGAGATACTGCAAGCAAAGCAGAAACCTCGT CAGGCCGAAAGAAAGCAACCGTATCGAGAACCGAGTGA GAGGCAACCTGGAGAATTGTTCTGAGTGCCGAACCCAC ACTGCAGCAGATCAGCCACATCGCCCGAGCAGCTGGGCTCGAG AAGGATGTGGTCCGAGTGTGGTCTGTAACCGCGCAGAAGG GCAAGCGATCAAGCAGCGACTATGCACAACCGAGAGGATTG GGCTGCTGGGTCTCTTCTCAGGGGACCGAGTGTCTTCT CTGGCCCCAGGGCCCATTGGTACCCAGGCTATGGGAGCC CTCACTTCACTGCACTGTACTCCTCGTCCCTTCCCTGAGGG GGAAGCCTTCCCCCTGTCTGTCAACACTCTGGGCTCTCCC

TABLE 6-continued

AAV2-TRE-OSK Vector Sequences		
SEQ ID NO:	Component	Sequence
		ATGCATTCAACGCTAGCGGAGCGGCCACGAACCTCTC TGTAAAGCAAGCAGGAGATGTGAAGAAAACCCGGGCCTGC ATGATGTAACATGATGGAGACGGAGCTGAAGCGCCGGC CCGAGCAAACCTGGGGGGCGCGGGCAACTCCACCGCG CGCGGCCGGCGCAACGAAAAAACGCCGACCGCGTCAA GCGCCCATGAATGCTTCATGGTGTGGTCCCAGCGGGCAGCG CGAAGATGGCCAGAGAAACCCAAGATGACAACCTCGGAGA TCAGCAAGCAGCCTGGGGCGCCAGTGGAACCTTTGTCGGAGAC GGAGAAGCGCCGTTCATGAGCAGGCTAAGCGGCTCGGAGGG CTGCACATGAAGGAGCACCGGATTATAATACGGCCCGGC GAAAACCAAGACGCTCATGAAAGAGATAAGTACAGCTGCC CGCGGGCTGCTGGCCCCCGGGCAATAGCATGGGAGCGGG GTCGGGTGGCGCCGGCTGGCGGGCGTGAACCGAGCGA TGGACAGTTACGCGCACATGAACGGCTGGAGCAACGGCAGCTA CAGCATGATGCAAGGACAGCTGGCTACCCAGCAGCACCCGGC CTCAATGCGCACGGCGAGCGAGATGCAAGCCATGACCCCT ACGACGTGAGCGCCCTGCACTGAACTCCATGACCAGCTCGA GACCTACATGAACGGCTGCCACCTACAGCATGCTCTACTCG CAGCAGGGCACCCCTGGCATGGCTCTGGCTCCATGGGTTACCTC TGGTCAAGTCGAGGCGAGTCCAGGCCCCCTGTGGTTACCTC TTCTCCCACCTCAGGGCGCCCTGCCAGGCCGGGACTCCCG GACATGATCAGCATGATCTCCCGGGCGAGGTGCGGAAC CCGCGCCCCCAGCAGACTTCATGTCCTCAGCAGTACCAAGAG CGGCCCCGGTGGCCACGGGCAATTACGGCACACTGCCCTC TCACACATGGCATGGCTCCGGGAGGGCAAGGGAAAGTCCTC TAACATGCGGGACGTGGAGGAAATCCGGCCACTCGAGAT GGCTGTAGCGACGCGTGTCCATTTTCCACGTTCGCG TCTGGCCGGCGGGAAAGGAGAGAAGACACTGCGCTCAAGCAGGTG CCCCGAATAACCGCTGGGGAGGAGCTCCACATGAAGCG ACTTCCCCAGTGCTTCCGGCCCTATGACCTGGCGGG GCGACCGTGGGCCACAGACCTGGAGAGCGGGAGGCCGGTGC CTTGGCGGGTAGCAACCTGGGCCCTACCTCGGAGAGAGAC CGAGGAGTTCAACGATCTCTGGACCTGGACTCATGGCCACCGTGT CCTCGTCAGCGTCAGCCTCTTCGTCGTCGCGTGCAGCAG CGGCCCTGCCAGGGCCCTCACCTGCGACCTTACCTATCCG ATCCGGGGCGGAACGACCCGGCGTGGCCCGGGCGCACCG GCGAGGCTCTATGCAAGGAGTCCGCTCCCTCCGAC GGCTCCCTCAACCTGGCGACATCAACGACGTGAGCCCTCG GGCGGCTTGTGGCGAGCTCTGGGCCAGAATTGGACCCCG TGTACATTCCGGCGCAGCAGCGCAGCGCAGGTGGGGGCT GATGGGAAGTTGTGTGAAGGGCTGCTGAGCGCCCTGGC AGCAGTACGGCAGCCGTCGGTACAGCGTCAGCAAAGCA GCCCTGACGGCAGCCACCCGGTGTGGTGGGCCCTACAAACGG CGGGCCGGCGCAGTGGCCCAAGATCAAGCAGGAGGGCGT TCTCGTCACCCACTTGGGCTGGACCCCTCTAGCAATG GCCACCGGGCTGACACGACTTCCCCCTGGGCGGAGCT CCCCAGCAGGACTACCCGACCCCTGGGTCTGAGGAAGTGT AGCAGCAGGAGTGTACCCCTGGCCTCCCTCCCGG TCATCCCCACCGGGCCAATTACCCATCTTCTGGCCGA TCAGATGCAAGCGCAAGTCCCGCGTCCATTACCAAGAGCTC ATGCCACCCGGTCTGCACTGCAAGGAGGCCAAGCAGGAA GGGAAGACGATCTGGCCCCGGAAAAGGACGCCACCAAC TTGTGATTACGCGGGCTGCGCAAAACCTACACAAAGAGTT CATCTCAAGGCACACCTGCGAACCCACACAGGTGAGAAAC ACCATGTAAGTGGACGGCAGTGGATGGAATTGCCCCG AGATGAAGTGGACGGCAGTGGTAACACAGCAGGAGGCC CGGTTCCAGTGCACCGAGGAGCATTTCAGGTGG ACCACCTGCCTTACACATGAAGAGGATTTAAATGACTAG TGCAGCGAGCGGGGACCCATGGCCAATTGTTATGCA TATAATGGTACAAAATAAGGAAATAGCATCACAAATT ATAAGGATTTTTCACTGCAATTCTAGTTGTGTTGTCAA ACTCATCAATGATCTTATCATGTCGGATCGGTACCG CCAAATTCCGATAAGGATCTTCTAGAGCATGGCTACGT TAAGTAGCATGGGGTTAACATTAACATCAAGGAACCC GTGATGGAGTTGGCCTCCCTCTCGCGCTCGCTCG CTGAGGGCGGGGACCAAGGTGCGCCGAGCGCCGGCT CCGGCGGCCCTAGTGAAGCGAGGGAGCGAGCT CCTAATTCCGACGGGAGGAGCTGGCTCGAGCATGG TCATAGCTGTTCTGTGTGAAATTGTTATCGCTCACAA CACACAAACATACGAGCCGGAGCATAAGTGTAAAGC CTGGG

TABLE 6-continued

AAV2-TRE-OSK Vector Sequences		
SEQ ID NO:	Component	Sequence
16	ITR - forward	TGCCTAATGAGTGAGCTAACTCACATTAAATTGCGTTGCGCTCA CTGCCCGCTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATT AATGAATCGGCCAACGCGGGGGAGAGGGGGTTGCGTATTGG GCGCTTCCGCTTCCTCGCTCACTGACTCGCTCGCTCGTC GTTCGGTGCGGGAGCGGTATCAGCTCACTCAAAGCGGTAA TACGGTTACACAGAATCAGGGATAACGCAGGAAGAACAT GTGAGCAAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCC GCGTGTGGCGTTTCCATAGGCTCCGCCCCCTGACGAGC ATCACAAAAATCGACGCTCAAGTCAGAGGTGGCAAACCCGAC AGGACTATAAAGATACCAGGCGTTCCCCCTGGAAGCTCCCTC GTGCGCTCTCTGTTCCGACCTGCGCTTAACGGGATACCTGT CCGGCTTCTCCCTCGGGAAAGCGTGGCGCTTCTCATAGCTC ACGCTGTAGGTATCTCAGTCGGTGTAGGTGTTGCTCCAAG CTGGGCTGTGTCACGAACCCCCGTCAGCCCAGCGCTGCG CCTTATCCGTAACATCGTCTTGAGTCAACCCGGTAAGACA CGACTTATCGGCACTGGCAGCAGCACTGGTAACAGGATTAGC AGAGCGAGGTATGTAGGGGTGCTACAGAGTTCTGAAGTGGT GGCCTAACTACGGCTACACTAGAAGAACAGTATTGGTATCTG CGCTCTGCTGAAGGCAGTTACCTTCGAAAAAGAGTTGGTAGC TCTTGATCCGCAAACAAACACCCTGGTAGCGGTAGCGGTTTT TTGTTGCAAGCAGCATACCGCAGAAAAAAAGGATCTCA AGAAGATCTTGTATTTTACGGGCTGACGCTCAGTGG AACGAAAATCTCAGTTAAGGGATTGGTATGAGATTATCAA AAAGGATCTCACCTAGATCCTTTAAATTAAAAAATGAAGTTT TAAATCATCTAAAGTTATGAGTAAACTGGTCTGACAGT TAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTATTCA TATCAGGATTATCAATACCATATTTGAAAAGCCGTTCTG TAATGAAGGAAAATCACCAGGGCAGTTCCATAGGATGCCA AGATCCTGGTATCGCTCGGACTCGTCAACATCAA TACAACCTATTAAATTCCCTCGTCAAAAATAGGTTATCAAG TGAGAAATCACCAGTGAATGACGACTGAATCCGTGAGAATGGC AAAAGTTATGCTTCTCCAGACTTGTCAACAGGCCAGC CATTCAGCTCGTCATCAAATCACTCGCATCAACCAAACCGTT ATTCACTCGTGAATGCGCTGCGAACAGAAATACCGATCG CTGTTAAAGACAATTACAAACAGGAATCGATGCAACCGGC GCAGGAACACTGCCAGGGCATCAACAAATTTCACCTGATC AGGATATTCTCTAATACCTGGATGCTTTCCAGGATC GCAGTGGTGAGTAACCATGCACTCATCAGGAGTACGGATAAAAT GCTTGATGGTGGAAAGAGGCATAATTCCGTAGCCAGTTAG TCTGACCATCTCATCTGTAACATCATGGCAACGCTACCTTGC CCATGTTCAAGAACAACTCTGGCGCATCGGGCTTCCATACA ATCGATAGATTGTCGCACTGATTGCCGACATTATCGCGAGC CCATTATACCCATATAAACAGCATCCATGTTGAATTAAAT CGCGCCCTAGAGCAAGACGTTCCCGTTGAAATATGGCTCATAC TCTCTTTCAATATTATGAGCATTATCAGGGTTATTG TCTCATGAGGGATACATATTGAATGTTAGAAAAATAAA CAAATAGGGGTTCCGCGCACATTCCCGAAAAAGTGCCACCTG ACGTCTAAGAAACCAATTATTATCATGACATTAACCTATAAAA TAGGCGTATCACGAGGCCCTTGTGTC
32	ITR - reverse	CTTAATTAGGCTGCGCCTGCTCGCTCACTGAGGCCGCCG GGCAAAGCCGGCGTCGGGCACCTTGGTGGCCGCCCTCA GTGAGCGAGCGAGCGCGAGAGGGAGTGGCAACTCCATCA CTAGGGTTCTGTAGTTAATGATTAACCCGCATGCTACTT
35	OCT4-2A- SOX2-2A- KLF4 (Whole insert sequence including Tet operators, SV40, and ITRs)	CTAGGGTTCTGTAGTTAATGATTAACCCGCATGCTACTT ATCTACGTAGGCCATGCTCTAGGAAGAGATCGGAATTCTTACTCC CTATCAGTGTAGAGAACGTATGAGAGTTACTCCCTATCAGTGTAGA TGATAGAGAACGTATGCGACACTTACTCCCTATCAGTGTAGA GAACGTATAAGGAGTTACTCCCTATCAGTGTAGAGAACGTATCAG TGACCACTTACTCCCTATCAGTGTAGAGAACGTATCAG TTTACTCCCTATCAGTGTAGAGAACGTATCAGTGTAG CCTATCAGTGTAGAGAACGTATAAGCTTACGGTGTACGGT

TABLE 6-continued

AAV2-TRE-OSK Vector Sequences		
SEQ ID NO:	Component	Sequence
		GGGCGCCTATAAAAGCAGAGCTGTTAGTGAACCGTCAGATC GCCTGGAGCAATTCCACAACACTTTGTCTATACCAACTTC CGTACCACTTCCCTACCCCTGTAAGAGCGCCGGGCCACCATGGC GGGACACCTGGCTCGGATTTCGCCTTCTCGCCCCCTCCAGGT GGTGGAGGTGATGGCCAGGGGGCCGGAGCCGGCTGGGTG ATCCTCGGACCTGGCTAAGCTCCAAGGCCCTCCGGAGGGCC AGGAATCAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG ATCCCCCATGCCCCCGCCGTATGAGTTCTGTGGGGGGATGG CGTACTGTGGGCCCAAGGTTGGAGTGGGGCTAGTGCCTCAAGG CGGCTGGAGAACCTCTAGCCTGAGGGCGAAGCAGGAGTCGGG GTGAGAGACAACCTCGATGGGGCTCCCGAGGCGCTGCACCG TCACCCCTGGTGCGCTGAAGCTGGAGAAGGGAGAAGCTGGAGCA AAACCCGGAGGAGTCCAGGACATCAAAAGCTCTGCAGAAAGAA CTCGAGCAATTGCCAAGCTCTGAAGCAGAAGAGGATCACCC TGGGATATAACAGGCCGATGTGGGCTCACCTGGGGTTCT AATTGGGAAAGGTATTCAAGCCAAACGACCATCTGCCCTTGGAG GCTCTGCAGCTTAGCTCAAGAACATGTGAAGCTGGGGCCT TGCTGCAGAAGTGGTGGAGGAGGCTGACAAACAATGAAAATCT TCAGGAGATATGCAAAGCAGAAACCCCTGTGAGGCCGAAG AGAAAAGCGAACCCAGTATCGAGAACCGAGTGGAGAGGCAACCTGG AGAATTGTTCCCTGCAGTGCCTGGAAACCCCAACTGCAGCAGAT CAGCCACATGCCAGCAGCTGGCTCGAGAAGGATGTGGTC CGAGTGTGGTCTGTAACCGGCCAGAAGGGCAAGCGATCAA GCTAGCGGAGCGGCCAGCAACTTCTCTGTAAAGCAAG CAGGAGATGTGAAGAAAACCCGGGCTGATGATGTACAA CATGATGGAGACGGAGCTGAAGCGCCGGCCGCAGCAACACT TCGGGGGGCGGCCAACCTCACCGCGGCCGGCGCGCGCG GCAACCAGAAAACAGCCCGGACCGCGTCAAGCGGCCATGAA TGCTCTCATGGTGTGGTCCCGGGCAGCGGCCAGATGGCC CAGGAGAACCCAAGATGCAAACTCGGAGATCAGCAAGCGCC TGGGCGCCAGGTGGAAACTTTCGAGACGGAGAAGCGGCC GTTCATCGAGGCTAAGCGCTCCGAGCCCTGCCACATGAAG GAGCACCCGGATTATAAAACCGCCCCGGCGAAAACCAAGA CGCTCATGAAGAAGGATAAGTACACGCTGCCCGGGCTGCT GGCCCTCCGGGCAATAGCATGGCAGCGGGGTGGGTGGG GCCGGCCTGGCGCGGGCTGAACAGCGCATGGACAGTTACG CGCACATGAACGGCTGGAGCAACGGCAGCTACAGCATGATGCA GGACCAGCTGGCTACCGCAGCACCGGGCTCAATGCGAC GGCCAGGGCAGATGCAAGCCATGCAACCGTACGACGCTGAGGG CCCTGCAGTACAACCTCCATGACCGACTCGCAGACCTACATGAA CGGCTCGCCACCTACAGCATGTCCTACTCGCAGCAGGCC CCTGGCATGGCTTGGCTCATGGGTTGGTGGCTAAGTC AGGGCAGCTCCAGCCCCCTGTGGTACCTTCTCCCTCCACTC CAGGGCGCCCTGCCAGGGCGGGACCTCCGGGACATGATCAGC ATGTATCTCCCGCGCCAGGTGCGGGAACCCGCCCGCC CGAGACTTCACATGTCACACTACCAGAGCGGCCGGTGC CGGCACGCCCATTAACGCCACACTGCCCTCTCACACATGGCA TGGGCTCCGGAGGGAGGGAAAGTCTTCTAACATGCCGGG ACGTGGAGAAAATCCGGCCACTCGAGATGGCTGAGCG CGCCTGCTCCCATCTTCTCACGTCGCGTCTGGCCCGCG GGAAAGGGAGAACACACTGCGCTAAGCAGGTGCCCCAATAACC GCTGGCGGGAGGAGCTCTCCACATGAAGCGACTTCCCCAGT GCTTCCCGCCGCCCTATGACTGGCGGCCGAGCGTGGC ACAGACCTGGAGAGCGCGGGAGCGGGCTGCGGCTGCGCG GCAACCTGGCGCCCTACCTCGGAGAGAGACCGAGGAGTCAA CGATCTCTGGACCTGGACTTATTCTCTCAATTGCGCTGACC CATCTCCGGAGTCAGTGGCCGCACCGTGTCTCGTCAGCGT CAGCCTCTCTGTCGTCGCGCTGAGCAGCGCCCTGCAG CGGCCCTCACCTGCAGCTCACCTATCCGATCCGGGCCGG AACGACCCGGGGCTGGCGCCGGGGCAGGGGGGGAGGCCCTCC TCTATGGCAGGGAGTCGGCTCCCTCCCGTCAAGCGCTCCCTCAA CCTGGCGGACATCAACGACGTGAGGCCCTCGGGCGCTCGTG GCCGAGCTCTGGGGCAGAATTGGACCCGGTGTACATTCCG CGCAGCAGCCGAGGCCAGGTGGCGGGCTGATGGGCAAGTT CGTGTGAAGCGCTCGTGAAGGCCCTGGCAGCGAGTACGGC AGCCCGTGGTCACTCAGCGTCAAGCAAAGGAGGCCCTGACGGCA

TABLE 6-continued

AAV2-TRE-OSK Vector Sequences

SEQ ID NO:	Component	Sequence
		GCCACCCGGTGGTGGCGCCCTACAACGGGGCGCCG CACGTGCCCAAGATCAAGCAGGAGGCGTCTTCGTGACC CACTTGGCCGCTGGACCCCCCTCTCAGCAATGGCCACCGGCG CTGCACACGACTTCCCCCTGGGCGCAGCTCCCAGCAGGAC TACCCCGACCTGGCTTGAGGAAGTGTGAGCAGCAGGAC TGTACCCCTGCCCTGCCGTTCTCCCGCTTCCATCCCCACC CGGGGCCAATTACCCATCCTTCTGCCGATCAGATGCAAGCC GCAAGTCCCAGCCCTCATTACCAAGAGCTATGCCACCCGGT TCTTGATGCCAGAGGAGCCCAAGCCAAGAGGGAAAGACAT CGTGGCCCGAAAAGGACGCCACCCACACTTGTGATTACGC GGGCTGCGCAAACCTACACAAAGAGTCCCATCTCAAGGCA CACCTGCAACCCACACAGGTGAGAAACCTTACCAACTGTGACT GGGACGGCTGTGGATGGAAATTGCCCCGCTCAGATGAACTGAC CAGGCACATCCGTAACACACGGGGCACGCCGTTCCAGTGC CAAAAATGCGACCGAGCATTTCAGGTGAGCACACCTCGCCT TACACATGAAGAGGCATTAAATGACTAGTGCAGCAGCGG CCGACCATGGCCCAACTTGTATTGAGCTTATAATGGTTAC AAATAAAGCATAGCATCACAATTTCACAAATAAGCATT TTTCACTGCATTCTAGTTGTGTTGTCCAACATCAATGT ATCTTATCATGCTGGATCTCGGTACCGATCCAATTCCGA TAAGGATCTCCTAGAGCATGGTACGTAGATAAGTAGCATGG CGGGTTAATCATTAACACAAGGAACCCCTA

TABLE 7

AAV2-CMV-rtTA3V16 Vector Sequences

SEQ ID NO:	Component	Sequence
17	CMV promoter	GTGATGCGGTTTGGCAGTACATCAATGGCGTGGATAGCG GTTTGACTCACGGGATTCCAAGTCTCCACCCATTGACG TCAATGGAGTTGTGTTGGCACCAAAATCAACGGGACTTT CCAAAATGCTGTAACAACCTCGCCCCATTGACGCAAATGG GGGGTAGGCGTGTACGGTGGAGGTATATAAGCAGAGC T
18	CMV enhancer	GACATTGATTATTGACTAGTTAACATAGTAATCAATTACG GGGTATTAGTTCATAGCCATATATGGAGTTCCGGTTAC ATAACTTACGGTAAATGGCCGCTGGCTGACCGCCAAACG ACCCCGCCATTGACGTCATAATGACGTATGTTCCATA GTAACGCCAATAGGAGCTTCCATTGACGTCATGGGTGGA GTATTTCAGCTAAACTGCCACTTGGCAGTACATCAAGGT ATCATATGCCAAGTACGCCCTATTGACGTCATGACGGT AAATGCCCGCCTGGATTATGCCAGTACATGACCTTATG GGACTTCCACTTGGCAGTACATCACTACGTATTAGTCATCG CTATTACCATG
19	rtTA3 Advanced nucleic acid sequence	ATGTCTAGACTGGACAAGAGCAAAATCATAAACAGCGCTC TGGAAATTACTCAATGGAGTCGGTATCGAAGGCCCTGACGAC AAGGAAACTCGCTAAAGCTGGGAGTTGAGCAGCTTAC CTGTACTGGCACGTAGAAACAAGCGGCCCTGCTCGATG CCCTGCCAATGAGATGCTGGACAGGCATCATACCCACAG CTGCCCCCTGGAAAGGGAGTCATGCCAAGACTTCTGGGA ACAACGCCAAGTCATACCGCTGTGCTCTCTCACATCGC GACGGGCTAAAGTCATCTGGCACCCGCAACAGAGA AACAGTACGAAACCCCTGGAAATCAGCTCGCGTCTGT CAGCAAGGCTTCTCCCTGGAGAACGCCACTGTACGCTCTGT CGCCGTGGGCCACTTACACTGGGCTGCGTATTGGAGGAAC AGGAGCATCAAGTCAAGGAAAGAGAGAACCTA CCACCGATTCTATGCCCTACTTCTGAAGCAAGCAATTGAG CTGTTGCGACCGGCAGGGAGCGAACCTGCCCTCCCTTTCGG CCTGGAACATAATCATATGTGGCTGGAGAACAGCTAAAG TGCAGAACGCCGGGGCAGCGACGCCCTTGACGATT ACTTAGACATGCTCCAGCCGATGCCCTTGACGACTTGT CTTGATATGCTGCCCTGCTGACGCTTGACGATTTGACCTT GACATGCTCCCCGGTAA

TABLE 7-continued

AAV2-CMV-rtTA3V16 Vector Sequences		
SEQ ID NO:	Component	Sequence
20	rtTA3 Advanced amino acid	MSRLDKSKIINSALLELLNNGVGIEGLTRKLAQKLGVEQPTLYW HVKNKRALLDALPIEMLDRHHTHSCPLEGESWQDFLRNNNAKS YRCALLSHRDGAKVHLGTRPTEKQYETLENQLAFLCQQGFSL ENALYALSAVGHFTLGCVLEBQEHOVAKEERETPTDSMPL LKQAIELFDRQGAEPALFGLLELIICGLEKQLKCESGGPTDALD DFDLDMLPADALDDFDLDMLPG*
21	AAV2-CMV- rtTA3V16 (full plasmid sequence)	T CGCGCGTTT CCGGT GATGACGGTGAAAACCTCTGACACATG CAGCTCCCGGAGACTGTCA CAGCTTGCTGTGAAGCGGATGC CGGGAGCAGACAAGCCCGT CAGGGCCGT CAGCGGGT GTT GGCGGGTGT CCGGGT CGGCTTA ACTATGCCGCATCAGAGC AGATTG TACTGAGAGTGCACCATATGCCGTGTGAATACC GCACAGATGCGTAAGGGAGAAAATACCGCATCAGGCCCAT TCGCCATT CAGGCTGCCA CTGTTGGGAAGGGC ATCGT GCGGGCCTCTCGCTATTACGCCAGCTGGCAGAAGGGGA TGTGCTGCAAGGGATTAAGTTGGTAACGCCAGGGTTTT CCAGTCACGACGTTGTA AAAACGACGGCAGTGAATTGACG CGTATTGGGATACTATGGTGTCTTGACGTATGCGGTGTGA AATACCGCACAGATGCGTAAGGGAGAAAATACCGCATCAGG CGCCCCCTGCAGGGCAGCTGCCGCTCGCTCGCTACTGAGG CGCCCGGGCAAAGGCCGGCGTCGGGCGACCTTGGTGC CGGGCCTCAGTGAGCAGCGAGCAGCAGAGGGAGTGG CCA ACTC CATCACTAGGGGTCTCTGCCGCGCTCGTCCGC ACGATCTCAATT CGGCCATTACGCCGGATCGGCTCGAGG AGCTTGGCCATTGCA TACGTTGATCCATATCATAATATG TACATT TATATTGGCTCATGTC CAACATTACGCCATGTTG ACATTGATT ATTGACTAGTTATTAA TAGTAA TACCAATTACGG GGTCATTAGTTCATAGCCCATA TATGGAGTTCCGCGT TACA TAACCTAACGTTAATGCCGCCCTGGCTGACCGCCCAACGA CCCCCGCCATTGACGTC AATAATGACGTATGTTCCCATAG TAACGCCAATAGGGACTTCCATTGACGTCAATGGTGGAG TATTTAGCCTAAACTGCCCACTTGGCAGTACATCAAGTGT TCATATGCCAAGTACGCCCTATTGACGTC AATGACGGTA AATGGCCCGCCATTGACGTC AATGACCTTATGG GACTTTCTACTTGGCAGTACATCTACGTTATTGTCATCGCT ATTACCATGGTGTGCGTTTGGCAGTACATCAATGGCG TGGATAGCGGTTTGTCACTGCCGGATTCCAAGTCTCACC CCATTGACGTC AATGGAGTTGTTGGCACC AAAATCAA CGGGACTTCCAAAATGTCGTAACACCTCGCCCATGAC GCAAATGGCGGTAGGGCTGACGGTCAATGGGAGGTCTATATA AGCAGAGCTCGTTAGTGAACCGT CAGATGCCCTGGAGAC GCCATCCACGCTGTTGACCTCATAGAAGACACGGGAC CGATCCAGCCTCGCGGCCCGAATTCAACATGCTAGACT GGACAAGAGCAAATCATAAACAGCGCTCTGGAAATTACTC AATGGAGTCGGTATGAGGGCTGACGACAAGGAACACTCG CTCAAAGCTGGGAGTTGAGCAGCCTACCCGTACTGGCAC GTGAAGACAAGCGGCCCTGCTGATGCCCTGCCAATCG AGATGCTGGACAGGCATCATACCCACAGCTGCCCTGG AGGCAGTCATGGCAAGACTTCTGCCGGAACAACGCCAAG TCATACCGCTGCTCCCTC TCACTCGCGACGGGCTAA AGTGCATCTCGGCACCGCCAAACAGAGAAACAGTACGAA ACCCCTGGAAAATCAGCTCGCGTCCCTGTGTCAAGGCTT CTCCCTGGAGAACGCACTGTA CGCTCTGTCCGGCTGGGC ACTTTACACTGGGCTGGTATTGGAGGAACAGGACATCA AGTAGCAAAGAGGAAGAGAGACACCTACCCACCGATTCT ATGCCCCCACTTCTGAAAGCAAGCAATTGAGCTTGTGACCG GCAGGGAGGCCAACCTGCCCTCCCTTTCGGCCTGGAACTAA TCATATGTGGCTGGAGAACAGCTAAAGTGCAGAAGCGG CGGGCCGACCGACGCCCTGACGATT TTGACTTGTAGACATGC TCCCAGCGATGCCCTTGACGACTTGTGACCTTGATATGCTG CCTGCTGACGCTTGTGACGATT TGACCTTGACATGCTCCC GGGTAACTAAGTAAAGGATCATTTAATTAATCGATAAAG ATCTGGCCGCTCGGCCCTAATCAACCTCTGGATTACAAAAT TTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCTTT TACGCTATGTGGATACCGCTGTTAATGCCCTTGATATGCTG TATTGCTTCCCGTATGGCTTTCA TTTTCTCCTCCCTGTATAA ATCCTGGTTGTCTCTTTATGAGGAGTTGTCGGCCCTGGT CAGGGCAACTGGCTGGGCTGGTGC ACTGTGTTGTCAGCAG CCCCCACTGGTGGGCCATTGCCACCCCTGTCAGCTCC TCCGGGACTTTCGCTTCCCCCTCCCTATTGCCACGGCGGA ACTCATGCCGCCCTGCCCTGCCCTGCTGGACAGGGCTC GGCTGTTGGGCACTGACAATTCCGTGGTGTGGGAAA

TABLE 7-continued

AAV2-CMV-rtTA3V16 Vector Sequences		
SEQ ID NO:	Component	Sequence
		TCATCGTCCCTTCCTGGCTGCTGCCCTGTGTTGCCACCTGG ATTCTGCGCGGGACGTCCTCTGCTACGTCCTCGGCCCTC AATCCAGCGGACCTTCCTCCCGCGCCTGCTGCCGGCTCT CGGGCCTCTCCCGCGCTTCGCCCTCGCCCTCAGACGAGTC GGATCTCCCTTGCGGCCCTCCCGCAGACATGATAAAGA TACATTGATGAGTTGGAAACACCAACTAGAATGCAGT GAAAAAAATGCTTATTGTGAAATTGTGATGCTATTGCT TTATTGTAACCATTTAAAGCTGAATAAAACAAGTTAACAA CAACAATTGCAATTCTATGTTCAAGGTTAGGGGGAGA TGTGGGAGGTTTAAAGCAAGTAAAACCTCTACAAATGT GGTAACTAGCGCGTGCGCCGCAGGAACCCCTAGTGATGG AGTTGCCCACTCCCTCTGCGCGCTCGCTCGCTACTGAG GCCGGCGACCAAAGGTCGCCAGCAGCCCGGGCTTGGCC GGCGGCCCTCAGTGAGCGAGGGAGCGCGCAGCTGCTGCA GGATCCAATGGCGCGCGAGCTTGGCTCGAGCATGGTCAT AGCTGTTCTGTGAAATTGTTATCGCTCACAATTCCAC ACAACATACGAGCGGAGCATAAAGTGAAAGCTGGGG TGCCCTAATGAGCTAAGTCACATTAATTGCGTGCCTG CACTGCCGCTTCAGTCGGAAACCTGCTGCGCAGCTG CATTAATGAATGGCCAACGGCGGGGAGAGGCGTTTGC GTATTGGGCGCTGTTCCCTCGCTACTGACTCGCTGC GCTCGTCTGGCTGCGGAGCGGTATCAGCTCACTCA AAGCGGTAATACGTTATCACAGAAATCAGGGATAACG CAGGAAGAAACATGTGAGCAAAAGGCAGCAAAGGCA GGAACCGTAAAAGGCCGTTGCTGCCGTTTCCATAGG CTCCGCCCTGAGCAGGATCACA AAAATGACGCTCAA GTCAGAGGTGGCAGAACCCGACAGGACTATAAAGATA GGCGTTCCCTGGAAAGCTCCCTCGCGCTCTCTGTTCC GACCTGCCGCTTACCGGATACTGTCGCCCTTCTCCCTC GGGAAGCGTGGCGCTTCATAGCTCACGCTGTAGGTATC TCAGTTGGTGTAGGTCGCTCCAGCTGGCTGTG CACGAACCCCCGTTAGCCGACCGCTGCCCTATCCGG TAACATCGCTTGAGTCAACCCGGTAAGACACGACTTAT CGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGC GAGGTATGTTAGGCGGTGCTACAGAGTTCTGAAGTGGTGG CCTAACTACGCTACACTAGAAGAACAGTATTGTTATCTG CGCTCTGCTGAAGCCAGTTACCTTCGGAAAAGAGTTGGTA GCTCTGATCCCGAAACAAACACCCTGTAACCGCTGTT TTTTGTTGCAAGCAGCAATTACGCGCAGAAAAAG ATCTCAAGAAGATCCTTGATCTTTCTACGGGCTGACG CTCAGTGGAACGAAACCTACGTTAAGGGATTTCGGTATG AGATTATCAAAGGAGCTTCACCTAGATCTTTAAATTA AAAATGAAGTTAAATCAATCTAAAGTATATGAGTAAA CTTGGTCTGACAGTTAGAAAACATCGAGCATCAAATGA AACTGCAATTATCATATCAGGATTATCAATACCATATT TGAAAAGGCCGTTCTGATGAAAGGAGAAAACCTACCGA GGCAGTCCATAGGATGCGAGATCTGGTATCGCTGCG ATTCCGACTCGTCAACATCAATAACACCTATTATCC CTCGTCAAAAATAGGTATCAAGTGAGAAATCACCATGA GTGACGACTGAATCCGGTGAGAATGGCAAAAGTTATGCA TTCTTCCAGCTGTCACACAGGCAAGCCATTACGCTCGT CATCAAAATCACTCGCATCAACCAAACCGTTATTCATCGT GATTGCCCTGAGCGAACGAAATACGCGATCGTGTAA AAGGACAATTACAAACAGGAATCGAATGCAACCCGGCGAG GAACACTGCCAGCGCATCAACAAATTTCACCTGAATCAG GATATTCTCTAATACCTGGAATGCTGTTTCCAGGGATC GCAGTGGTGTAGTAACCTGATCATCAGGAGTACGGATAA AATGCTGATGGTCCGGAGGGCATAAATCCGTAGGCC GTTAGTGTGACCATCTCATGTAACATCATTGGCAACGC TACCTTGGCATTTGAGAACAACTCGCGCATCGGGC TCCCCATACATCGATAGATTGTCGCCACCTGATTGCCGAC ATTATCGCGAGGCCATTATACCCATATAAATCAGCATCCA TGGTGGAAATTAAATCGGGCTAGAGCAAGACGTTCCCGT TGAATATGGCTCATCTCTTCTTTCAATATTGAGAC ATTTATCAGGTTATTGTCATGAGCGGATACATATT ATGTTAGAAAATAACAAATAGGGGTTCCGCGACA TTCCCCGAAAAGTGCACCTGACGTCTAAGAAACCA TATCATGACATTAACTATAAAATAGGCGTATCACGAGG CCTTTGTC

TABLE 7-continued

AAV2-CMV-rtTA3V16 Vector Sequences		
SEQ ID NO:	Component	Sequence
		CCTCAGTGAGGGAGCGAGGCCAGAGAGGGAGTGGCAA CTCCATCACTAGGGGTTCC
33	ITR-reverse	AGGAACCCCTAGTGATGGAGTTGGCACTCCCTCTGCGC GTCGCTCGCTACTGAGGGCGGGCGACCAAAGGTGCGCC GACGCCCCGGCTTGCCTGGCGCTCAGTGAGCGAGCG AGCGCGCAGCTGCCTGCAGG
23	WPRE	AATCAACCTCTGATTACAAAATTGTGAAAGATTGACTGG TATTCTTAACATATGTTGCTCTTACGCTATGTGATAACGC TGCTTAAATGCCTTGTATCATGCTATTGCTTCCGTATGGC TTTCATTCTCTCTCTGTATAAATCTCGTTGCTGCTCTT TATGAGGAGTTGTTGGCCCGTGTCAAGGCAACCGTGGCGTGG GTGCACTGTGTTGCTGACGCAACCCCCACTGGTTGGGCA TTGCCAACCTGTCACTCCTTCCGGGACTTTCGCTTCC CCCTCCCATTGCCACGGCGAACCTCATCGCCGCTGCC GCCCCGTGCTGGACAGGGCTGGCTGTTGGCACTGACA ATTCCGGTGTGTTGCTGGGAAATCATGTCCTTCTTGTG CTGCTCGCTGTGTTGCCACCTGGATTCTGCGCGGACGTC CTTCTGCTACGTCCTTCGGCCCTAACAGCGGACCTTCC TTCCCGGGCTGCTGCCGGCTGCGGCTCTTCCGCGT TCGCCCTCGCCCTCAGCGAGTCGGATCTCCCTTGGCG CCTCCCCG
36	Full CMV- rtTA3V16 sequence (including ITRs)	CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCC CGGGCAAGCCGGCGTCGGCGACCTTGGTCGCCCG CCTCAGTGAGCGAGCGAGCGCAGAGAGGGAGTGGCAA CTCCCATCACTAGGGGTTCCCTGCGGCCGCTCGTCCGCA CTCAATTCGGCCATTACGGCCGATCGGCTCGAGGAGCT TGGCCCATGGCATACTGGTATCCATATCATAATATGTACA TTTATATGGCTCATGTCACATTACGCCATGTGACATT GATTATTGACTAGTTATAATAGTAATCAATTACGGGTCA TTAGTTCATAGCCCATATATGGAGTTCGGGTTACATAACT TACGGTAATGGCCCGCCTGGCTGACGCCAACGACCCCC GCCCATGGCTCAATAATGACGTATGTTCCCATGTAACG CCAATAGGGACTTCCATTGACGTCAATGGTGGAGTATT ACGCTAAACTGCCCCACTGGCAGTACATCAAGTGTATCATA TGCCAAAGTACGCCCCCTATTGACGTCAATGACGGTAATGG CCCGCTGGCATTATGCCAGTACATGACCTTATGGACTT TCCTACTGGCAGTACATCTACGTTAGTCATCGCTATTAC CATGGTGATGGGTTTGGCAGTACATCAATGGCGTGGAT AGCGGTTGACTCACGGGGATTCCAAGTCTCACCCATT GACGTCAATGGGAGTTGTTTGGCACCAAATCAACGGG ACTTTCAAATGTCGTAACAACCTCGCCCCATTGACGCAA ATGGGGGTAGGGCTGTCAGGTGGGAGGTCTATATAAGCA GAGCTCGTTAGTGACGACCGTCAGATGCCCTGGAGACGCC CCACGCTGTTTGACCTCCATAGAACAGACCGGGACCGATC CAGCCTCGCGGCCCGAATTACACCATGTCAGACTGGACA AGAGCAAATCATAAACAGCGCTCTGGAATTACTCAATGG AGTCGGTATCGAAGGCCCTGACGACAAGGAAACTCGCTAA AAGCTGGGAGTTGAGCAGCTACCCCTGACTGGCACGTGA AGAACAGCGGGCCCTGCTCGATGCCCTGCCAATCGAGAT GCTGGACAGGCATCATACCCACAGCTGCCCTGGAGGC GAGTCATGGCAAGACTTCTGCGGAACAAAGCCAAGTCAT ACCGCTGTGCTCTCTCATCGGAGCGGGCTAACAGTG CATCTCGGCACCCGCCAACAGAGAACAGTACGAAACCC TGGAAAATCAGCTCGCGTTCTGTGTCAGCAAGGCTCTCC CTGGAGAACCGACTGTACGCTCTGTCAGCTGGGCCACTT TACACTGGGCTGCGTATGGAGGAACAGGAGCATCAAGTA GCAAAAGAGGAAGAGAGAACACCTACCAACGATTCTATGC CCCCACTCTGAAGCAAGGAAATTGAGCTGTCAGCGGAG GGAGCGGAACCTGCCCTCCCTTCCGGCTGGAAACTAATCAT ATGTGGCCTGGAGAACAGCTAAAGTGGAAAGCGGGGG CCGACCGACGCCCTTGACGATTGACTAGACATGTC AGCCGATGCCCTTGACGACTTGAACCTTGACCTGATATGCTGCC CTGACGCTCTTGACGATTGACCTTGACATGCTCCCGGG TAACTAAGTAAGGATCATCTTAATTAAATCGATAAGGATCT GGCGCCCTGGCTAATCAACCTCTGATTACAAAATTGT GAAAGATGACTGGTATTCTTAACATGTTGCTCTTAC CTATGTGGATAACGCTGCTTTAATGCTTGTATCATGCTATT CTATCCCCTATGGCTTCACTTCTCCCTGTATAAATCC TGTTGCTGTCCTTTATGAGGAGTTGCCCCGTTGTCAG

TABLE 7-continued

AAV2-CMV-rtTA3V16 Vector Sequences		
SEQ ID NO:	Component	Sequence
		GCAACAGTGGCGTGGTGTGCACGTGTGTTGCTGACGCCAACCC CCACTGGTTGGGCATTGCCACCCCTGTGCTAGCTCTTTCC GGGACTTTCGCTTCCCCCTCCCTATTGCCACGGCGGAACCT CATCGCCGGCTGCCCTGCCCGCTGCTGGACAGGGGCTCGGC TGTGGGCACTGACAATTCCGTGGTGTGCGGGGAAATCA TCGTCCTTCTTGCTGCCCTGTGTTGCCACCTGGATT CTGCGCGGGACGTCTCTGCTACGTCCTCGGCCCTCAA TCCAGCGGACCTTCCTCCCGCGGCCCTGCTGCCGGCTCTGC GCCCTCTCCCGCTTCGCCCTCAGACGAGTCGG ATCTCCCTTGGGCCGCTCCCCGCCAGACATGATAAGATA CATTGATGAGTTGGACAAACCAACTAGAATGAGTGA AAAAAAATGCTTATTGTGAAATTGTGATGCTATTGCTTA TTTGTAAACCATTATAAGCTGCAATAAACAAAGTTAACACAA CAATTGCAATTCTATGTTCAAGGTTCAAGGGGGAGATGT GGGAGGTTTAAAGCAAGTAAAACCTCTACAAATGTGGT AACTAGGGCGTGC GGCGCAGAACCCCTAGTGTGGAGT TGGCCACTCCCTCTGCGCGCTCGCTCGCTCACTGAGGCG GGGCACCAAGGTGCGCCGACGCCGGCTTGCGCCGG CGGCCTAGTGAGCGAGCGAGCGCAGCTGCCAGG

TABLE 8

AAV2-CMV-rtTA4 V16 Vector Sequences		
SEQ ID NO:	Component	Sequence
24	CMV promoter	GTGATGCGTTTGGCAGTACATCAATGGCGTGGATAGCGGT TTGACTCACGGGATTCCAAGTCTCCACCCATTGACGTCAAT GGGAGTTTGGCACCCAAATCAACGGGACTTTCAAAT GTGTAACAACACTCCGCCATTGACGCAAATGGCGTAGGCG TGTACGGTGGAGGTATATAAGCAGAGCT
25	CMV enhancer	GACATTGATTATTGACTAGTTAATAGTAATCAATTACGGG GTCTTACGGTAAATGGCCCGCTGGCTGACGCCAACGACCCCG CCCATTGACGTCATAATGACGTATGTTCCATAGTAAACGCA ATAGGGACTTCCATTGACGTCATGGGTGGAGTATTACGCT AAACTGCCCACCTGGCAGTACATCAAGTGTATCATATGCCAAG TACCCCCCTATTGACGTCATAATGACGTTAATGCCGGCTTG CATTATGCCCACTACATGACCTTATGGACTTTCTACTTGGCA GTACATCTACGTTAGTCATCGTATTACCATG
26	rtTA4 Advanced nucleic acid sequence	ATGCCCCTGGATAAGAGCAAGGTAAATAATAGCGCACTCG AACTCCCAACGGCGTGGCATCGAAGGTCTGACTACTCGAAA GCTCGCCAGAAATTGGGTGTGGAGCAACCTACATTGTTATTG CATGTCAGAACAAAAGAGCCCTGCTGGACGCTTCCCTATTG AAATGCTTGACGGCATCACACTCATTCCTGCCCTTGAGGT CGAGAGTTGGCAAGATTTCTCGAAACAATGCAAAGTCTAC CGCTGCGCACTTTGTCCTAGGGATGGAGCAAAAGTGCACC TGGGACCCAGGCAACAGAGAACATAAGGAGCTCTCGAGA ACCAAGTTGGCTTCTGTGCCAACAGGGTTCTCACTGAAAAT GCCCTTACGCACTGTCAGCCGGTGGACATTTCACCTGGGTG CGTTCTGAGGAGCAAGAACATCAGGTGCTAAGGAGGAGCG CGAGACTCCAACCAACTGATTCTATGCCACCTTGTGCTAAACAG GCCATTGAACTTTGATAGACAGGGTGTGAAACCTGCCCTTCT CTTGGGTTGGAGCTGATTATTGTGCTCTGAAAAACAGCTG AAATGTTAAAGTGGTGGCCACTGACGCCCTCGATGATTTCG ACCTGGATATGCTGCCAGCCATGCACTTGATGATTTCGATTG GATATGCTTCCAGCCAGCAGTGGACGACTTCGATTGGACA TGCTTCCGGTTAA
27	rtTA4 Advanced amino acid sequence	MSRLDKSKVINSALLELNGVIEGLTTRKLAQKLGVQEQLYWH VKNKRALLDALPIEMLDRHHTHSCPLEVESWQDFLRNNAKSYRC ALLSHRDGAKVHLGTRPTEKQYETLENQLAFQLCQQGFSLENALY ALSAVGHFTLGCVLEEQEHQVAKEERETPTDSMPPLKQAIELF DROGAEPAPFLFGLIELIICGLEKQLKCESGGPTDALDDFDLDMLP DALDDFDLDMLPADALDDFDLDMLP

TABLE 8-continued

AAV2-CMV-rtTA4 V16 Vector Sequences

SEQ ID NO:	Component	Sequence
28	AAV2- CMV- rtTA4V16	TCGCGCGTTTCCGGTGTAGACGGTGAAAACCTCTGACACATGCA GCTCCCGGAGACTGTACAGCTTGTCTGTAAGGGATGCCGG AGCAGACAAGGCCGTCAAGGGCGCTCAGCGGGTGTGGCGGG TGTGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTAC TGAGAGTCACCATATGCGGTGTGAATAACCGCACAGATGCGT AAAGGAGAAAATACCGCATCAGGGCATTGCCATTAGGGCTG CGCAACTGTTGGAAAGGGCGATCGGTGCGGGCTCTCGCTAT TACCCAGCTGGCGAAAAGGGGATGTCTGCAAGGGGATTAA GTTGGGTAACGCCAGGGTTTCCCAGTCAGCAGTTGTAAAAC GACGGCCAGTGAATTGACGGTATTGGGATACTATGGTTGCTT TGACGTATGCGGTGTGAATAACCGCACAGATGCGTAAGGAGA AAATACCCCATCAGGCGCCCTGCAGGCAGCTGCGGCTCGCT CGCTCACTGAGGCCGGCAAAGGCCGGCGTGGCGCA CCTTGGTGCAGGGCCTCAGTGAGCGAGCGCGCAGAGA GGGAGTGGCAACTCCATCACTAGGGGTTCTGCGGCCGCTCG GTCCGACGATCTCAATTGCCATTACGCCGATCCGGCTC GAGGAGCTTGGCCATTGCACTACGGTGTATCCATATCATAATA TGTCACATTATATTGGCTCATGTCACATTACGCCATGTTGA CATTGATTATTGACTAGTTATTAAATGTAATCAATTACGGGTC ATTAGTTCATAGCCCATAATGGAGTTCGGGTTACATAACTTA CGGTAATGGCCCGCTGGCTGACCGCCAACGACCCCCGGCC ATTGACGTAAATAGCTGATGTTCCCATAGAACGCCAATA GGGACTTTCCATTGACGTCAATGGTGGAGTATTACGCTAAA CTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTAC GCCCACTATTGACGTCAATGACGGTAATGGCCGCTGGC TATGCCAGTACATGACCTTATGGACTTCTACTTGGCAGTA CATCTACGTATTAGTCATCGCTTACCATGGTGTGCGGTTT GGCAGTACATCAATGGCGTGGTAGCGGTTGACTCACGGG ATTCCAAGTCTCACCCATTGACGTCAATGGAGTTGTTT GGCACCAAATCAACGGGACTTCCAAATGCTGAACAACCTC CGCCCAATTGACGCAAATGGCGTAGGGTGTACGGTGGGA GGTCTATATAAGCAGAGCTGGTTAGTGAACCGTCAGTC TGGAGACGCCATTGACGTCACTACGGTGTGAGAACAGCACC GGGACCGATCCAGCCTGGGGGGGAATTACCATGTC CTTGGATAAGAGCAAGGTAATAATAGCGCACTCGAACCTC AACGGCGTGGCATCGAAGGCTGACTACTCGAAAGCTGCC AGAAGATTGGGTGGAGCAACCTACATTGTTGGCATGCAA GAACAAAAGGCCCTGCTGGACCTCTTCTATTGAAATGCTT GCAAGGATTTCTCGAAACATGCAAAGTCTACCCTGGGAACC AGGCAACAGAGAAAATACGAGACTCTCGAGAACAGTTG GTTTCTGCGAACAGGGTTCTCACTTGAAGGACCCCTT CGCACTGTCAGCGTTGGACATTACCTGGGGTGCCTT AGGAGCAAGAACATCAGGTTGCAAGGGAGCGAGACTC CAAAACTGATTCTATGCCACCTTGTGAAACAGGCCATTGA ACTTTCTGATAGCACAGGGTGTGACGCTTCTCTGGG TGGAGCTGATTATTGGGTCTCGAAAAACAGCTGAAATGTGA AAAGTGGTGGCCCTACTGACGCCCTCATGTTGACCTGGAT ATGTCGCAAGGGCTGACTTGTGATTTGCAATTGGATATGCT TCCAGCGACGCACTGGACGACTTCGATTGGACATGCTT GGTTAACTAAGTAAGGATCATCTTAATTAAATGATAAGGATC TGGCGCTCGGCTTAATCAACCTCTGATTACAAAATTG AAAGATTGACTGGTATTCTTAACTATGTTGCTCTTACGCTA TGTTGAGTACGCTCTTAAATGCTTGTATCATGCTATTGCTT CCGTATGGCTTCAATTCTCTCTGTATAAAATCTGGTGCT GTCTCTTATGAGGAGTTGGGGCCGTGTCAGGCAACGTTG GTGGTGTGCACTGTGTTGCTGACGCAACCCCCACTGGTTGG GCATTGCCAACCTGTCAGCTCTTCCGGACTTGC CCCCTCCATTGCCAACGGCGAAACTCATGCCGCTGCC CCGCTGCTGGACAGGGCTGGCTGTTGGGACTGACAATT GTGGTGTGTCGGGAAATCATGTCCTTCTGGCTGCTCG CTGTGTCACCTGGGATTCTGGCGGGACGTC TCCCTCGGCCCTCAATCCAGCGGACCTTCTCCGCC CTGCCGGCTCTGGGCCCTCTCGCGTCTTCGCCCTGCC GACGAGTCGGATCTCCCTTGGGCCCTCCCGCAGACATG ATAAGATAACATTGATGAGTTGACAAACCAACTAGAAATG AGTAAAAAAATGTTATTGTGAATTGATGCTATTG TTATTGTAACCAATTAAAGCTGAATAACAAAGTAAACA ACAATTGCAATTGTTATGAGTTGACGTTAGGGGAGATGTG GGAGGTTTTAAAGCAAGTAAACCTCTACAAATGTGGTAAC TAGCGCGTGGGCCGAGGAACCCCTAGTGTGAGTTGCCA

TABLE 8-continued

AAV2-CMV-rtTA4 V16 Vector Sequences		
SEQ ID NO:	Component	Sequence
		CCTCTCTCGCCGCTCGCTACTGAGGCCGGCGACC AAAGTCGCCGACGCCGGCTTGCCTGGCGCTCAGTG AGCAGCGAGCGCAGCTGCCCTGCAGGATCCAATGGCG CCGAGCTGGCTGAGCATGGTCATAGCTGTTCCCTGTGA ATTGTTATCCGCTACAATCCACACAACATAAGCGCGGAAG CATAAAGTGTAAAGCCTGGGTGCTAATGAGTGAGCTAAC ACATTAATTGCGTGCCTCACTGCCGCTTCCAGTCGGAA ACCTGTCGTCGAGCTGATTAATGAAATCGGCCAACCGCG GAGGGCGGTTGCGTATTGGCGCTGTTCCGCTTCCCGCTCA CTGACTCGCTGCCCTCGCTCGGCTGCCGAGCGGTATC AGCTCACTAAAGCGGTATACGGTTATCACAGAATCAGGG GATAACCGAGGAAGAACATGTGAGGAAAAGGCCAGCAAAG GCCAGGAACCGTAAAAGGCCGGCTTGCTGGCGTTTCCATA GGCTCCGCCCTGAGCATCACAAAATGACGCTCAAG TCAGAGGTGGGAAACCCGACAGGACTATAAGATAACCAGGC GTTTCCCCCTGGAAGGCTCCCTGCGCTCTCTGTTCCGACCC TGGCGCTTACCGGATACTGCGCTTCCCTTCCGGAAAGC GTGGCGCTTCTCATAGCTCACGCTGTAGGTATCTCAGTCGGT GTAGGTGTTGCGCTCAAGCTGGCTGTGTCACGAACCCCC GTTTCAGCCGACCGCTGCCCTATCCGTAACTATGCTTGA ACTGGTAACAGGATTAGCAGAGGAGGTATGTAGGGCGTGC ACAGAGTTCTGAAGTGGCTAACACGGCTACACTAGAA GAACAGTATTGGTATCTGCGCTGTGAGCCAGTTACCTTC GGAAAAAGAGTTGGTAGCTTGTGATCCGGAAACAAACCAAC GCTGGTAGCGGGTGGTTTTTTGTTGCAAGCAGCAGATTACCG GCAGAAAAAAAGGATCTAAGAAGATCCTTGATCTTCTAC GGGGTCTGACGCTCAGTGGAAAGAAAACTCAGTTAAGGGATT TTGGTCTAGGATTATAAAAGGATCTCACCTAGATCCTTT AAATAAAAATGAAGTTAAATCAATCTAAAGTATATATGAG TAAACTGGCTGACAGTTAGAAAACCTCATCGAGCATCAAAT GAAACTGCAATTATTATCATATCAGGATTATCAATACCATATTT TGAAAAAGCCGTTCTGTAATGAGGAGAAAACCTACCGAGG CAGTCCCATAGGATGGCAAGATCTGGTATCGGCTGCGGATTC CGACTCGTCAACATCAACACCTATTAAATTCCCTCGTCA AAAATAAGGTATCAAGTGAGAAATCACCATGAGTGACACT GAATCCGGTAGGAAATGCCAAAAGTTTATGCAATTCTTCCAGA CTTGTCAACAGCCACCCATTACCGCTCTCATCAAATCACT CGCATCAACCAAACCGTTATTCTCGTGTGCGCTGAGGG AAACGAAATACGCGATCGCTTAAAGGACAATTACAAACA GGAAATCGAATGCAACCGCGCAGGAACACTGCGAGCCATCA ACAATATTTCACCTGAATCAGGATATTCTCTAATACCTGGAA TGTGTTTCCAGGGATCGCAGTGGTAGTAAACCATGCACTA TCAGGAGTACCGGATAATGCTGATGGTCGGAAGAGGCATA AAATCCGTCAGCCAGTTAGCTGACCATCTCATCTGAAACATC ATTGGCAACGCTACCTTGCATGTTCAAGAAACACTCTGGC GCATCGGCTTCCCATACAATCGATAGATTGTCGACCTGATT GCCCGACATTATCGCGAGCCATTATACCCATATAATCAGC ATCCATGTTGGAATTAAATCGCGCCTAGAGCAAGACGTTTC CGTGAATATGGCTCATACTCTCCCTTTCAATATTGAG CATTATCAGGGTTATTGTCATGAGGGATACATATTGAAAT GTATTAGAAAATAAAACAAATAGGGGTTCCGCGCACATTCC CCGAAAAGTGCCACCTGACGCTAAGAAACCATATTATCATG ACATTAACCTATAAAATAGGGTATCACGAGGCCCTTGTGTC
29	ITR-forward	CCTGCAGGCAGCTCGCGCTCGCTCACTGAGGCCGGCG GGCAAAGCCGGCGCTCGGGCACCTTGGTCGCCCGCCCTCA GTGAGCGAGCGAGCGCAGAGAGGGAGTGGCAACTCCATC ACTAGGGTTCCCT
34	ITR-reverse	AGGAACCCCTAGTGTGAGTTGGCACTCCTCTGCGCGC TCGCTCGCTCACTGAGGCCGGCGACCAAAGGTGCCCCGACGC CCGGGCTTGGCCGGCGCAGAGAGGGAGTGGCAACTCCATC GCTGCCCTGCAGG
30	SV40p	TAAGATACATTGATGAGTTGGACAAACCAACTAGAAATGCA GTGAAAAAAATGTTTATTGTGAAATTGTGATGCTATTGCTT TATTGTAACCATATAAGCTGCAATAACAAAGTT
31	WPRE	AATCAACCTCTGATTACAAAATTGTGAAAGATTGACTGGTA TCTTAACATGTTGCTCCTTACGCTATGTGGATACGCTGCT TTAATGCGTTGTATCATGCTATTGCTTCCGTATGGCTTCA

TABLE 8-continued

AAV2-CMV-rtTA4 V16 Vector Sequences		
SEQ ID NO:	Component	Sequence
		TTCTCCTCTGTATAAATCTGGTTGCTGTCCTTTATGAGGA GTTGTGGCCCGTGTCAAGCAACGTGGCGTGTGCACTGTG TTTGTGAGCAACCCCCACTGGTTGGGCATTGCCACACCT GTCAAGCTCTTCCGGACTTTCGCTTCCCCCTCCATTGCCC ACGGCGGAACCTCATCGCCGCTGCGCTTGCCGCTGCTGGACAG GGGCTCGGCTGGGACTGACAATTCTGTGGTGTGTCGG GAAATCATGTCCTTCTTGGCTGCGCTGTGTCCTTGCCACCT GGATTCTGGCGGGACGTCTCTGCTACGTCCCTTGCCCTC AATCAGGGAACCTCCCTCGCCGCTGCGCCGCTCTGC GGCTCTTCCCGCTCTCGCCTCGCCCTAGACGAGTCGGATC TCCCTTGGGCCGCTCCCCC
37	Full CMV- rtTA4V16 sequence (including ITRs)	CCTGCAGGCAGCTGCGCCTCGTCGCTCACTGAGGCCCG GGCAAAGCCGGCGTCGGGACCTTGGTCGCCCGCCCTCA GTGAGCGAGCGAGCGCAGAGAGGGAGTGCCAACCTCAC ACTAGGGTCTCTGCGGCGCTGGTCGCACTGATCTCAATT GGCATTACGGCCGATCCGGCTGAGGAGCTTGGCCATTG ATACGTTGATCCATATCATATAATGACATTATGGCTCA TGTCCAACATTACCGCATGTTGACATTGATTATTGACTAG TTAATAGTAATCAATTACGGGTCATTAGTTCATAGCCAT ATGGAGTTCCGGTGTACATAACTACGGTAATGGCCGCGT GCTGACCCCAACGACCCCGCCATTGACCTCAATAATGAC GTATGTTCCATGTAACGCCAATAGGGACTTCCATTGACG CAATGGGTGGAGTATTACGCTAAACTGCCACTTGGCAGTAC ATCAAGTGTATCATATGCCAAGTACGCCCTATTGACGTC TGACGGTAAATGGCCCGCTGGCATTATGCCAGTACATGACC TTATGGACTTCTACTGGCAGTACATCTACGTATTAGTC CGCTATTACCATGGTATGGCTTGGCAGTACATCAATGG CGTGGATAGCGGTTGACTCACGGGATTCCAAGTCTCCAC CCATTGACGTCATGGGATTGTTGGCACCAAATCAACG GGACTTTCAAATGCTGTAACAAACTCCGCCATTGACGCAA ATGGCGTAGGCGTGTACGGTGGAGGTCTATATAAGCAGA GCTCGTTAGTGAACCGTCAGATCGCTGGAGACGCCATCAC GCTGTTTGACCTCCATAGAAGACACGGGACGATCCAGC CCGGGCCCCGAATTCAACCATGTCGGCTTGGATAAGAGCA GTAATAATAGCAGCTGAACCTCTCAACGGCGTGGGCATCG AAAGTCTGACTACTGAAAGCTGCCAGAAATTGGGTGTG GCAACCTACATTGATGGCATGTCAGAACAAAAGGCCCTG CTGGACGCTTCTCTTGAAGTCAGGTTGACAGGCATCACACT ATTCTGCCCTTGAGGTCGAGAGTTGGCAAGATTCTCCGA AAACATGCAAAGTCTACCGCTGCCAATTGTCCTCCATAGG ATGGAGCAAAGTGCACCTGGAACCGGCCAACAGAGAAC AATACGAGACTCTGAGAACCAAGTTGGCTTCTGTGCCA GGGTTCTCACTGAAATGCCCTTACGCACGTGTCAGCC GACATTTCACCTGGGGTGCCTTGGAGGAGCAAGAACATCA GGTGCTAAGGAGGAGCGCAGACTCCAACCACTGATTCTATG CCACCTTGTGAAACAGCATTGAACTTTGATAGACAG GTGCTGAACCTGCTTCTCTGGGGTTGGAGCTGATTATTG GGTCTGAAAAACAGCTGAAATGTGAAAGTGGTGGCCTACTG ACGCCCCCTGATGATTTCGACTGGATATGCTGCCAGCGATG ACTGATGATTTCGATTGGATATGCTTCAAGCCAGCAGCTGG ACGACTTCGATTGGACATGCTTCCCGGTTAACTAAGTA TCATCTTAATTAAATGATAAGGATCTGCCCTCGGCTTAA TCAACCTCTGGATTACAAAATTGTAAGAGTGTGACTGGT CTTAACTATGTTGCTCTTTAGCTATGTTGATACGCTGCTT AATGCCCTTGTATCATGCTATTGCTCCGTTGGCTTCTT CTCTCTTGTATAAATCTGGTTGCTGTCCTTTATGAGGAGT TGTGGCCCGTGTGAGGCAACGTGACAATTCCGTGGTGTG TGTGACGCCAACCCCCACTGGTTGGGGCATTGCCACACCTG CAGCTCTTCCGGACTTCGCTTCCCTCCCTATTGCCAC GGCGAACTCATGCCGCTGCCCTGCCGCTGCTGGACAGGG GCTCGGCTGTGGGACTGACAATTCCGTGGTGTGCTGG AATCATCTCTTCCCTGGCTGCTCGCTGTGTTGCCACCTGG ATTCTGCGGGAGCTCTCTGCTACGTCCCTCGCCCTCA TCCAGCGGACCTTCCCTCCCGGCCCTGCTGCCGCTGCC CTCTTCCCGCTTCCGCCCTGCCCTCAGACGAGTCGGATCTCC CTTGGGCCCTCCCGCCAGACATGATAAGATACTTGTG AGTTGGACAAACCAACACTAGAATGCACTGAAAAAAATG TATTGTAATTGATGCTATTGCTTATTGTAACCATTA TAAGCTGCAATAAACAAAGTAAACAAACAAATTGCA TATGTTTCAGGTTGAGGGAGATGTGGGAGGTTTTAAAGC AAAGTAAAACCTCTACAAATGTGTTAACTAGCCGTCGG

TABLE 8-continued

AAV2-CMV-rtTA4 V16 Vector Sequences		
SEQ ID NO:	Component	Sequence
		AGAACCCCTAAGTGATGGAGTTGGCACTCCCTCTGGCGGC TCGCTCGTCACTGAGGCCGGGACAAAGGTGCCCCGACCGC CCGGCTTGGCCGGCGCCTCAGTGAGCGAGCGAGCGCA GCTGCGCTCGAGGATCCAATGGCGCGAGCTTGGCTCGAGC ATGGTCATAGCTGTTCTGTGAAATTGTTATCCGCTCACAA TTCCACACAACATACGACCGGAAGCATAAAGTGTAAAGCTG GGGTGCTAATGAGTGAGCTAACATCAATTGCGTTGCGC TCACTGCCCCCTTCCAGTCGGGAAACCTGCTGCGCAGCTG ATTAATGAATCGGCCAACCGCGGGGGAGAGCGGTTGCGTAT TGGCGCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGG TCGTCGGCTGCGCGAGCGGTATCAGCTCACTAAAGCGGT AAATACGGTTATCCACAGAATCAGGGATAACCGCAGGAAGAA CATGTGAGCAGGAAAGGCCAGCAAAGGGCAGGAACCGTAAAAA GGCCGCGTTGCGGTTTTCATAGGCTCCGCCCCCTGACG AGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACC CGCAGGACTATAAAGATACCCAGCGTTTCCCCTGGAAGCTC CCTCGCGCTCTCCGACCCCTGCCGTTACCGGATACC TGTCGCTTCTCCCTCGGAAAGCGTGGCTTTCTCATAGC TCACGCTGAGGTATCTCAGITCGGTGAGGTGCTTGTGCTCAA GCTGGGTGTGTGACGAACCCCCGTTAGCCGACCGCTG GCCTTATCGGTAACTATCGCTTGTGAGTCCAACCCGGTAAGAC ACGACTTATCGCACTGCCAGCAGCACTGGTAACAGGATTAG CAGAGCGAGGTATGAGCGGTCTACAGAGTTCTGAAGTGG TGGCCTAATACGGCTACACTAGAAGAACAGTATTGGTATCT GCGCTCTGCTGAGGCAAGTACCTTCGGAAAAGAGTTGGT CTCTTGATCGGCAAACAAACCCACCGCTGGTAGCGGTTTT TTTGGTCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTC AAGAAGATCCTTGATCTTCTACGGGTCTGACGCTCAGTG GAACGAAAACCTACGTTAAGGGATTGGTATGAGATTATCA AAAAGGATCTCACCTAGATCCTTTAAATTAAAAATGAAGTT TTAAATCAATCTAAAGTATATGAGTAAACTGGTGTGACAG TTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTATTC ATATCAGGATTATCAATACCATATTGGAAAAGCCGTTCTG TAATGAAGGAGAAAACCTACCGAGGCACTTCCATAGGATGGC AAGATCTGGTATCGGCTGCGATTCCGACTCGTCAAACATCA ATACAACCTTTAAATTCCCTCGTCAAATAAGGTTATCAA GTGAGAAATCACCATGAGTGAGCAACTGTTAGGAATGCAACCG CCAAAAGTTATGCAATTCTTCCAGACTTGTCAACAGCCAG CCATTACGCTCGTCATCAAATCACTCGCATCAACAAACCGT TATTCACTCGTGTGCGCTGAGCGAAACGAAATACGCGATC GCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCG GCGCAGGAAACACTGCCAGCGCATCAACAAATTTCACCTGAA TCAGGATATTCTCTAAACTCTGAATGCTGTTCCAGGGAT CGCAGTGGTGAAGTACCATGCATCATCAGGAGTACGGATAAA ATGCTTGATGGTGGAAAGGGCATAATTCCGTAGCCAGTTT AGTCGACCATCTCATCTGAAACATATTGGCAACGCTACCTT GCCATGTTTCAAGAACACTGGCGCATCGGCTTCCCATAC AATGAGATGATTGCGACCTGATTGCCGACATTATCGCGAG CCCATTATACCCATATAATCAGCATCCATTGGAATTAA CGCGGCTAGAGCAAGACGTTCCCGTTGAATATGGCTCATAC TCCTCTTTTCAATATTGAGCATTTCAGGGTTATTGTC TCATGAGCGGATACATATTGAGTATTAGAAAAATAAAC AATAGGGTTCCCGGCACATTCCCCAAAAGTGCACCTGAC GTCTAAGAACCAATTATCATGACATTAACCTATAAAAATA GGCGTATCACGAGGCCCTTGTC

SEQUENCE LISTING

Sequence total quantity: 37

SEQ ID NO: 1 moltype = DNA length = 1080

FEATURE Location/Qualifiers

source 1..1080

mol_type = other DNA

organism = Homo sapiens

SEQUENCE: 1

atggcgccgac acctggcttc ggatttcggc ttctcgcccc ctccaggtgg tggaggtgat 60
ggcccgagggg ggccggagcc gggctgggtt gatcctcgaa cttccaaaggc 120

-continued

cctcctggag ggccaggaat cgggcgggg gttgggccaag gctctgaggt gtggggatt 180
cccccatgcc ccccgccgta tgacttctgt gggggatgg cgtaactgtgg gcccagggt 240
ggagtggggc tagtgccca aggcggcttg gagaccttcg acgctgaggg cgaagcagga 300
gtcggggtgg agagcaactc cgatggggcc tccccggagc cctgcacagt cacccttgt 360
gcccgtgaagg tggagaagga gaagctggag caaaacccgg aggagtccca ggacatcaa 420
gctctgaga aagaactcga gcaatttgcg aagctctgaa agcagaagag gatcacctg 480
ggatatacac acggcgatgt ggggtcacc ctgggggtt tatttggaa ggtattcagc 540
caaacgacca tctgcggctt tgaggctctg cagcttactg tcaagaacat gtgtactg 600
cggcccttgc tgcagaagtg ggtggaggaa gctgacaaca atgaaaatct tcaggagata 660
tgcaaagcag aaacctctgt gcacccggaa aqagaaaaacg gaaccagat cgacaaacg 720
gtgagaggca acctggagaa ttgttctg cagtgcggaa aacccacat gcacgacatc 780
agccacatcg cccagcagct tgggtcggag aaggatgtgg tccgagtggt gttctgtaa 840
cggcccaaga agggcaagcg atcaagcagc gactatgcac aacgagagga ttttgaggct 900
gtctgggttc cttttcctgg gggacggatgt tccttcctt tggcccaagg gccccattt 960
gttaccccgag ctatggag ccctcactt actgcactgt actctcggt cccttcctt 1020
gagggggaaag cttttccccct tttctctgtc accactctgtg gctctccat gcatcaaac 1080
 SEQ ID NO: 2 moltype = AA length = 360
FEATURE Location/Qualifiers
source 1..360
mol_type = protein
organism = Homo sapiens
 SEQUENCE: 2
MAGHLASDFA FSPPPGGGGD GPGLPEPGWV DPPRTWLSPQGV PPGGPGIGPG VGPGEVWGI 60
PPCPPEYEF CCGMAYCQPQV GVGLVPQGGL ETSQPEGEAG VGVESNSDGA SPEPCTVTPG 120
AVKLEKEKLE QNPEESODIK ALQKELEQFKA KLLKQKRITL GYTQADVGLT LGVLFGKVFS 180
QTICRFEAL QLSFKNMCKL RPLLQKWWEE ADNNENLQEII CKAETLVQAR KRKRRTSIEENR 240
VRGNLENLFL QCPKPTLQQI SHIAQQQLGLE KDVRVWPNCN RRQKGKRSSS DYAQREDFEA 300
AGSPFSGGPV SFPLAPGPHF GTPGYGSOPH TALYSSVPP EGAEAFPPVSV TTLGSPMHSN 360
 SEQ ID NO: 3 moltype = DNA length = 951
FEATURE Location/Qualifiers
source 1..951
mol_type = other DNA
organism = Homo sapiens
 SEQUENCE: 3
atgtacaaca ttagggagac ggagctgaag cgcgcggggc cgcagcaaac ttccgggggc 60
ggcgccggca actccaccgc ggcggcgccc ggcggcaacc agaaaaacag cccggacgc 120
gtcaaggccg ccataatgc ctccatgttg tggtcccccggc ggcagcggcgc caagatggcc 180
caggagaacc ccaagatgc caactcgagatcagcaacg gcctggggcgc cgagtggaaa 240
cttttgcgg agacggagaa ggcgcgttc atcgacgagg ctaagcggtt gcgacgcgtg 300
cacatgaagg agcaccggaa ttataataac cggcccccggc ggaaaaccaa gacgcgtatg 360
aqaaggatc agtacacgtc gcccggccgg ctgtggcggcc cggccggccaa tagcatggcg 420
agcggggatcg ggttggggcgc cggttggggc gccggcgtga accagcgttggcgtatc 480
gcccacatgc acggctggag caacggcggc tacacgtatc tgcaggacca gctgggttac 540
ccgcacggcc cggggctcaa tgcgcacggc gcacggcggc tgcagccat gcacgcgtac 600
gacgtggacg ccctgtcgatc caactccatcg accagctcgac agacgttacat gacggcgtcg 660
ccacactatac gatgttctt ctcgcacggc ggcacccctgg cgtatgttctt tggctccatg 720
ggttcggtgg tcaagttccgaa ggccacgttc agccccctgg tggttacctt ttccctccac 780
tccaggggcgc cctgtccaggc cggggacctt cgggacatgaa tcaagatgtt tctcccccgc 840
gcccgggtgc cggaaacccgc cgcggccggc agacttacaca tggccggccca ctaccagac 900
ggccgggtgc cggcgcacggc cattaacggc acactggccc ttcacacatg 951
 SEQ ID NO: 4 moltype = AA length = 317
FEATURE Location/Qualifiers
source 1..317
mol_type = protein
organism = Homo sapiens
 SEQUENCE: 4
MYNMMETELK PPGPQQTSGG GGGNAAAAA GGNQKNSPDR VKRPMNAFMV WSRGQRKMA 60
QENPKMHNSE ISKRLGAEWK LLSETEKRPF IDEAKRLRAL HMKEHPDYKY RPRRKTKTLM 120
KDKYTLPGG LLAPGGNSMA SGVGVGAGLG AGVNQRMDSY AHMNGWSNGS YSMMDQQLGY 180
PQHPGLNAHG AAQMOPMHRY DVSAQYNSM TSSQTYMNGS PTYSMSYSSQ GTPGMALGSM 240
GSVVKSEASS SPPVVTSSSH SRAPCQAGDL RDMISMYLPG AEVPEPAAPS RLHMSQHYQS 300
GPVPGTAING TLPLSHM 317
 SEQ ID NO: 5 moltype = DNA length = 1410
FEATURE Location/Qualifiers
source 1..1410
mol_type = other DNA
organism = Homo sapiens
 SEQUENCE: 5
atggctgtca ggcacgcgtc gctccatct ttctccacgt tcgcgtctgg cccggccggaa 60
agggagaaga cactgcgtca agcagggtggcc cccaaataacc gctggggggaa ggagctctcc 120
acatgttccca gacttccccccatc agtgcgttcc ggcggcccccattt atgacgttccg ggcggccggacc 180
gtggccacag acctggagag cggccggagcc ggtgcggctt gccggccggtag caacgttccg 240

-continued

```

cccttacetc ggagagagac cgaggagttc aacgatctcc tggacctgga cttaattctc 300
tccaatttcg tgaccatcc tccggagtca gtggccgcca ccgtgtctc gtcagcgta 360
gcctctttt cgtcgccgc gtcgagcgc ggcctgcca ggcgcctc cactgcagc 420
ttcacccatc cgatccgggc cggAACGAC ccggcgctgg cgccgggggg cacggcgga 480
ggctctct atggcaggga gtccgctccc cttccgacgg ctcccttcaa cctggcgac 540
atcaacgacg tgagccccctc gggeggttc gtggccgagc ttctggggcc agaattggac 600
ccgggtgtaca ttcggcgca cgacccgcg ccggcagggtt ggggtgtat gggcaagg 660
gtgctgaagg cgtcgctgag cggccctggc agcgagtagc cgacccggc ggtcatcagc 720
gtcagcaaag gcagccctga cgccggccac ccgggtgggg tggegecccta caacggcg 780
ccggccgca cgtggcccaaa gataaaggc gaggccgtcttccgtgcac ccacttggc 840
gtggacccctc ttcggacaa tgccggcccg ccggctgcaac acgacttccc cctggggcg 900
cagctcccca gcaggactac cccgacccctg ggtcttgagg aagtgtgag cagcaggagc 960
tgtcaccctg ccctggcgct tccctccggc ttccatcccc accccggggcc caattacca 1020
tccttcctgc cggatccatg gcacccgcg gtcggccgc tccattacca agagctcatg 1080
ccacccgggtt cctcgatgcc agaggagccc aagccaaaga ggggaagacg atcggtggcc 1140
cgaaaaaaaggc cggccacccca cacttggat tacggggcttccggccaaac ctacacaaag 1200
agttcccatc tcaaggcaca cctgcgaacc cacacagggtt agaaaacotta ccactgtgac 1260
tgggaacggctt gtggatggaa attcggccgc tcagatgaaac tgaccaggca ctacccgtaaa 1320
cacacggggc accggccgtt ccagtgcacaa aaatgcgacc gaggatcc cagggtcgac 1380
cacctcgccct tacacatcaa gaggcatttt 1410

```

```

SEQ ID NO: 6 moltype = AA length = 470
FEATURE Location/Qualifiers
source 1..470
mol_type = protein
organism = Homo sapiens
SEQUENCE: 6
MAVSALLPS FSTFASGPAG REKTLRQAGA PNNRWREELS HMKRLPPVLP GRPYDLAAAT 60
VATDLESGGA GAACGGSNLA PLPRRETEEF NDLLDLDLFI SNSLTHPPES VAATVSSAS 120
ASSSSSPSSS GPASAPSTCS FTYPIRAGND PGVAPGGTGG GLLYGRESAP PPTAEPNLAD 180
INDVSPSGGF VAEELLRPELD PVYIPQQPQ PPGGGLMGKF VLKASLSAPG SEYGSPSVIS 240
VSKGSPDGSH PVVVAHYNGG PRPTCPKIKQ EA VSSCTHLG AGPPLSNHGR PAAHDPLGR 300
QLPSRTTPTL GLEEVLSSRD CHPALPLPPG FHPHPGPNPY SFLPDQMOPQ VPPLHYQELM 360
PPGSCMPEEP KPKRGRRSWP RKRTATHTCD YAGCGKTYTK SSHLKAHLRT HTGEKPYHCD 420
WDGCGWKFAR SDELTRHYRK HTGHRPFQCO KCDRAFSRSD HLALHMKRHF 470

```

```

SEQ ID NO: 7 moltype = DNA length = 376
FEATURE Location/Qualifiers
source 1..376
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 7
tttactccct atcaatgtata gagaacgttat gaagaggttt cttccctatca gtgatagaga 60
acgtatgcg actttactcc ctatcaatgtata tagagaacgtt ataaaggaggtt tactccctat 120
caatgtatgtata gaaacgtatgtata ccgttactt ccctatcaatgtata gatagagaac gtatctacat 180
tttactccct atcaatgtata gagaacgttat atccagttt cttccctatca gtgatagaga 240
acgtatgtata gtttagggctgtacgggtggc gcctataaaa gcagagctcg tttatgttac 300
cgtcagatcg cttggagacaa ttccacaaca cttttgttctt ataccaacctt ccgttaccac 360
ttccttaccct cgtaaa 376

```

```

SEQ ID NO: 8 moltype = DNA length = 57
FEATURE Location/Qualifiers
source 1..57
mol_type = other DNA
organism = Teschovirus A
SEQUENCE: 8
ggcacgaact tctctctgtt aaagcaagca ggagatgtt aagaaaaccc cgggcct 57

```

```

SEQ ID NO: 9 moltype = AA length = 19
FEATURE Location/Qualifiers
source 1..19
mol_type = protein
organism = Teschovirus A
SEQUENCE: 9
ATNFSLLKQA GDVEENPGP 19

```

```

SEQ ID NO: 10 moltype = DNA length = 54
FEATURE Location/Qualifiers
source 1..54
mol_type = other DNA
organism = Thosea asigna virus
SEQUENCE: 10
gagggcaggg gaaatgtttt aacatgcggg gacgtggagg aaaatccccc cccca 54

```

```

SEQ ID NO: 11 moltype = AA length = 18
FEATURE Location/Qualifiers

```

-continued

-continued

gacctggcgg	cggcgaccgt	ggccacagac	ctggagagcg	gcccggccgg	tgcggcttc	3300
ggcggttagca	acctggcgcc	cctactcg	agagagaccc	aggagtccaa	cgatctctcg	3360
gacctggact	ttattcttc	caatcgctg	accatcttc	cgagtcgt	ggccggccacc	3420
gtgtcctctgt	cagcgtcagc	ctcccttc	tcgtcgccgt	cgagcagccg	ccctgcacgc	3480
gcccctcca	cctcgacgtt	cacatatcg	atccggccgc	ggaacgaccc	ggcgctggcg	3540
ceggcgccca	cgggcgagg	cctctctat	ggcaggaggat	cgctcccccc	tccgacggct	3600
ccttcaacc	tggcgacat	caacgcgtg	agccccctcg	ggggcttcgt	ggccgagctc	3660
ctcgcccgac	aattggaccc	ggttacatt	ccgcgcagc	agccgcagcc	gccagggtgc	3720
gggctgtatgg	gcaagtctgt	gctgaaggcg	tcgtcgacg	ccccctggcg	cgagtacccg	3780
agccctgtgg	tcatcgacgt	cagcaacagg	ageccctgac	cgagccaccc	ggtgtgtgt	3840
gcccctatac	acggcgccgc	gcccgcacg	tgcggccat	gcaaggcaga	ggcggtctt	3900
tctgtcaccc	acttggcg	tggccccct	ctcagcaatg	gcaacggcc	ggctgcacac	3960
gacttcccc	tggggcgca	gtcccccc	aggactacc	cgaccctgg	tcttgaggaa	4020
gtgtcgacca	cgaggact	tcacccctc	ctggcgctt	ctcccgctt	ccatcccccac	4080
ccggggccca	attaccatc	ctteetcgcc	gatcagatgc	agccgcaga	cccgccgctc	4140
cattacaag	actctatgc	acccgttc	tgcgtccac	aggagcccaa	gccaagagg	4200
ggaagacgt	ctggcccc	gaaaaggacc	gcccacccaca	cttgcgtat	cgccggcttc	4260
ggcaaaaccc	acacaagag	ttccatctc	aaggcacacc	tgcgaacca	cacaggtag	4320
aaacaccttacc	actgtgact	ggacggctgt	ggatggaaat	tcggccgctc	agatgaactg	4380
accaggact	accgttaaca	cacggggc	cgcccgctc	atgcgcacca	4440	
gcatttcca	ggtcggacca	cctcgcc	cacatgaaga	ggcatttt	aatgactagt	4500
gcgcgcacg	gcccgcacat	gcccacactt	tttattgc	ttataatgg	ttacaatataa	4560
agoaatagca	tcacaatatt	cacaatataa	gcatttttt	cactgcattc	tagttgtgt	4620
ttgtccaaac	tcatcaatgt	atcttcat	gtctggatct	cggtacccga	tccaaatcc	4680
cgataaggat	cttcctagag	catggctacg	tagataatg	gatggcg	ggggttat	4740
actacaagga	acccctagt	atggatgtt	ccactccctc	tctgcgcgt	cgctcgctca	4800
ctgaggccgg	gogaccaaag	gtcgccgac	gcccgggtt	tgcggccgc	gctcagtg	4860
gcgagcgc	gogcgcctt	attaaccta	attcatccca	atggcgcc	gagttgg	4920
cgagcatgg	cat					4933

SEQ ID NO: 14	moltype = DNA	length = 3594				
FEATURE	Location/Qualifiers					
source	1..3594					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 14						
atgcggggac	acctggctc	ggatttcgc	ttctcgcccc	ctccaggtgg	tggaggtgt	60
ggggcagggg	ggccggagcc	gggctgggtt	gatcctcg	gcttgcgt	cttcaaggc	120
cctccctgg	ggccggat	cggggccgggg	gttggccac	gtctcgagg	gtgggggtt	180
cccccatgcc	cccccgctg	tgatgttc	ggggggatgg	cgtaactgtt	gcccggatgt	240
ggagtggggg	tagtgc	aggcgctt	gjacac	ctc	agccgtgggg	300
gtcggttgg	agagcaact	cgatggggcc	tcccg	ggag	cctgcacgt	360
gcccgtgg	ttggagaa	gaagatgggg	caaaacccgg	aggagtc	ccca	420
gtctgcaga	aagaactcg	gcaatttgc	aaatctcg	tgac	ggacatccaa	480
ggatatacc	aggccgtat	ggggatcc	ctgggggtt	tatttggaa	ggtattcag	540
caaacgacca	tctgcgtt	tgaggetcg	cagettagt	tcaagaacat	gtgtaa	600
cgcccttgc	tgcagaatg	ggtgaggaa	gatggacaa	atgaaaatct	tcaaggat	660
tgcggccatcg	aaacccctcg	cgaggcc	aaagaaaa	gg	cgagaacccg	720
gtgagaggca	acctggagaa	tttgc	ctcg	ggcc	aaaccacact	780
agccacatcg	cccagcag	tgggtcg	aaaggatgtt	tcgc	gttctgt	840
cgccgcaga	agggc	atcaacgc	gactatc	gac	ttttgggg	900
gctgggttgc	cttttcagg	ggggacatgt	tccttctc	tgg	cccaagg	960
gttaccccttgc	gtatgggg	ccctactc	actgcactgt	acttc	cccttc	1020
gaggggggaa	ctttttccc	tgttc	tcgt	tcgt	ccatcaac	1080
gttagccgca	ggggccac	gaatcttc	ctgtt	aaac	gacat	1140
aaaaacccatcg	ctgcatcgat	gtacaatcg	atggagacgg	atgc	ggggcccg	1200
cagcaaaactt	cgggggccgg	cgccggca	tccac	cccg	cgccggccgg	1260
aaaaaacacgc	cgggccgcgt	caagggccc	atgaatgc	ct	tatgtgtt	1320
cagccgcgc	agatggccca	ggagaacccc	aaatgcaca	actcg	ggat	1380
ctggggccgg	atggggaaact	tttgc	gggg	ggcc	tttgc	1440
aacccatcg	ctgcatcgat	gtacaatcg	atggagacgg	atgc	ggggccgg	1500
aaaaccaaga	cgctcatgaa	gaaggataag	tacacgt	tc	gggggggt	1560
ggcgccaaata	gatggcg	cggggtcg	gtgggc	gccc	gggg	1620
cagcgatcg	acagttaac	gcacatgaa	ggctggac	cc	ggcg	1680
caggacc	tggtgttcc	cgacaccc	ggc	ct	atcg	1740
cagcccatgc	accgtac	cgta	tcgt	actc	atcg	1800
acatcatg	acggctcgcc	cac	tc	atcg	ccggccgg	1860
atggcttgc	gttccatgg	ttcgttgg	aa	gtcc	ggcc	1920
gttaccccttgc	cctccact	cagg	ggcc	ggcc	tttgc	1980
agcatgtatc	tcccggccgc	cgagg	ttcc	cc	attc	2040
tccca	accagacgg	ccgg	tc	atcg	cccttc	2100
tcacacatgg	catggcg	cg	gg	at	ccggccgt	2160
gaggaaaatc	ccggccca	cgagatgg	gtc	cg	atcttctcc	2220
acgttgcgt	ctggccgg	ggaaagg	aa	gac	tttgc	2280
aaccgcgtgc	ggggagg	actcc	cc	cc	atcc	2340
ccctatgacc	tgccggccgg	gaccgtgg	ac	ac	ccgg	2400

-continued

gtttgcggcg	gttagcaaccc	ggcgcggcc	cctcgaggaa	agaccgaggaa	gttcaacccat	2460
ctctctggacc	tggactttat	tcttcggcc	tcgctgaccc	atccctccgg	gtcagtggcc	2520
gccaccgtgt	cctcgctcgc	gtcagectcc	tcttcgttgt	cgccgttgt	cagcggccct	2580
gcccggcgc	cctccaccc	cagttcacc	tatccgtacc	ggccggggaa	cgaccggggc	2640
gtggcgcggg	ggggcgcggg	cggaggcctc	ctctatggca	gggagtccgc	tccccctccg	2700
acggctccct	tcaacccggc	ggacatcaac	gacgtgagcc	cctcgggccg	cttcgtggcc	2760
gagctctgc	ggccagaatt	ggaccgggt	tacatccgc	cgccagggcc	gcagccggca	2820
gggtggggc	tgatggccaa	gttcgtgt	aaggcgtcgc	tgagccccc	ttggcagcgg	2880
tacggcggcc	ctgcggcat	cagegtcago	aaaggcagcc	ctgacggcag	ccaccgggt	2940
gtgtggcgc	cctcaacccg	cgggccggc	cgccatgtgc	ccaatccaa	gcaggaggcg	3000
gtcttcttcgt	gcacccatc	ggggcgtgg	cccccttc	gcaatggca	ccggccggct	3060
gcacacgact	tccccctggg	ggccgagtc	ccacccggaa	ctacccggac	cctgggtctt	3120
gaggaagtgc	tgagcagcag	ggactgtcac	cctccctgc	cgcttcctcc	cggttccat	3180
ccccccacccg	ggcccaattt	ccatcccttc	ctggccgatc	agatcggccc	gcaagtcccg	3240
ccgcgtccatt	accaagagct	catgcaccc	ggttccctgc	tgccagggaa	gcccggcca	3300
aaagggggaa	gacgtcggt	ggccggaaa	aggaccggca	cccacactt	tgattacccg	3360
ggctgcggca	aaacctacac	aaaggttcc	catctcaagg	cacacctgcg	aacccacaca	3420
ggtgagaaac	tttaccactg	tgactggac	ggctgtgtat	ggaaattcgc	ccgctcagat	3480
gaactgacca	ggcactaccg	taaacacac	gggcacccgc	cgttccagtg	ccaaaaatgc	3540
gaccgagcat	tttccaggtc	ggaccaccc	gccttacaca	tgaagaggca	tttt	3594

SEQ ID NO: 15	moltype = DNA	length = 7250				
FEATURE	Location/Qualifiers					
source	1..7250					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 15						
tcgcgcgttt	cggtgtatgc	gggtaaaacc	tctgacacat	gcagctcccg	gagactgtca	60
caagctgtct	gtaaagggtat	ggccggagca	gacaaggccc	tcagggccgg	tcaggggtgt	120
ttggcgggggt	tcggggctgg	cttactatg	cgccatcaga	gcagatttga	ctgagagtgc	180
accatatgcg	tggtgaaaata	ccgcacatcg	cgcttaaggag	aaaataccgc	atcaggcgcc	240
attcgccatt	caggctggc	aacttgggg	aaggggcgtac	ggtgccgggg	tcttcgttat	300
tacgccact	ggcggaaagg	ggatgtgt	caaggcgatt	aagtgggtt	acgcagggtt	360
tttcccagtc	acgacgttgc	aaaacgcgg	ccagtgatt	gacgcgtatt	gggatccatg	420
attacgcgc	attaatattaa	ggccctaatt	aggctgcgt	ctcgctcg	cactgaggcc	480
ggccggggca	agccggggc	tcggggcacc	tttggcgc	cgccctcagt	gagcggcga	540
ggcgcggagg	agggagggtgc	caactccatc	actagggggt	ccttgtatgt	aatgattaa	600
ccgcctatgt	acttatctac	gtagccatgc	tcttaggaga	tcggaaatttct	ttactcccta	660
tcagtgtat	agaacgtatg	aaggtttac	tcctatcag	tgatagagaa	cgtatgcaga	720
ctttactccc	tatcgtatg	agagaacgt	taaggatgtt	actccctatc	agtgtatag	780
aaagtatgtac	cagttactc	cctatcgt	atagagaac	tatctacagt	ttactcccta	840
tcagtgtat	agaacgtata	tccagttac	tcctatcag	tgatagagaa	cgtataagct	900
ttaggcgtgt	acgggtggcc	ccttataaaa	caagatgtgt	ttagtgaaacc	gtcaatcgcc	960
ctggagacat	tccacaacac	ttttgttta	taccaactt	cgatccactt	tccttccctc	1020
gtaaaggccg	cgccgcacca	ttgggggaca	cctggcttc	gatttcgct	tctcgcccc	1080
tccagggtgt	ggaggtgtat	ggccaggggg	ggccggagccg	ggctgggtgt	atcctcgac	1140
ctcgatcggc	ttccaaaggcc	ctccgtgg	gccaaggatc	ggccgggggg	ttggggcagg	1200
ctctggggatc	ttggggatc	ccccatccc	ccccccgtat	gatgtctgt	ggggatggc	1260
gtactgtgg	ccccagggtt	gatgtgggt	atgtcccaa	ggccgggtttg	agacccctca	1320
gcctgaggcc	gaagcaggag	tcgggggtga	gagcaactcc	gatggggct	ccccggagcc	1380
ctgcacccgt	acccctgtgt	ccgtgtatgc	ggagaaggag	aagctggac	aaaacccgg	1440
ggagtcccg	gacatcaaag	ctctgcgaa	agaacttcgaa	caatttgcc	agctctgtaa	1500
gcagaaggatc	atcacccgg	gatatacaca	ggccgtgt	gggctcaccc	tgggggtct	1560
atttggaaag	gtattcagcc	aaacgaccat	ctgcccgtt	gaggctctgc	agcttagtt	1620
caagaacatc	tgtaaagctg	ggccctgtt	gcagaatgtt	gtggaggaa	ctgacaacaa	1680
tgaaaatctt	caggatgtat	gcaaaatgg	aaccctcg	caggccggaa	agagaaaagcg	1740
aaccatgtatc	gataccggag	tggaggat	ccttggaaat	ttttccctgc	agtgccggaa	1800
acccacatcg	cagcagatca	gccacatcg	ccagcagtt	gggctcgaga	aggatgtgtt	1860
cccgatgtgg	ttctgttacc	ggccggccgaa	ggcaagcga	tcaagcggcg	actatgcaca	1920
acgagaggat	tttgggtgt	ctgggtctcc	tttctcgagg	ggccggatgt	cctttccct	1980
ggccccccagg	ccccattttgc	gtaccccg	ctatggggac	cctcacttca	ctgcactgt	2040
cttcctcggtc	cttttccctg	agggggaaac	ctttccctt	gtctctgtca	ccactctggg	2100
cttcctccatg	cattcaaaac	ctagggccac	ggggccacac	aacttcttc	tgttaaagca	2160
agcaggatgt	gttggaaagaa	accccccggcc	tgcacatgt	tacaacatgt	tggagacgg	2220
gctgaaggccg	ccccggccgc	agccaaactt	ggggggccgg	ggccggcaact	ccaccggggc	2280
ggccggccggc	ggcaaccc	aaaacggccc	ggaccggc	aagccggcca	tgaatgcctt	2340
catgggtgtgg	tcccgccggc	agccggccaa	gatggccca	gagaacccca	agatgcacaa	2400
ctcggagatc	agcaacggcc	tggggccca	gtggaaactt	ttgtcggt	cgccggaggcg	2460
gcccgtatc	gacgaggatc	agccggctcg	agccgtgcac	atgaaggagc	acccggattt	2520
taaataccgg	ccccggccgg	aaaccaagac	gtctcatgt	aaggataatg	acacgtcgcc	2580
cgccggccgt	ctggccccc	ggcccaatag	catggc	gaggccgg	ttggccggcc	2640
cctggccggc	ggcgtgtacc	agcgtatgt	cagttacccg	catatgtac	gctggagccaa	2700
ccggcagctac	agcatgtatc	aggaccagct	ggggctacc	cagccacccgg	gcctcaatgc	2760
gcacggcggca	gcccgtatgc	ccgctacgac	gtgagccccc	tgcacttacaa	2820	
cttcctcggt	agctcgccaa	cctacatgaa	cggtctcgcc	acctacagca	tgtctactc	2880
gcagcaggcc	acccctggca	ttggctttgg	ctccatgggt	tgcgtgggt	agtcggaggc	2940

-continued

cagctccagg	ccccctgtgg	ttaccttcc	ctcccactcc	agggcgcct	gccaggccgg	3000
ggacacctgg	gacatgtaca	gcatgtatcc	ccccggcgcc	gaggtgcgg	aaccggccgc	3060
ccccagaga	cttcacatgt	cccagcacta	ccagagcgge	ccgggtgcgg	gcacggccat	3120
taacggcaca	ctgccccctc	cacacatggc	atgcggctcc	ggcgaggggca	ggggaaagtct	3180
tctaacatgc	ggggacgtgg	aggaaaatcc	cgccccactc	gagatggctg	tcagcgacgc	3240
getgtccca	tctttctcca	cgttcgctc	tggcccgccg	ggaaggggaga	agacactgag	3300
tcaagcagg	ccccgaata	accgtggcg	ggaggagctc	tcccacatga	agcgaacttcc	3360
ccccatgtt	ccccggcgcc	cctatgacct	ggcgccggcg	accgtggcca	cagacttgga	3420
gagcgggaga	gccccgtggg	cttgggggg	tagcaacctg	gcgcctcac	ctcgaggaga	3480
gaccggagg	ttcacatgc	tcctggaccc	ggactttat	ctctccaaat	cgtgtaccca	3540
tctccggag	tcgtggccg	ccacccgtc	ctcgtagcc	tcagctctc	tttgcgtcgc	3600
gccccgtgg	agccccctg	ccagcgcc	ctccacccgc	agcttaccc	atccgatcc	3660
ggccgggaa	gaccggggcg	tggccgggg	ccgcacgggg	ggaggectcc	tctatggcag	3720
ggagtcggct	ccccctccga	cggtccccc	caacctggcg	gacatcaacg	acgtgaggcc	3780
ctcgccggc	ttcggtggcg	agcteetgg	gccaaggattg	gaccgggtt	acattccgccc	3840
gcacgcagg	caggcccgag	gtggccgggt	gttggcaag	ttcggtgtga	aggcgctcgct	3900
gagcggccct	ggcagcgagt	acggcagccc	gtcggtcattc	agcgtcagca	aaggcagccc	3960
tgcggcagc	caccgggtgg	tgttggcc	ctacaacggc	ggcccgccgc	gcacgtgccc	4020
caagatcaag	caggaggccg	tcttcgtcg	caccacccgt	ggcgtgtggac	ccccctctcag	4080
caatggccac	cggccggctg	caacacgtt	ccccctgggg	cgccagctcc	ccagcaggac	4140
taccccgacc	ctgggtcttg	aggaagtgt	gacgagcagg	gactgttacc	ctgcctgtcc	4200
gttccctccc	ggcttccate	ccaccccggg	gcccaattac	ccatccccc	tgeccgatca	4260
gatgcagccg	caagtcggc	cgctccatta	ccaagagctc	atgcaccaccc	gttccctgcat	4320
gcccagggag	ccccaggcaa	agagggggaa	acgatcggt	ccccggaaaa	ggacggccac	4380
ccacacttgt	gattacgggg	gctggggca	aacctacaca	aagagtccc	atctcaaggc	4440
acacactgca	acccacacag	gtgagaaacc	ttaccactgt	gactggggac	gctgtggatg	4500
gaattccgc	cgctcgatgc	aactgaccgg	gcaactacccgt	aaacacccgg	ggcacccggcc	4560
gttcccgatgc	ccaaaatgc	acccggatt	ttccaggctc	gaccaccc	ccttacacat	4620
gaagaggccat	ttttaaatga	ctatgtcg	cagccggcga	ccatggccca	acttgtttat	4680
tgcagcttat	aatggttaca	aataaaggca	tagcatcaca	aatttcacaa	ataaaagcat	4740
tttttcaact	cattctcgat	gtgggttgc	caaaactcata	aatgtatctt	atcatgtctg	4800
gatctcggt	cggatccaa	atccccata	aggatctcc	tagagatgg	ctacgttagat	4860
aagttagatc	gggggttaat	cattaactac	aaggaaaccc	tagtgtatgg	gttggccact	4920
ccctctctgc	gcgcgtcgctc	gctcaactgg	gccggggcgc	caaaggcgc	ccgacgcccc	4980
gggtttggcc	ggggccggctc	agtggcgag	cgagcggcgc	gccttaat	acctaattca	5040
tcccaatggc	gcgcggagct	tggctcgag	atggctcatag	ctgtttctg	tgtgaaattt	5100
ttatccgctc	acaatccac	acaacatacg	agccggaaac	ataaaatgt	aagcttgggg	5160
tgcctaatga	gtgagctaac	tcacattaat	tgcgttgc	tcactgccc	ctttccagtc	5220
ggggaaacctg	tcgttgc	tcgtatgtt	aatccggccaa	cgccggggga	gaggcggtt	5280
gcgttattgg	cgcttgc	cttcctcg	cactgactcg	ctgcgtcg	tcgttgcgt	5340
ggccgcgacgc	gtatcgctc	actcaaaagg	ggttataatgg	ttatccacag	aatcagggg	5400
taacgcagg	aagaacatgt	gagcaaaagg	ccagcaaaag	gccaggaaac	gtaaaaaggc	5460
cgcggtcg	cggtttttcc	atggctcc	ccccctcg	gagcatcaca	aaaatcgac	5520
ctcaagtcg	agggtggcgaa	acccgacagg	actataaagg	taccaggct	ttcccccctgg	5580
aaactccctc	gtgcgtctc	ctgttcc	cctccgc	acccgatacc	tgccgcctt	5640
tcccccctcg	ggaaggctgg	cgcttctca	tagtcacgc	tgttaggtt	tcagttcggt	5700
gttaggtcg	cgctccaa	tgggtgtgt	gcaacggaa	ccccgttc	ccgacccgtg	5760
cgcttatacc	gttaactatc	gttttgcgt	caacccggta	agacacgact	tatcgccact	5820
ggcagcaggc	actgttaaca	ggatggcg	aggcggtat	tgtaggggt	ctacagatgt	5880
cttgaagtgg	ttggcctaact	acggctacac	tagaagaaca	gtatttgtt	tctgcgtct	5940
gtgtggcoca	gttacccctcg	gaaaaggat	tggtgtct	tgatccggca	aacaaacac	6000
cgctggtagc	gggtgtttt	ttgttgc	gcagcggat	acgcggcaga	aaaaaggatc	6060
tcaagaagat	cctttgtatc	tttctacggg	gtctgacgc	cagtggaaac	aaaactca	6120
ttaagggtt	ttggtcatga	gattatcaa	aaggatctt	accttagatcc	ttttaattta	6180
aaaatgtt	ttttaat	tctaaatgt	atatgtat	acttggctc	acagtttagaa	6240
aaactcatcg	agcatatcg	gaaaactcg	tttattcata	tcaggat	caataccata	6300
ttttgaaaa	acccgtttt	tgtatgtt	agaaaaactca	ccggggc	ttccataggat	6360
ggcaagatcc	ttgtatcggt	ctgcgttcc	gactcg	ttccataggat	aacatcaata	6420
ttccccctcg	tcaaaaataa	gggttataat	tgagaaatca	ccatgtatgt	cgactgtatc	6480
cggtgagaat	ggcaaaaatgt	ttatgttcc	tttcccgact	tgttcaacag	gccagccatt	6540
acgcctcg	tcaaaaaatc	tcgcgttcc	caaaaccgt	tttccatgt	attgcgcctg	6600
agcgaaacgc	aatacgcgt	cgctgtttt	aggacaat	caaacaggaa	tcgtatgtt	6660
ccggcgcagg	aacactgcca	gcccgttcc	aatatccat	cctgtatcg	gatattttcc	6720
taatacttgc	aatgtgtt	tcccgatgtt	cgcaatgtt	agtaacccat	catcatcagg	6780
agtacggata	aaatgttgc	ttgttgc	aggcataat	tccgttcc	agtttagtct	6840
gaccatctca	tctgttacat	catttgc	gttaccc	ccatgttca	gaaacaactc	6900
tggcgcatcg	ggcttccat	acaatcgata	gattgtcg	cctgttgc	cgacattatc	6960
gctggccat	ttataaccat	ataaaatcg	atccatgtt	gaatttata	cgccgcctaga	7020
gcaagacgtt	tcccgatgt	tatgttgc	actcttctt	tttcaat	attgtggat	7080
ttatcagggt	tattgtctca	tgagcgat	catatttgc	tgtttagt	aaaataaaca	7140
aataggggtt	ccgcgcacat	ttccccggaa	agtgccac	gacgttca	aaaccat	7200
tatcatgaca	ttaacatata	aaaatgttgc	tatcgttgc	cccttttgc	7250	

-continued

```

mol_type = other DNA
organism = synthetic construct

SEQUENCE: 16
ccttaattag gtcgcgcgtc cgctcgctca ctgaggccgc cccgggaaag cccggggctc 60
ggcgacatt tggtcgcccgc gcctcagtga gcgagcgcgc ggcgcagagag ggagtggcca 120
actccatcac taggggttcc t 141

SEQ ID NO: 17      moltype = DNA length = 204
FEATURE          Location/Qualifiers
source           1..204
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 17
gtgatgcgggt tttggcagta catcaatggg cgtggatagc gggttgactc acggggattt 60
cgaagtctcc accccattga cgtcaatggg agttttttt ggcaccaaaa tcaacggac 120
tttccaaaat gtcgtaacaa ctccggccca ttgacgcaaa tggcggtag ggcgtgtacgg 180
tgggagggtct atataagcag agct 204

SEQ ID NO: 18      moltype = DNA length = 380
FEATURE          Location/Qualifiers
source           1..380
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 18
gacattgatt attgactagt tattaaatagt aatcaattac ggggtcatta gttcatagcc 60
catatatggg gttccgcgtt acataacta cggtaaatgg cccgcctggc tgaccccca 120
acgaccggccg cccattgcgc tcaataatga cgtatgttcc catagtaacg ccaataggaa 180
cttccatttgc acgtcaatgg gtggagttt tacgcttaaac tgccacttgc gcaatgtacatc 240
aagtgtatca tatgccaatgc acggccctta ttgacgtaaa tgacggtaaa tggccggct 300
ggcattatgc ccagtatgc accttatggg actttccatc ttggcagtac atctacgtat 360
tagtcatcgc tattaccatg 380

SEQ ID NO: 19      moltype = DNA length = 747
FEATURE          Location/Qualifiers
source           1..747
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 19
atgtctagac tggacaagag caaaatcata aacagcgctc tggaaattact caatggagtc 60
ggtatcgaag gctgcgcgc aaggaaatctc gctcaaaagc tgggagttga gcagcctacc 120
ctgtactggc acgtaaagaa caagcgggcc ctgctcgatg ccctgccaat cgagatgtcg 180
gacaggcatc atacccacag ctggccctgt gaaggcgcgcgat catggcaaga ctttctgcgg 240
aaacaacgcaca agtcatacccg ctgtctctc ctctcacatc ggcgcggggc taaaatgc 300
ctcggcaccgc gcccaacaga gaaacagtc gaaacccctgg aaaatcagct cgcgttctcg 360
tgtcagcaag gtttcccttgc gggaaacgcga ctgtacgctc tggccgcgtt gggccacttt 420
acaactgggtc gctgtatggg ggaacaggag catcaagtag caaaagagaga aagagagaca 480
cttaccacccatcattctggc cccacttgc aagcaagcata ttgagctgtt cgacggccag 540
ggagccgaaac ctgccttcttgc gaaactatca tttggccgtt gggaaaacag 600
ctaaagtgcg aaagcggccgg gcccgcgc gccccttgcgcgat ttttgcatt agacatgc 660
ccagccatgc cccttgcgcgat ctttgcattt gatatgtgc ctgtgcgcgc tcttgcgcgat 720
tttgacccatc acatgtcccc cgggtaa 747

SEQ ID NO: 20      moltype = AA length = 248
FEATURE          Location/Qualifiers
source           1..248
mol_type = protein
organism = synthetic construct

SEQUENCE: 20
MSRLDKSKII NSALELLNGV GIEGLTTRKL AOKLGVEOPT LYWHVKNKRA LLDALPIEML 60
DRHHHTHSCPFL EGESWQDFLR NNAKSYRCAL LSHRDGAKVHL LGTRPTEKQY ETLENQLAFL 120
CQQGFSLENA LYALSAVGHF TLGVCLLEEQB HOVAKERET PTTDSMPPLL KQAIBLFDRQ 180
GAEPAPFLFGL ELIICGLEKQ LKCESGGPTD ALDDFDLML PADALDDDFDL DMLPADALDD 240
FDLDMPLPG 248

SEQ ID NO: 21      moltype = DNA length = 5435
FEATURE          Location/Qualifiers
source           1..5435
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 21
tcgcgcgttt cgggtatgac ggtaaaaacc tctgacacat gcagctcccg gagactgtca 60
cagcttgcgtt gtaageggat gcccggagca gacaaggccgc tcagggcgcc tcagcgggtg 120
ttggcggttgc tggggctgg cttaactatgc cggcatcaga gcagattgtt ctgagatgtc 180
accatatgcg gtgtgaaata ccgcacatgc gcgtaaggag aaaataccgc atcaggcgcc 240
attcgcattt caggctgcgc aactgttggg aaggcgatc ggtgcggggc tcttcgtat 300
tacgcgcgcgtt ggcgcggggg ggtatgtgcgta caaggcgatc aagttgggtt acggccagggt 360

```

-continued

tttcccagtc	acgacgttgt	aaaacgacgg	ccagtgaatt	gacgcgtatt	gggatactat	420
ggttgttttg	acgtatcgcg	tgtgaaatac	cgcacagatc	cgtaaggaga	aaataccgca	480
tcaggcgc	ctgcaggcag	ctgcgcgtc	gctcgctac	tgaggccgc	cgggcaaagc	540
ccggcgctcg	ggcgaccttt	ggtcgccccg	cctcagtgag	cgagcgacgc	cgcagagagg	600
gagtggccaa	ctccatca	aggggttct	gcccgcgtc	gttccgcacg	atctcaattc	660
ggccattacg	gocggatccg	gctcgaggag	cttggcccat	tgcatacgtt	gtatccat	720
cataaatatgt	acatttat	tggctcatg	ccaacattac	cgccatgtt	acattgatta	780
ttgactatgtt	attaatagta	atcaatagg	gggtcattag	ttcatagccc	atatatggag	840
ttccgcgtta	cataacttac	ggtaaatggc	ccgcctggc	gaccgeccaa	cgaccccgc	900
ccattgacgt	caataatgac	gtatgttcc	atagtaacgc	caataggac	tttccatgt	960
cgtcaatggg	ttggatgttt	acgtaaact	gcccacttgc	cagtatca	agtgtatcat	1020
atgccaagta	cgccccctat	tgacgtca	gacggtaata	ggccgcctg	gcattatgcc	1080
cagtagatg	ccttatggga	cttctact	tggcagttaca	tctacgtt	agtcatcgct	1140
attaccatgg	tgatgcgtt	ttggcagttac	atcaatggc	gtggatagcg	gtttgactca	1200
cggggat	caagtctca	ccccatgtac	gtcaatgggg	gtttgtttt	gcaccaaata	1260
caacgggact	ttccaaatgt	tcgtaaaca	tccggccat	tgacgcaata	gggcgttgg	1320
cgtgtacgg	gggaggctta	tataagcaga	gctcggttag	tgaaccgtca	gategcctgg	1380
agacgcac	cacgtgttt	tgacccat	agaagacac	gggacccatc	cagectccgc	1440
ggccccgaa	tcacatgtc	tagactggac	aagagcaaaa	tcataaaacag	cgcctggaa	1500
ttaactcaatg	gagtcgttat	cgaaggctgc	acgacaaagg	aactcgctca	aaagctggga	1560
gttgagcgc	ctaccctgt	ctggaoacgt	aagaacaagg	gggcctgtc	cgatgcctg	1620
ccaaatcgaga	tgctggacag	gcatacata	cacagctgc	ccctggaaagg	cgagtcatgg	1680
caagactt	tgccgaacaa	cgcgaatgt	taccgtgtt	ctccctctc	acatcgccac	1740
ggggctaaag	tgcatctcg	cacccggccca	acagagaaac	atgacaaac	cctggaaat	1800
cagctcgct	tcctgtgtca	gcaaggctt	tcctggaga	acgcactgt	cgctgtgtcc	1860
gcccgtggcc	actttact	gggtgcgt	ttggaggaa	aggagatca	agtacaaaa	1920
gaggaaagag	agacacat	cacggat	atggccccc	ttctgaagca	agcaatttgg	1980
ctgttcgacc	ggcaggag	cgaaatgt	ttcttttgc	gcctggaa	aatcatatgt	2040
ggcctggaca	aacagctaa	gtgegaa	ggggggcga	ccgacgcct	tgacgat	2100
gacttagaca	tgctccc	cgatgcctt	gacgacttgc	accttgcatt	gctgcgtgt	2160
gacgcttgc	acgatgttgc	ccttgcatt	ctccccgggt	aactaagtaa	ggatcatctt	2220
attaaatcg	ataaggat	ggccgcctcg	gcctaatca	cctctggatt	acaaaattt	2280
tgaagatgt	actgttattc	ttaactatgt	tgctcctt	acgctatgt	gatacgctc	2340
ttaatgc	ttgtatcat	ctattgc	ccgtatgg	ttcattttt	cctcttgc	2400
taaatcttgc	ttgtgttgc	ttttgagga	gttggggccc	gttgcaggc	aacgtggcgt	2460
gggtgtgc	gttgggtgc	acgcaatccc	cactgggttgc	ggcattgc	ccacctgtca	2520
gctcccttcc	gggacttgc	ctttccctt	ccctattgc	acggcgaa	tcatgcgc	2580
ctgccttgc	cgctgttgc	caggggctcg	gctgttggc	actgacatt	ccgtgggtt	2640
gtcggggaaa	tcategtt	ttctgtgt	gctgcgtt	gttgcacact	ggattctcg	2700
cgggacgtt	ttctgtgt	cacccggcc	cctcaatcca	ggggaccttc	cttccgcgg	2760
cctgctgc	gtctgcgc	cttccgg	tcttcgcctt	ccgcctcaga	cgagtcgtt	2820
ctcccttgc	ggcgcetccc	cgccagacat	gataagata	attgtatgt	ttggacaaac	2880
cacaatcaga	atgcgtgt	aaaaatgtt	tatttgcatt	atttgcatt	ctattgc	2940
atttgcatt	attataagct	gcaataaa	agttacaaac	aacaatgtca	ttcattttt	3000
gtttcaggtt	cagggggaga	tgtgggggt	tttttaa	agttaaaaac	tctacaat	3060
tggtaactag	cgcggtggc	cgcaggaa	cctagtatgt	gagttggc	ctccctct	3120
ggcgcgctcg	tcgtgtact	agggggggg	accaaaagg	ccgcgacgg	cgggcttgc	3180
ccggggggcc	tcgtgtact	tcgtgtact	tcgtgtact	tcgtgtact	tcgtgtact	3240
gagcttgc	cgagcatgt	catatgtt	tcttgtgt	atttgtt	cgctcaca	3300
tccacacaac	atacgaccc	gaagcata	gtgtaa	tggggtgc	aatgatgt	3360
ctaactcaca	ttaatgc	tgctgtact	ccggctt	cagtcggaa	acctgtcg	3420
ccagctgc	taatgtat	gcaacgc	ggggaggg	gttgcgt	ttggcgt	3480
ttccgcgttcc	tcgtgtact	actcgct	ctcggtgt	ccggctggc	gagcgat	3540
agctcactca	aaggcggt	tacggtt	cacagaat	ggggataa	caggaa	3600
catgtgc	aaaggcc	aaaaggcc	gaaccgt	aaaggcc	tgctgcgt	3660
tttccatagg	ctccgc	ctgagac	tcacaaaa	tcacaaaa	gtcagagg	3720
gcaaaaccc	acaggactat	aaagat	ggcg	tttgcgt	ccctgtcg	3780
ctctctgtt	ccgaccctgc	cgcttacgg	ataccgtt	cccttctt	cttgcggaa	3840
cggtggcgtt	tctcatgt	caacgtgt	gtatctgt	tcgggttgc	tcgtgcgt	3900
caagctggc	ttgtgttgc	aacccctgt	tcagccgc	cgctgcgt	tatccggta	3960
ctatcg	tttttttgc	ggttgc	tcacat	tcacat	gtcact	4020
taacaggatt	agcagagc	ggtatgtt	tcgtgttgc	tcgtgttgc	tcgtgttgc	4080
taactacggc	tacactagaa	gaacagt	tgttatgt	tcgtgttgc	tcgtgttgc	4140
cttcggaaa	agagtgtt	gtctgtat	ccggcaaa	accacccgt	gtagcggt	4200
tttttttgc	tgc	aggat	tcgtgttgc	tcgtgttgc	tcgtgttgc	4260
gatcttttgc	acggggtct	acgttgc	tcgtgttgc	tcgtgttgc	tcgtgttgc	4320
catgagatta	tcaaaaagg	tcttacca	gatc	tttgcgt	tcgtgttgc	4380
atcaatctaa	agtatata	gtat	tcgtgttgc	tcgtgttgc	tcgtgttgc	4440
caaataat	tgc	attat	tcat	tcat	tcgtgttgc	4500
tttctgtat	gaaggag	actc	tcgtgttgc	tcgtgttgc	tcgtgttgc	4560
tcgtgtcg	atccgact	tcgtgttgc	tcgtgttgc	tcgtgttgc	tcgtgttgc	4620
aataagg	tcaag	aatc	tcgtgttgc	tcgtgttgc	tcgtgttgc	4680
aggttat	tttgc	agact	tcgtgttgc	tcgtgttgc	tcgtgttgc	4740
atcactcg	tcaacc	tcgtt	tcgtgttgc	tcgtgttgc	tcgtgttgc	4800
cgatcg	ttaaagg	aaat	tcgtgttgc	tcgtgttgc	tcgtgttgc	4860
tgccagcg	tcaacaat	ttt	tcgtgttgc	tcgtgttgc	tcgtgttgc	4920

-continued

tgttttccca	gggatcgag	tggtagtaa	ccatgcata	tcaggagtac	ggataaaaatg	4980
cttgcgttc	ggaaggaggc	taaattccgt	cagccagttt	agtctgacca	tctcatctgt	5040
aacatcattg	gcaacgtac	cttgcctatg	tttcagaaac	aactctggcg	catcgggctt	5100
ccccatacaat	cgatagattt	tcgcaccta	ttgcccaca	ttatcgccag	cccatattata	5160
ccccataaaa	tcagcatcca	tgttggaaatt	taatcgccgc	ctagagcaag	acgttcccg	5220
ttgaatatgg	ctcatactct	tccttttca	attattatgg	agcattttac	agggttattt	5280
tccatgagc	ggatacatat	ttgaatgtat	tttagaaaaat	aaacaatag	gggttcccg	5340
cacattcccc	cgaaaaagtgc	cacctgacgt	ctaagaaacc	attattatca	tgacattaaac	5400
ctataaaaat	aggcgtatca	cgaggccctt	ttgtc			5435
 SEQ ID NO: 22						
FEATURE						
source						
	1..141					
	mol_type = other DNA					
SEQUENCE: 22						
cctgcaggca	gctgcgcgtc	cgctcgctca	ctgaggccgc	ccgggcaaaag	cccgccgtc	60
gggcgacctt	ttgtcgcccg	gcctcagtga	gcgagcgcgc	gcgcagagag	ggagtggcca	120
actccatcac	tagggttcc	t				141
 SEQ ID NO: 23						
FEATURE						
source						
	1..589					
	mol_type = other DNA					
SEQUENCE: 23						
aatcaacatc	tggattacaa	aatttgtaa	agattgaact	gtattctta	ctatgttgct	60
ccttttaacgc	tatgtgata	cgctgctta	atgcctttgt	atcatgtat	tgctcccg	120
atggcttca	ttttcttc	cttgtataaa	tcctgggtgc	tgtctttta	tgaggagtt	180
tggcccggtt	ttaggcac	tggcggtgt	tgcactgtgt	ttgctgacgc	aaccccaact	240
ggttggggca	ttgcacac	ctgtcagetc	cttccggcgt	cttgcgtt	ccccctccct	300
attggccacgg	cggaaactat	cgccgcctgc	cttggccgcgt	gctggacagg	ggctcggt	360
tttggcactt	acaattccgt	gggttgtcg	gggaaatcat	cgctcttcc	ttggctgtc	420
gcctgtgtt	ccacctggat	tctgcgcgg	acgtccttct	gtacgtccc	ttcggccctc	480
aatccagogg	accttcctt	ccgcggccgt	ctgcccgttc	tgccgcctt	tcggcgctt	540
cgccctcgcc	ctcagacgag	tccgatctcc	cttggggccg	cttcccccgc		589
 SEQ ID NO: 24						
FEATURE						
source						
	1..204					
	mol_type = other DNA					
SEQUENCE: 24						
gtgatgcgggt	tttgcgtt	catcaatggg	cgtggatagc	ggtttgactc	acggggattt	60
ccaaatctcc	accccatatga	cgtcaatggg	agttttgttt	ggcacaaaaa	tcaacggac	120
tttccaaat	gtcgtaacaa	ctccggccca	ttgacgcaa	ttggcggtag	gcgtgtacgg	180
ttggagggtct	atataagcag	agtc				204
 SEQ ID NO: 25						
FEATURE						
source						
	1..380					
	mol_type = other DNA					
SEQUENCE: 25						
gacattgatt	attgactgt	tattaatagt	aatcaattac	ggggtcattta	gttcatagcc	60
catatatgg	ttcccggtt	acataactta	cggtaaatgg	ccgcctgc	tgaccgc	120
acgacccccc	ccccatgc	tcaataatga	cgtatgtcc	catagtaac	ccaataggga	180
cttccatttgc	acgtcaatgg	gtggagt	tacgctaa	tgcctacttgc	gcagatc	240
aagtgtatca	tatgcgtt	acgcccccta	ttgacgtcaa	tgacgtt	ttggccgcct	300
ggcattatgc	ccagatcat	accttgcgg	acttcttac	ttggcgat	atctacgtat	360
tagtcatgc	tattaccat	gt				380
 SEQ ID NO: 26						
FEATURE						
source						
	1..747					
	mol_type = other DNA					
SEQUENCE: 26						
atgtcccgct	tggataaagag	caaggtaata	aatagcgcac	tcgaacttct	caacggcg	60
ggcgcgtca	ggatcgaaag	gtctgactac	tcgaaagctc	gcccgaaaat	ttgggtgt	120
ttgttattgtc	atgtcaagaa	caaaaagagcc	ctgtcgac	cttcttctat	tgaatgtt	180
gacaggcatac	acactcattt	ctgc	gagggtcgaga	gttgc	aaaaatgc	240
aacaatgc	atgccttacc	ctgcgcactt	ttgtcccata	gggtatgg	aaaagtgcac	300
ctggaaacca	ggccaaacaga	gaaacaatac	gagactctcg	agaaccgtt	ggctttctt	360
tgccaaacagg	ggtttctact	tgaaaatgc	cttacgcac	tgtcagccgt	tggat	420
accctgggtt	gcgttcttgc	ggagcaagaa	catcaggat	ctaggagga	gcgcgagact	480

-continued

ccaaccactg attcttatgcc acctttgtct aaacaggcca ttgaacttt cgatagacag
 ggtgctgaa ctgccttct ctccgggtt gagctgatta ttgtgtct cgaaaaacac
 ctgaaatgtg aaagtgggtt ccctaactgac gccctcgat atttcgacct ggatatgtc
 ccacccatg cacttgatg tttcgattt gatatgttcc cagccgacgc actggacac
 tttcgatttg acatgttcc cgggtta

SEQ ID NO: 27 moltype = AA length = 248
FEATURE Location/Qualifiers
source 1..248
mol_type = protein
organism = synthetic construct

SEQUENCE: 27
 MSLRLDKSKVII NSALELLNNGV GIEGLTTRKL AQKLGVEQPT LYWHVKNKRA LLDALPIEML 60
 DRHHHTHSCPL EVESWQDFLR NNAKSYRCAL LSHRDGAKVH LGTRPTEKQY ETLENQLAFL 120
 CQQGFSLENA LYALSAVGHF TLGCVLLEEQE HQVAKERET PTTDSMPPLL KQAIELFDRQ 180
 GAEPAPLFLGQ ELIICGLEKQ LKCCESGGPTD ALDDPFDLML PADALDDFDL DMLPADALDD 240
 FDLDMLPG

SEQ ID NO: 28 moltype = DNA length = 5435
FEATURE Location/Qualifiers
source 1..5435
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 28
 tcgcgcgtt cgggtatgac ggtaaaacc tctgacacat gcagctccc gagactgtca 60
 caacctgtct gtaaggcgat gccccggacca gacaaccccg tcagggcgcg tcaggggtt 120
 ttggcggtt tcggggctgg cttaaactatg cggcatcaga gcagatgtt ctgagagtgc 180
 accatatcgcc gtgtgaaata cccgacacat gctgttgggg aaaataccggc atcaggcgcc 240
 attcggccat caggctcgcc aacttgttggg aaggggatc ggtgcggccg tcttcgtat 300
 taacggccat ggcgaaaggd ggtatgttcc caaggccatg aagtgggttgc acggccgggtt 360
 tttcccgatc acgacgttgc aaaacgacgg ccagtgttgcatt gacgcgtt gggataactat 420
 ggttgcgttgc acgtatgcgg tttgttgcata cgcacagat cgttaaggaga aaataccgc 480
 ctgcggccctt ctgcaggccat ctgcgcgttc gtcgtctcac ttggggccgcg cggggcaaaagc 540
 cccggcgctcg ggcgaccctt ggtgcggccat ctcgttgc ctagccggccg cggagagg 600
 gagttggccaa ctccatcact aggggttcc gggccgcgtt ggtccgcacg attcattca 660
 ggccattacg gccggatccg gtcggaggag ctggcccat tgcatatcgat gtatccat 720
 cataatatcg acatattatg tggctcatgt ccaacatcat cgcctatgttgcatttgcattat 780
 ttgactatgtt attaatatgtt atcaattatcg ggggttcatatgttcatatggcc atatatggag 840
 tttccgcgttata cataacttac ggttaatggc cccgcgttgc gaccgccttgc cggccatccgc 900
 ccattgtacgtt caataatgcac gtatgttcc atatgttgc ctttcattgc 960
 cgttcaatggg tggatgttgc acgttataact gcccacttgc ctttcattgc atgttgcattat 1020
 atgcacatggc cggccctatc tgacgttgcat gacgttgcattatgcgttgcattatgc 1080
 cttttatcgatc cttttatggaa cttttatcgatc tttttatcgatc tttttatcgatc 1140
 atttccatggg tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1200
 cggggattttc caagtctccca cccccatggc gtcacatgggaa gtttttttttgcacccat 1260
 acggccatggg tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1320
 cttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1380
 agacgcacatc cttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1440
 gggcccaatggc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1500
 tcacccatggc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1560
 ctccatggc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1620
 gttggacacat tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1680
 cttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1740
 caagatggc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1800
 gggcccaatggc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1860
 tcacccatggc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1920
 gttggacacat tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 1980
 cttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2040
 gggcccaatggc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2100
 tcacccatggc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2160
 gttggacacat tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2220
 aattttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2280
 tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2340
 tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2400
 tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2460
 ggtgtgcactt gttttatcgatc acgttgcactt gttttatcgatc tttttatcgatc 2520
 gttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2580
 gttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2640
 gttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2700
 gggccatggc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2760
 cttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2820
 cttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2880
 cttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 2940
 aaaaatgttgc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 3000
 attttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 3060
 tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc tttttatcgatc 3120

-continued

gcgcgctcg	tcgctcaactg	aggccggcg	accaaaggc	gcccga	cgccgttgc	3180
ccggggcccc	tcaagtggcg	agcgacgcg	cagctgcctg	caggatcca	atggcgcc	3240
gagcttgg	cgagcatgg	catagcttt	tctgtgtg	aattgttac	cgctcaca	3300
tccacacaac	atacgagccg	gaagcataaa	gtgtaaagcc	tggggtgct	aatgagttag	3360
ctaactcaca	ttaatttgt	tgcgctca	gcccgttc	cagtcggaa	acctgtcg	3420
ccagctcgat	taatgaatcg	gccaacgcg	ggggagaggc	ggtttgcgt	ttggggcg	3480
ttccgcttcc	tcgctca	actcgctcg	ctcggtcg	cggtcgcc	gagcggtatc	3540
agotcactca	aaggcggtaa	tacggttac	cacagaatca	ggggataacg	caggaaagaa	3600
catgtgagca	aaggccage	aaaaggccag	gaaccgtaa	aaggccgt	tgctggcg	3660
tttccatagg	ctccgc	ctcgacgca	tcacaaaaat	cgacgtcaa	gtcaqaggt	3720
gcaaaacccg	acaggat	aaagatcca	ggcggttccc	cctggaa	ccctcg	3780
cttcctgtt	ccgaccctgc	cgcttacccg	atacctgtcc	gccttttccc	cttccggaa	3840
cgtggcgctt	tctcatagct	cacgtgtg	gtatctcgt	tcgggtgt	tcggtcg	3900
caagctggc	tgtgtgcac	aacc	tcagccccac	cgctgcgc	tatecggt	3960
ctatcgctt	gagtccaa	cggtaagaca	cgacttatcg	ccactggc	cagccact	4020
taacaggatt	agcagacg	ggtatgt	cggtgtaca	gagtttgc	agtgtgg	4080
taactacggc	tacactagaa	gaacagtatt	tggtatctgc	gtctgtc	agccgtac	4140
cttcggaaaa	agagttgtt	gctcttgc	cgccaaacaa	accacccgt	gtacgggt	4200
ttttttgtt	tgc	agattacgc	cagaaaaaaa	ggatctca	aagatcc	4260
gatcttttct	acggggtctg	acgtcgat	gaacggaa	tcacgtta	ggat	4320
catgagatta	tcaaaaagg	tcttaccta	gatc	tttta	aattaaaaat	4380
atcaatctaa	agtatata	agtaacttgc	gtctgac	tagaaaaact	catcgac	4440
caa	atgaa	tgc	attatca	ccat	ttttt	4500
tttctgtat	gaaggagaaa	actacc	cgat	ttccat	gatctgt	4560
tcgg	tgc	attc	gtc	aaac	atcttcc	4620
aataagg	tca	atgtg	gac	actccgt	agaatgg	4680
aagt	tttgc	at	tttgc	aaac	ggcc	4740
atca	tc	actcg	cg	tttcc	ccat	4800
gegat	cg	ttaa	agg	atc	aaac	4860
tgcc	cg	ca	at	ttt	ctt	4920
tg	ttt	cc	gg	atc	ttt	4980
ctt	gt	ttt	gg	atc	ttt	5040
aa	at	ttt	gg	atc	ttt	5100
cc	at	ttt	gg	atc	ttt	5160
cc	at	ttt	gg	atc	ttt	5220
tt	at	ttt	gg	atc	ttt	5280
tc	at	ttt	gg	atc	ttt	5340
ca	at	ttt	gg	atc	ttt	5400
ct	at	ttt	gg	atc	ttt	5435

SEQ ID NO: 29 moltype = DNA length = 141
 FEATURE Location/Qualifiers
 source 1..141
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 29
 cctgcaggca gtcgtcgctc ctgaggccgc cgggcaaa cccgggcgtc 60
 ggccgacatt tggcgcccc cgctca gtcgacgc ggcgcaggag ggagtggcca 120
 actccatcac taggggttcc t 141

SEQ ID NO: 30 moltype = DNA length = 122
 FEATURE Location/Qualifiers
 source 1..122
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 30
 taagatata tttttttttt ggacaaacca caactagaat gcagtggaaa aatgtttta 60
 ttgtgtat ttgtgtat ttgtgtat tataagctc aataaacaag 120
 tt 122

SEQ ID NO: 31 moltype = DNA length = 589
 FEATURE Location/Qualifiers
 source 1..589
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 31
 atcaacactc tggattacaa aatttgcggaa agattgtact gtattttaa ctatgttgc 60
 ccttttacgc tttttttttt atgtgttata atgcctttt atcatgtat tgcttccgt 120
 atggctttca tttttttttt ctgtataaa tccgttgcgt tggtttttt tgaggatgg 180
 tggcccggtt tcaggcaacg tggtttttt tgcaactgtgt tggtgtacgc aaccggccact 240
 ggttggggca ttggccaccac ctgtca gtc ctttccggaa ctttccgtt ccccccctt 300
 attggccacgg cggaaactcat cggccgttgc ctttccggct gttggacagg ggctgggtg 360
 ttggggactt gcaatccgtt ggtttgtcg gggaaatcat ctttccgttcc ttggctgtc 420
 gctgtgtt ccacctggat tttttttttt gtcacgtccc ttggccctt 480
 aatccagccg accttccctt cggccgttgc tggccggctt tccggctt 540
 cggcccttgc ctcagacgag ctttccggcc 589

-continued

```

SEQ ID NO: 32      moltype = DNA  length = 141
FEATURE          Location/Qualifiers
source           1..141
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 32
aggaaccctt agtgatggag ttggccactc cctctctgcg cgctcgctcg ctcaactgagg 60
ccgggcgacc aaaggctgcc cgacgcccgg gctttgcccgg ggccgcctca gtgagcgagc 120
gagcgcgcag ctgcctgcag g 141

SEQ ID NO: 33      moltype = DNA  length = 141
FEATURE          Location/Qualifiers
source           1..141
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 33
aggaaccctt agtgatggag ttggccactc cctctctgcg cgctcgctcg ctcaactgagg 60
ccgggcgacc aaaggctgcc cgacgcccgg gctttgcccgg ggccgcctca gtgagcgagc 120
gagcgcgcag ctgcctgcag g 141

SEQ ID NO: 34      moltype = DNA  length = 141
FEATURE          Location/Qualifiers
source           1..141
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 34
aggaaccctt agtgatggag ttggccactc cctctctgcg cgctcgctcg ctcaactgagg 60
ccgggcgacc aaaggctgcc cgacgcccgg gctttgcccgg ggccgcctca gtgagcgagc 120
gagcgcgcag ctgcctgcag g 141

SEQ ID NO: 35      moltype = DNA  length = 4460
FEATURE          Location/Qualifiers
source           1..4460
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 35
ccttaattag gtcgcgcgtc cgctcgctca ctgaggccgc ccgggcaaaag cccgggcgtc 60
ggggccacctt tggccggccg gcctcaagtgc ggcgagcgagc ggcgcagagag ggatggccca 120
actccatcac taggggttcc ttgttagttaa tgatataaccgc gccatgtcat ttatctacgt 180
agccatgtc taggaatgtc ggaattcttt actccctatc agttagatgg aacgtatgaa 240
gatgtttactc cttatcgtt atagagaacg tatgcagact ttactcccta tcagtatgaa 300
agaaacgtata aggatgttac tccatcatgc tgatagatggaa cgtatgacca gtttactccc 360
tatcagtgtt agagaacgtt ttcatacggtt actccctatc agttagatgg aacgtatatc 420
cagtttactc cttatcgtt atagagaacg tataaggctt aggcgtgtac ggtggccgccc 480
tataaaaagca gagctcggtt agtgaaccgtt cagatcgccg ggagcaattt cacaacactt 540
ttgttactt ccaatcttcc gtaccacttcc ctacccttgcg aaagcggccg cgccaccatg 600
ggccggacacc tggcttcggg tttgccttc tecccccttc cagggtgggg aggtgatggg 660
ccaggggggc cggagccggg ctgggttgcgat ctcggactt ggctaaacctt ccaaggccct 720
cctggggggc caggaatccgg gccgggggtt gggccagggtt ctgggtgtt ggggatttccc 780
ccatggcccccc cggccgtatgg gttctgtggg gggatggccgt actgtggggcc ccagggttgg 840
gtgggggttag tggcccaagg cgggttgggg acctctcgcgat ctggccggca agcaggatgc 900
gggggttggaga gcaactccgg tggggcccttc cccggagccctt qcaccgtcac ccctgtgtcc 960
gtgaagctgg agaaggagaa gctggagcaa aacccggagg agtcccaggaa catcaaaatgc 1020
ctgcagaaag aactcgacaa atttggccaaatgc ctctctgaaagc agaagaggat caccctggaa 1080
tatacacacgg cccatgtggg gtcacccctg ggggttctat ttggggaaaggattt cccatgttccaa 1140
acgaccatcttcc ggcgttgcgtt ggcgttgcgtt cttatgttca agaataatgc taatgttcc 1200
cccttgcgttcc agaagtgggtt ggagaaatgc gacaacaatgc aaaatcttca ggagatatgc 1260
aaagcggaaaa ccctcgatgc gggccggaaa agaaagcgaaa ccagtatgcgaa ccggcgatgc 1320
agaggcggaaa tggagaatattt gttctgtccgcg tggccggaaa ccacactgcgaa ccggcgatgc 1380
cacatcgccc accatgttcc gtcgttgcgtt gatgttgcgtt ctgttacccgg 1440
cgccagaagg gcaaggcgatc aaggcggcgtatgc cacaacatgc gagaggatgc tgaggctgt 1500
gggttcttcc ttcagggggg accagtgtcc tttccctgtt ccccgaggccc ccatttttgtt 1560
accccgccgtt atggggccccc tccatgttactt ctcgggtccccc ttccctgttgcg 1620
ggggaaatgc tttccctgtt ctctgttccgcg acttccgtggccat tccatgttca ttcaaaatgc 1680
agccggccgtt gggccggccaa tttccctgtt tttaaaggaaatgc caggatgttgcgtt tttaaaggaaatgc 1740
ccggccgttcc tttccctgtt tttaaaggaaatgc caggatgttgcgtt tttaaaggaaatgc 1800
caaacttccgg gggggccggccgg ccggccacttcc accggccggccgg ccggccggccgg caaccaggaaa 1860
aacaggccggccgg acccggttccaa gggccggccatgc aatgccttca tgggttggccgcg 1920
ccggccgttccaa gggccggccggccgg ccggccacttcc accggccggccgg ccggccggccgg 1980
ggccggccgtt gggaaatttt gtcggagacg gagaaggccgcg ctttcatgcgaa ccggccgttcc 2040
ccggccgttccgg ccgttgcacat gaaaggccgcg ccggattata aataccggccccc ccggccggccgg 2100
accaagacgc tcatgttacttcc ggtataaggatgc acgctgttccgcg ccggccgttcc 2160
ggcaatagca tggccggccgg ggttgggggtt gggccggccggcc tggccggccgg ccgttaccc 2220
cgcacatggaca gttacccggccaaatgc catgttacttcc gcaaggccgcg ccgttaccc 2280
gaccaggccgttcc gtttccctgttccatgttca accggccggccgg ccggccgttcc 2340

```

-continued

cccatgcacc	gtacgacgt	gaggcgcctg	cagtacaact	ccatgaccag	ctcgagacc	2400
tacatgaacg	gtcggccac	ctacagcatg	tcctactcgc	agcaggccac	cccttgcatg	2460
gtcttgggt	ccatgggtc	gggtggteag	tcggaggcoca	gtccagccc	ccctgtggtt	2520
acctcttct	ccaccccaag	ggccgcctgc	caggccgggg	acctccggga	catgatcagc	2580
atgttatctc	ccggccgcga	ggtgcggaa	ccggccgccc	ccagcagact	tcacatgtcc	2640
cagcaactacc	agageggccc	ggtgcgggg	acggccattt	acggcacact	gccccctcta	2700
cacatggcat	gggggtccgg	cgagggcagg	ggaagtcttc	taacatgccc	ggacgtggag	2760
aaaaatcccg	gcccactcg	gtggctgc	agegacgcgc	tgctccccc	tttctccacg	2820
ttcggctctg	ggccggcggt	aaggagaag	acactgcgtc	aaggcagggtc	ccccaataac	2880
cgtggcgccc	aggagcttc	ccacatggat	cgtgtttccc	cgtgtttccc	ggggccccc	2940
tatgacatgg	ggggggggac	cgtggccaca	gactggaga	ggggggggac	gggtggggct	3000
tgccgggtta	gcaacctggc	gccccctactt	cgagagaga	cgaggaggat	caacgatctc	3060
ctggacctgg	actttttct	cttcaattcg	ctgacccatc	ctccggagtc	agtggccgcc	3120
accgtgtct	cgtcagcgtc	agccctcttc	tgctcgctgc	cgtcgacgac	ccggccctgc	3180
agegegecc	ccacatgcag	cttcaacctat	cgatccggg	ccggggacga	ccggggcggt	3240
ggccggggcg	gcaacggccg	ggggcccttc	tatggcagg	agtccgttcc	ccctccgacg	3300
gtcccttca	acctggcgga	catcaacgc	gtgagccctt	cgggccggct	cgtggccag	3360
ctctcgccg	cagaatttgg	ccgggtgtat	atccgcgc	agcagccca	gcccgggggt	3420
gggggggtga	ttggggcaagtt	cgtgtgtga	ggtgtgtgt	ggggccctgg	cagcgagttac	3480
ggcagcccg	cggtcatcg	cgtcggaaa	ggcagccctg	acggcggca	cccggtgggt	3540
gtggcgccct	acaacggccg	ggccgcgcgc	acgtggccca	agatcaagca	ggaggcggtc	3600
tcttcgttca	ccacttgggg	cggtggaccc	cctctca	atggccaccc	gcccggctgc	3660
cacgacttcc	ccctggggcg	cgatccccc	agcaggactt	ccccggaccc	gggttggtag	3720
gaagtgttga	ggaggcaggga	ctgttccat	ggccctggcc	ttccctccgg	tttccatccc	3780
caccggggc	ccaatttaccc	atccttctgt	cccgatcaga	tgccagecgca	agtccggccg	3840
ctccattacc	aagagctcat	gcccacccgt	tctgtatgc	cagaggaggc	caagccaaag	3900
agggggaaag	gatctggcc	ccggggaaaag	acggccaccc	acacttgta	ttacggggcc	3960
tgccggcaaa	cctacacaaa	gatgtttccat	ctcaaggcac	acctcgac	ccacacagg	4020
gaaaaaccc	accactgttga	ctgggacggc	tgtggatgg	aattcgcccg	ctcagatgaa	4080
ctgaccaggc	actacatgtt	acacacgggg	caccggccgt	tccagtgc	aaaatgcgac	4140
cggcatttt	ccagggtgg	ccacatcgcc	tttccatgtt	tttccatgtt	ttaatatgact	4200
agtgcgcgc	ggggccggacc	atggggccaa	tgtttttttt	cagcttataa	ttgttacaaa	4260
taaagcaata	gatctacaaa	tttcacaaaat	aaagcatttt	tttactgtca	ttctatgtt	4320
ggtttgcata	aactcatcaa	tgtatcttat	catgtcttgc	tctcggtacc	ggatccaaat	4380
tcccgataag	gatcttctt	gagcatggct	acgttagataa	gtagcatggc	gggttaatca	4440
ttaactacaa	ggacccctta					4460

SEQ ID NO: 36	moltype = DNA	length = 2735				
FEATURE	Location/Qualifiers					
source	1..2735					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 36						
cctgcaggca	gtgtcgccgt	cgctcgctca	ctgaggccgc	ccgggcaaaag	ccggggcgctc	60
ggggcgcaccc	ttgtcgcccg	gcctca	gtcgacgc	g	gggtggcc	120
actccatcac	taggggttcc	tgccggccgt	cggtccgcac	gatctcaatt	cgccattac	180
ggccggatcc	ggctcgagga	gttgcggcc	ttgcatactg	tgtatccata	tcataatag	240
taatattatc	ttggctcatg	tccaa	ccgcattat	tttgcattat	tttgcattat	300
tataatagt	aatcaattac	ggggtcatt	tttgcatacg	catatatgg	tttgcgtt	360
acataactta	cggttaatgg	cccgccttgc	tgaccgc	acgacccccc	cccattgcac	420
taataatga	cgatgttcc	catagta	ccaaatagg	tttccat	acgtcaatgg	480
gtggagttt	tacgttacaa	tgccca	cgatcata	aagtgtatca	tatgc	540
acgccccctt	tttgcgttac	tgacggtaaa	ttggccgc	ggcattatgc	ccagtatcg	600
accttatggg	actttctac	ttggcgttac	atctacgtat	tagtcat	tcattaccat	660
gtgtatgggt	tttgcgttac	catatgttgc	cggtggat	ggtttgc	acggggattt	720
ccaagtgttcc	acccatgtt	cgtaatgg	cgatgttgc	tttgcacaaa	tcaacgggac	780
tttccaaat	gtcgttacaa	ctccggccca	tttgcacaaa	ttggccgttgc	gggtgtacgg	840
tgggggttct	atataagcag	agtcgttta	gttgcacgt	agatgcctg	gagacccat	900
ccacgcgttt	tttgcgttca	tagacac	cgggacccat	ccagcctccg	cgggccccc	960
tttccatgtt	cttgcgttac	atcataatgg	cggtggat	ggtttgc	acggggattt	1020
ggatgttgc	tttgcgttac	caagacaaa	atcataatgg	cgatgttgc	tttgcacaaa	1080
cctaccctgt	acttgcacgt	gaagaacaag	cgggccctgc	tcgtatgcct	gccaatcg	1140
atgtctggaca	ggcatacatac	ccacacgtc	ccccgttgc	g	gcaagactt	1200
cttgcggca	acggcaacgt	atccatgttgc	gttgcgtt	ccatcgca	cggggttgc	1260
gtgtatgttcc	cgacccgttcc	aaacagaaa	cgatgttgc	tttgcacaaa	tcaacgggac	1320
tttccatgtt	atcataatgg	tttgcacaaa	tttgcacaaa	tttgcacaaa	tttgcacaaa	1380
cacttttac	ttgggtgttgc	attggaggaa	caggacatc	aagtgcac	aaagggaa	1440
gagacacac	ccaccat	tatggccca	tttgcacaaa	tttgcacaaa	tttgcacaaa	1500
cggtgggg	ccggacactgc	tttgcacaaa	tttgcacaaa	tttgcacaaa	tttgcacaaa	1560
aaacagat	aaatgtgttgc	tttgcacaaa	tttgcacaaa	tttgcacaaa	tttgcacaaa	1620
atgtctggat	ccggatgttgc	tttgcacaaa	tttgcacaaa	tttgcacaaa	tttgcacaaa	1680
gacgat	tttgcacaaa	tttgcacaaa	tttgcacaaa	tttgcacaaa	tttgcacaaa	1740
gataaggatc	tttgcgttcc	ggcataatca	acccatgttgc	tttgcacaaa	tttgcacaaa	1800
gactggat	tttgcgttcc	tttgcacaaa	tttgcacaaa	tttgcacaaa	tttgcacaaa	1860
tttgcgttcc	tttgcgttcc	tttgcacaaa	tttgcacaaa	tttgcacaaa	tttgcacaaa	1920
tttgcgttcc	tttgcgttcc	tttgcacaaa	tttgcacaaa	tttgcacaaa	tttgcacaaa	1980

-continued

tgtgtttgt	gacgcacacc	ccactgggt	gggcattgcc	accacctgtc	agtccttgc	2040
cgggacttgc	gottttcccc	tcctatgg	cacggcgaa	ctcatecgcc	cctgccttgc	2100
ccgctgtgg	acaggggctc	ggctgttgg	cactgacaat	tecgatgtt	tgtcgggaa	2160
atcategtcc	tttccttgg	tgctgcctg	tgttgcacc	tgatatttgc	gccccggctc	2220
cttctgtac	gtcccttgg	ccctcaatcc	agcgaccc	cttcccccgg	gcctgtgtcc	2280
ggctctgggg	ctcttccgc	gtcttcgcct	tcgcccctag	acgagtgg	tctcccttgc	2340
ggecgcttcc	ccggcagaca	tgataagata	cattgatgaa	tttggacaaa	ccacaactag	2400
aatgcgtga	aaaaaatgtc	tttattgtga	aatttgtat	gtatattgtt	tattttaac	2460
cattataagc	tgcaataaac	aagttacaa	caacaattgc	attcatttt	tgtttcaagg	2520
tcagggggg	atgtgggg	ttttttaaag	caagtaaaaac	ctctacaat	gtggtaacta	2580
gcccgtgtgg	ccggcaggaa	ccctagtgc	ggagttgg	actcccttc	tgccgcgtcg	2640
ctcgctact	gaggccgggc	gaccaaaagg	cgccccgacgc	ccgggttgc	ccggggccggc	2700
ctcagtgtac	gagcgacgc	gcacgtgcct	gcagg			2735

SEQ ID NO: 37 moltype = DNA length = 4946

FEATURE Location/Qualifiers
source 1..4946
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 37

cctgcaggca	gctgcgcgt	cgctgcgtca	ctgaggccgc	ccgggcaaa	cccggggcgtc	60
ggggcgcctt	tggtcgccgc	gcctcaagt	gcccggcgc	ggcggagag	ggagtggcca	120
actccatcac	taggggttcc	tgccggccgt	cggtccgcac	gatctcaatt	ccggccat	180
ggccggatcc	ggctcgagga	gttggccca	ttgcatacgt	tgtatccata	tcataatag	240
tacatttata	ttggcgtatg	tccacattt	ccggccatgtt	gacattgatt	attgactagt	300
tattaatagt	aatcaattac	ggggtcattt	gttcatgc	catatatgga	gttccgcgtt	360
acataactta	cggttaatgtt	ccggcgttgc	tgacccgc	acgaccccg	cccatgtacg	420
tcaataatga	cgtatgttcc	catatgttgc	ccataggaa	cttgcatttgc	acgtcaatgg	480
gtggagttt	tacgttaaac	tgcccaacttgc	gcagttatc	aagtgtatca	tatgcacaa	540
acgcccccta	ttgacgttca	tgacgtttaaa	tggccgcctt	ggcattatgc	ccagttatgc	600
accttatgttgc	atcttgcac	ttgcgttgc	atctacgtat	tagtcatgc	tattaccat	660
gtgatgcgtt	tttggcgtat	catcaatggg	ctgttgatgc	ggtttgactt	acggggattt	720
ccaaagtcttcc	accccatgtt	cgtcaatggg	agtttgcgtt	ggcacaaaa	tcaacgggac	780
tttccaaat	gtcgttacaa	ctccgcggca	tttgcgttgc	tggggcggt	gcgtgtacgg	840
tgggagggtt	atataacgc	agctcgttta	gttgcacccgt	agatgcgttgc	gagacccat	900
ccacgcgttcc	ttgacgttca	tagaagacac	ccggacccgt	ccagccttcg	cgggcccgaa	960
ttcaccatgtt	cccgcttgg	taagacaa	gtataaaaa	gcccacttgc	actcttcaac	1020
ggcgctgggg	tgcgttgtt	gactacttgc	aagctcgcc	agaaatttgg	tgtggagcaa	1080
cctacatgtt	atttgcgtt	caatgttgc	agagccctgc	tggacgcgtt	tccttatttgc	1140
atgtttgttgc	atgttgcac	tcatttcgtt	ccggccatgtt	tcgatgttgc	gcaagat	1200
cttcgaaatca	atgttgcac	cttgcgttgc	gcaattttgt	ccataggaa	tggagcaaa	1260
gtgcacccgtt	aaacccgttgc	aaacagagaa	caatacgttgc	ctctcgat	ccagttgcgt	1320
tttttgcgtt	acacgggttgc	ctcaatgttgc	atgcgttgc	acggcggttgc	1380	
catttttaccc	ttgggtgtgtt	tettgggg	caagaacatc	aggtgttgc	ggaggaggcgc	1440
gagactccaa	ccactgttttgc	tatgcaccc	tttgcgttgc	aggccatgttgc	acttttgcgt	1500
agacagggtt	ttgttgcac	tttttgcgttgc	gggttgggc	tgatttttgc	tgggttgcgtt	1560
aaacaggttgc	aatgttgcac	ttgttgcgttgc	actgcgttgc	tcgtatgttgc	cgacccgttgc	1620
atgttgcgttgc	ccgtatgttgc	ttgttgcgttgc	ttgttgcgttgc	ttgttgcgttgc	ttgttgcgttgc	1680
gacgacttcg	attttggat	gttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	1740
gataaggatc	ttggccgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	1800
gactgttatt	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	1860
tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	1920
tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	1980
tgtgtttgtt	gacgcacacc	ccactgggtt	gggcattgc	accacctgtc	agtccttgc	2040
cgggacttgc	gottttcccc	tcctatgg	cacggcgaa	ctcatecgcc	cctgccttgc	2100
ccgctgtgg	acaggggctc	ggctgttgg	cactgacaat	tecgatgtt	tgtcgggaa	2160
atcategtcc	tttccttgg	tgctgcctg	tgttgcacc	tgatatttgc	gccccggctc	2220
cttctgtac	gtcccttgg	ccctcaatcc	agcgaccc	cttcccccgg	gcctgtgtcc	2280
ggctctgggg	ctcttccgc	gtcttcgcct	tcgcccctag	acgagtgg	tctcccttgc	2340
ggecgcttcc	ccggcagaca	tgataagata	cattgatgaa	tttggacaaa	ccacaactag	2400
aatgcgttgc	aaaaaatgttgc	tttattgtga	aatttgcgttgc	gtatattgttgc	tattttaac	2460
cattataagc	tgcaataaac	aagttacaa	caacaattgc	attcatttt	tgtttcaagg	2520
tcagggggg	atgtgggg	ttttttaaag	caagtaaaaac	ctctacaat	gtggtaacta	2580
ggccgtgtgg	ccggcaggaa	ccctagtgttgc	ggagttgg	actcccttc	tgccgcgtcg	2640
ctcgctact	gaggccgggc	gaccaaaagg	cgccccgacgc	ccgggttgc	ccggggccggc	2700
ctcgctact	gaggccgggc	gacgtgttgc	cgacgttgc	aatggccgc	cgacgttgc	2760
tcgacgttgc	tttgcgttgc	aaatttgcgttgc	ccgttgcacaa	ttccacacaa	2820	
catacgatcc	ggaaggatcc	agtgttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	2880
attatgttgc	tttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	2940
ttaatgttgc	tttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	tttttgcgttgc	3000
ctcgctact	gactcgctgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	tttgcgttgc	3060
aaaggccgtt	atacggttat	ccacacaa	agggataac	gcagggaa	acatgttgc	3120
aaaaggccat	aaaaggccca	gaaaccgttgc	aaaggccgc	tttgcgttgc	ttttccat	3180
gtcccgcccc	cctgacgttgc	atcacaaaa	tcgacgttgc	agtcaggttgc	ggcgaaaccc	3240
gacaggacta	taaagatacc	aggcggttcc	ccctggaa	tcctcgatgc	gtctccgttgc	3300
tcggaccctgc	ccggcttacc	gataccatgc	cccttttgc	cttccggaa	cgctggcg	3360

-continued

tcttcatagc	tcacgcgtgta	ggtatctcg	ttcggtgtag	gtcgctcgct	ccaaagtggg	3420
ctgtgtgcac	gaaccccccg	ttcagccga	ccgcgtgcgc	ttatccggt	actatcgct	3480
tgatgtccaa	cccgtaagac	acgacttatac	gccacttgca	gcacggactg	gtaaacagg	3540
tagcagagcg	aggtatgtag	gcgggtgtac	agagttcttg	aagtgggtgc	ctaatacagg	3600
ctacataga	agaacagatgt	ttgtatctcg	cgtcttgcgt	aaagccatgtt	ccttcggaaa	3660
aagagtttgt	agcttctgtat	ccggcaaaaca	aaccacccgt	ggtagcggtg	gtttttttgt	3720
ttgcaagcag	cagattacgc	gcagaaaaaa	aggatctcaa	gaagatctt	tgatcttttc	3780
tacgggttgc	gacgctcaga	ggaaacggaa	ctcacgttaa	gggttttgg	tcatgagatt	3840
atcaaaaagg	atcttcactt	agatctttt	aaataaaaaa	tgaaaggat	tttaaatcatca	3900
aagtatata	gagtaaactt	ggtctgacag	tttagaaaaac	tcatcgagca	tcaaatgaaa	3960
ctgcaattt	ttcataatcag	gattatcaat	accatatttt	tgaaaaagcc	gtttctgtaa	4020
tgaaggagaa	aactccacca	ggcagttcca	taggtggca	agatctcggt	atcgctgtcc	4080
gattccgact	cgtccaaatc	caataacaca	tattaatttc	ccctcgctca	aaataagggtt	4140
atcaagttgg	aaatccacat	gatgtacgac	tgaatccgg	gaaatggca	aaatgtttag	4200
cattttttc	cagacttgtt	caacaggcca	gccattacgc	tcgtcatcaa	aatcaactcg	4260
atcaaccaa	ccgttattca	ttcgtgtatt	cgccgtacgg	aaacggaaata	cgcgtatccc	4320
gtttaaaaagg	caattacaaa	caaggatcga	atgcacaaagg	cgccaggaaaca	ctgcaggcgc	4380
atcaaaata	ttttccacctt	aatcaggata	ttttcttcaat	atcgttgc	ctgtttttcc	4440
agggatcgc	gtgggtgagta	accatgcata	atcaggagta	cggtttttat	gtttgtatgg	4500
cggaaaggcc	ataaaattccg	tcagcccgat	tagttgtacc	atcttcatcg	taatcatccat	4560
ggcaacgcgt	cctttcccat	gttttccggaa	caacttcgg	gcatcggtt	tccatataaa	4620
tccatagatt	gttcgcaccc	atttgcggcc	attatccgcg	gcgcattttat	accatataaa	4680
atcagcatcc	atgttggat	ttaatcgccg	ccttagagca	gacgtttccc	gttgaatatg	4740
gctcatactc	ttcccttttc	aatattattt	aagcatttat	cagggtttat	gtctcatgag	4800
cggatatacc	tttggatgtt	ttttagaaaa	taaaacaaata	gggtttcccg	gcacattttcc	4860
cggaaaatgt	ccacgtacgc	tctaaagaaatc	cattattatc	atgacattaa	cctataaaaaaa	4920
taggcgtatc	acgaggccct	tttgc				4946

1. A method for treating non-arteritic anterior ischemic optic neuropathy (NAION) in a subject in need thereof, the method comprising administering, to one or both eyes of the subject, a pharmaceutical composition comprising one or more polynucleotides encoding octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2), and Kruppel-like factor 4 (KLF4), but not Myc proto-oncogene (c-Myc), operatively linked to at least one promoter, wherein the method increases the number of healthy axons, enhances axon survival compared to vehicle treatment, improves retinal ganglion cell (RGC) function, or a combination thereof.
 - 2-30. (canceled)
 31. The method of claim 1, wherein the method does not reprogram a cell, tissue, or organ to a pluripotent state in the subject.
 32. The method of claim 1, wherein the method restores visual function in the subject.
 33. The method of claim 1, wherein the method improves retinal ganglion cell (RGC) function.
 34. The method of claim 33, wherein the RGC function is measured by electroretinogram (pERG).
 35. The method of claim 1, wherein OCT4, SOX2, and KLF4 are the only transcription factors encoded by the pharmaceutical composition.
 36. The method of claim 1, wherein the pharmaceutical composition does not comprise a polynucleotide encoding a Myc protein.
 37. The method of claim 1, wherein the pharmaceutical composition does not comprise a polynucleotide encoding Nanog.
 38. The method of claim 1, wherein the pharmaceutical composition is administered by intravitreal injection.
 39. The method of claim 1, wherein the pharmaceutical composition is administered by subretinal injection.
 40. The method of claim 1, wherein the pharmaceutical composition comprises an adeno-associated virus (AAV) vector.
 41. The method of claim 40, wherein AAV is an AAV2 vector.
 42. The method of claim 40, wherein AAV is an AAV9 vector.
 43. The method of claim 40, wherein AAV is an AAV. PHPb vector.
 44. The method of claim 1, wherein the pharmaceutical composition comprises a lentiviral vector.
 45. The method of claim 1, wherein the pharmaceutical composition comprises a lipid.
 46. The method of claim 1, wherein the at least one promoter comprises an inducible promoter.
 47. The method of claim 46, wherein the inducible promoter comprises a tetracycline response element (TRE), a mifepristone-responsive promoter, or a coumermycin-responsive promoter.
 48. The method of claim 47, wherein the promoter is a TRE3G promoter.
 49. The method of claim 46, wherein the method comprises administering an inducing agent that causes expression from the inducible promoter.
 50. The method of claim 49, wherein the inducing agent is a tetracycline-class antibiotic.
 51. The method of claim 49, wherein the inducing agent is a tetracycline.
 52. The method of claim 49, wherein the inducing agent is doxycycline.
 53. The method of claim 49, wherein the inducing agent is administered prior to administration of the pharmaceutical composition.
 54. The method of claim 49, wherein the inducing agent is administered after administration of the pharmaceutical composition.

55. The method of claim **49**, wherein the inducing agent is administered prior to and after administration of the pharmaceutical composition.

56. The method of claim **1**, wherein:

- i) OCT4 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 2;
- ii) SOX2 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 4; and/or
- iii) KLF4 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 6.

57. The method of claim **1**, wherein:

- i) OCT4 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 2;
- ii) SOX2 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 4; and/or
- iii) KLF4 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 6.

58. The method of claim **1**, wherein:

- i) OCT4 comprises the amino acid sequence of SEQ ID NO: 2;
- ii) SOX2 comprises the amino acid sequence of SEQ ID NO: 4; and/or
- iii) KLF4 comprises the amino acid sequence of SEQ ID NO: 6.

59. The method of claim **1**, wherein:

- i) the polynucleotide encoding OCT4 comprises a nucleic acid sequence having at least 90% identity to SEQ ID NO: 1;
- ii) the polynucleotide encoding SOX2 comprises a nucleic acid sequence having at least 90% identity to SEQ ID NO: 3; and/or
- iii) the polynucleotide encoding KLF4 comprises a nucleic acid sequence having at least 90% identity to SEQ ID NO: 5.

* * * * *